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Abstract 
 
Aims 
The aims of this thesis were to establish to what extent adult cancer patients receiving 
curative-intent chemotherapy potentially compromise their treatment and/or safety by 
using complementary and alternative medicine (CAM), and to identify which cancer 
patients use CAM at this time, why they use it, and who are most at risk.  
Additionally, it aimed to establish whether there was a need for an educational 
intervention to guide cancer patients on the safe use of CAM with chemotherapy, 
develop and publish the educational intervention and to evaluate the effectiveness of 
the intervention through surveying cancer patients and cancer care professionals, 
particularly doctors. 
 
Methods 
The thesis employed mixed methods, over several phases: a literature review, an 
observational study of 75 solid tumour patients receiving curative-intent 
chemotherapy for the first time and then, using results obtained as a framework, an 
educational brochure intervention was developed.  Qualitative methods were used to 
evaluate the potential acceptance and content of the educational brochure and also to 
determine the effectiveness of the brochure post publication and intervention. 
 
Results 
Patients receiving chemotherapy may be consuming CAM to treat cancer, to lessen 
chemotherapy side effects, for symptom management, or to treat conditions unrelated 
to their cancer.  Others may influence cancer patients in their CAM decision-making: 
practitioners, family, friends, spouse and even casual acquaintances met in waiting 
rooms and support groups.  Cancer patients do not necessarily volunteer their CAM 
consumption unless asked and prefer their cancer doctor to initiate discussions 
regarding CAM use.  Cancer doctors are reluctant to initiate CAM discussions with 
their patients.  
 
CAM that is systemically absorbed and biologically active is the most likely to 
interfere with concurrent chemotherapy and potentially cause harm to cancer patients.  
The curative-intent patient population are most at risk through taking biologically-
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active CAM adjuvant with chemotherapy, by altering chemotherapy dose intensity, 
which may adversely affect disease-free and overall survival.  Mind-body CAM, 
which has no biological activity, has shown efficacy above standard care when used 
for support by patients receiving chemotherapy and, when applied using reasonable 
patient specific precautions, is safe to use with adjuvant chemotherapy treatment. 
 
The curative-intent cancer patient study found 60% of the 75 participants were using 
CAM at the start of chemotherapy treatment.  Biologically-active CAM assessed as 
having potential to interact with prescribed chemotherapy through diminishing dose 
intensity was ingested by 27% of patients, all of whom had routinely used CAM prior 
to cancer diagnosis.  This was found to be statistically significant (β= +3.13, P = 
0.003).  CAM was used by 51% of patients for supportive care reasons and by 28% of 
patients with the intention of treating their cancer.  Thirteen percent of patients were 
told by a CAM advice-giver not to have chemotherapy.  The majority of patients 
(84%) would have liked to receive information on which CAM is safe to use with 
chemotherapy in a written handout form, before treatment commencement.   
 
Cancer patients receiving chemotherapy reported that the developed and published 
educational brochure was easy to understand and most (90%, n=30) thought the 
brochure had enough information to answer their CAM questions.  All cancer doctors 
(100%, n=17) perceived a need for the educational intervention, and recommended 
the brochure to their patients.  All cancer doctors thought the brochure made it easier 
for them to discuss CAM with their patients.  
 
Discussion 
The majority of patients receiving chemotherapy will consider taking CAM at some 
time during their treatment.  If biologically active, this CAM may alter their 
chemotherapy effectiveness.  Cancer patients may be receiving CAM advice to use 
biologically-active CAM at the time of receiving chemotherapy from uninformed 
sources and in some circumstances are advised not to proceed with chemotherapy 
treatment.  There can be a communication gap on CAM use between cancer patients 
and their cancer doctors, as cancer patients are often reluctant to declare their CAM 
use or intention and prefer their cancer doctor to ask.  Evidence-based guidance on the 
safe use of CAM with chemotherapy is desired by cancer patients and should be 
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communicated to cancer patients by cancer health professionals to enable patients to 
make informed decisions on CAM use at that time.  The evidence-based CAM-with-
chemotherapy patient brochure, developed through this thesis and now in use at adult 
day cancer care centres in Queensland, may be a useful adjunct for use by cancer 
doctors and associated cancer health professionals to educate patients on the potential 
dangers of biologically-active CAM use with chemotherapy and to provide patients 
with safe CAM alternatives.  
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1 Introduction 
Complementary and alternative medicine (CAM), an umbrella term found useful in 
the context of research, policy making and education,1 is defined as a broad and 
diverse group of treatments and products that are not widely used by conventional 
healthcare professions.2 CAM includes complementary medicine, which are 
treatments or products that are used alongside conventional medical treatment, and 
alternative medicine, which are treatments or products used instead of some, or all 
proffered conventional medical treatment.  Most CAM used by patients together with 
their conventional medical treatment fall into two subgroups, natural products and 
mind-body practices.  Natural products comprise substances such as herbs, vitamins, 
minerals and probiotics.  Mind-body practices are a diverse group of procedures or 
techniques sometimes administered by a practitioner, such as acupuncture, 
hypnotherapy, movement therapies, meditation, massage and healing touch.3   
 
Natural product CAM may be administered in a variety of ways, as is the case for 
pharmaceutical drug administration, with oral and topical being the primary routes of 
administration.  However, not all natural product CAM are biologically active.  For 
example, the practice of homeopathy administers natural product CAM in doses so 
low that biological activity cannot be achieved.4  The term “biologically active” is 
used as a descriptor in this thesis and is defined as the inherent capacity of a substance 
to alter one or more chemical or physiological functions of a cell, tissue, organ or 
organism.  Biological activity may reflect a “domino effect”, in which the alteration 
of one function disrupts the normal activity of one or more other functions.5   
 
The majority of cancer patients receiving chemotherapy will consider using CAM at 
some time during their treatment6 and, if so, may be compromising their treatment 
effectiveness, particularly if they are consuming CAM that has biological activity.7-12  
The potential for adverse outcomes associated with taking biologically-active CAM 
concurrently with chemotherapy is through interactions that may change the efficacy 
of chemotherapy.13  By contrast, natural product-derived CAM that has no evidence 
for biological activity by virtue of their extreme levels of dilution, e.g. homeopathy 
and Bach or Australian flower remedies, and mind-body CAM, are not generally 
associated with any concern for interaction with chemotherapy.   
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Cancer patients who use CAM during chemotherapy treatment are more likely to be 
women, their motivations for using CAM differ if being treated with curative or 
palliative intent, and they are likely to be influenced by others in their CAM 
decisions.14  Cancer patients receiving chemotherapy may also be contending with 
pseudoscientific alternative treatment advice, received from family, friends or CAM 
practitioners, that counters evidence-based information on cancer treatment and 
outcome expectation.6,15,16  Patients prefer their health care providers to initiate 
discussions regarding CAM use and do not necessarily volunteer their CAM 
consumption unless asked.11  The paucity of evidence for efficacy and safety for the 
use of biologically-active CAM during chemotherapy treatment may be countered by 
the fact that mind–body therapies have evidence for supportive care (above standard 
care) and may be recommended to patients looking for a complementary approach 
while receiving chemotherapy.17   
 
1.1 Thesis rationale 
Though there is much existing information on the general use of CAM by cancer 
patients, to date there is little published information on CAM use at the time of 
receiving chemotherapy: what CAM is used at that time, whether CAM taken 
compromises treatment or safety, or why cancer patients may take CAM with 
adjuvant chemotherapy.  Observations made over many years, as a practising cancer 
pharmacist interviewing cancer patients, many of whom used CAM, led to a desire for 
a greater understanding and more knowledge of CAM use adjuvant with 
chemotherapy.  The major thrust of this thesis was to analyse, interpret and then act 
upon information gained from surveying a sample population of cancer patients 
receiving curative-intent chemotherapy and from cancer doctors prescribing 
chemotherapy at the Sunshine Coast Cancer Care Service, Nambour Hospital, 
Queensland, Australia.  
 
1.2 Thesis approach 
The literature review (Chapter 2) did not find any study that exclusively examined 
CAM use in curative-intent cancer patients, which is a particularly vulnerable 
population because treatment success relies on appropriate dose intensity to gain 
optimal outcomes.  The major study forming the body of this thesis (Chapter 4) 
therefore examined a sample population of solid tumour cancer patients attending the 
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Sunshine Coast Cancer Service Day Unit and receiving curative-intent chemotherapy 
for the first time.  The study investigated patients’ CAM selection, their CAM 
selection influences and whether their ingested biologically-active CAM had the 
potential to interact with chemotherapy.  The study also captured the CAM-with-
chemotherapy educational requirements of these patients.  
Chapters 5, 6 and 7 outline the development, acceptance and effectiveness of a 
purpose-designed patient educational brochure on the safe use of CAM with 
chemotherapy.  Chapter 5 discusses the brochure’s development, content definition 
and the steps taken to facilitate publication by the Queensland Government Sunshine 
Coast Hospital and Health Service.  Chapter 6 discusses the draft brochure’s pilot 
evaluation by both cancer doctors and patients and the reasons for any changes.  The 
post-intervention study (Chapter 7) looks at whether the brochure aided discussions 
between doctors and their patients on the effects of CAM, helped patients understand 
the potential effects of CAM during their chemotherapy treatment and saved doctor 
consultation time.  The study in Chapter 7 also examined whether the brochure’s final 
content and appearance was acceptable to doctors and patients. 
Chapter 8 discusses key results, limitations and conclusions.  The appendices contain 
publications and ethical approvals and exemptions gained to perform each study and 
to publish findings.  The thesis results have been peer reviewed through the process of 
achieving eight publications in six different international journals, encompassing the 
Asia-Pacific, European and North American regions. 
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Chapter 2 
Literature review 
 
Content from this chapter has been published as: 
 
Smith PJ, Clavarino A, Long J, Steadman KJ. Why do some cancer patients receiving 
chemotherapy choose to take complementary and alternative medicines and what are 
the risks? Asia Pacific Journal of Clinical Oncology 2014; 10: 1-10  
 
Smith PJ, Steadman KJ. Antioxidant supplementation and cancer patients receiving 
curative-intent chemotherapy. Medical Journal of Australia, 2016; 204(5): 185. 
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2 Literature review  
 
2.1 Introduction 
Complementary and alternative medicine (CAM) encompasses a broad and diverse 
group of treatments and products that do not tend to be widely used by conventional 
healthcare professions.2  The decision to use these forms of treatment by cancer 
patients may, or may not, be practitioner driven.  CAM can be administered through 
mind-body therapies such as acupuncture, massage and meditation or as natural 
substances such as herbs, vitamins and minerals that may exert biological activity 
through systemic absorption.  CAM practitioners commonly combine mind–body 
therapies with biologically-active substances.  For example, a Traditional Chinese 
Medicine (TCM) practitioner may recommend acupuncture and/or biologically active 
herbs, and naturopaths may combine mind therapies with herbs and dietary 
supplement recommendations.  
 
Biologically-active CAM that is systemically absorbed is the most likely to interfere 
with concurrent chemotherapy and potentially cause harm to cancer patients.7-12  As 
biologically-active CAM, such as herbal products, are being sought by cancer patients 
with increasing frequency,18 conventional providers require an understanding of the 
CAM selection process to promote open disclosure and provide appropriate guidance 
and professional support,19,20 particularly at the time of the patient receiving 
chemotherapy.  This review aims to describe existing literature on the use of CAM by 
cancer patients receiving chemotherapy, and to identify gaps and issues that need to 
be addressed.   
 
2.2 Literature search strategy  
A database search was conducted to identify peer reviewed original research 
published from 2000 to 2016 investigating CAM use by cancer patients receiving 
chemotherapy.  The search included the databases Ovid-Medline and Embase, and the 
limits used for both searches were English, Human and Abstracts.  Articles were 
included if they were on the thesis topic and reported original research findings. 
 
The search subject headings used for the Ovid-Medline search were: exp 
Complementary Therapies/px, td [Psychology, Trends] AND exp drug therapy/ AND 
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exp antineoplastic agents/.  The keyword headings for the Ovid-Medline search were: 
(complementary medicine OR complementary therap* OR alternative medicine OR 
alternative therap* OR natural medicine OR natural therap* OR CAM).ti,ab AND 
chemotherapy*.ti,ab AND (cancer or tumor or tumour or neoplasm).ti,ab.  The search 
subject headings employed for the Embase search were: 'alternative medicine'/exp 
AND 'cancer chemotherapy'/exp.  The keyword headings used for the Embase search 
were: (complementary medicine OR complementary therap* OR alternative medicine 
OR alternative therap* OR natural medicine OR natural therap* OR CAM):ti,ab AND 
chemotherapy*:ti,ab AND (cancer or tumor or tumour or neoplasm):ti,ab.   
 
The most relevant articles located using the database searches above were used as the 
basis for two additional search approaches: Google Scholar was used to search for 
papers citing the article in question, and the reference lists within the publications 
were assessed for any relevant articles.  This approach allowed for the discovery of 
publications that were not captured by the database searches. 
 
2.3 CAM definition 
Prominent research and health organisations and academics have developed a variety 
of definitions for CAM that are ultimately quite similar in meaning: i.e. treatments 
and products that do not tend to be widely used by conventional health practitioners.  
 
The Cochrane Collaboration states that CAM is “a broad domain of healing resources 
that encompasses all health systems, modalities and practices and their accompanying 
theories and beliefs, other than those intrinsic to the politically dominant health 
systems of a particular society or culture in a given historical period.” 21  
 
The National Center for Complementary and Alternative Medicine (NCCAM) defines 
CAM as “a group of diverse medical and health care systems, practices, and products 
that are not presently considered to be part of conventional medicine”.  It is of note 
that NCCAM has recently changed its name to National Centre for Complementary 
and Integrative Health (NCCIH) and now uses the term “integrative” in preference to 
“alternative”.3   
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The term “integrative” or “integrated” medicine or therapy encompasses the use of 
CAM with conventional medical practice.  Definitions include “a system of healthcare 
that is patient-centred and collaborative, encompassing a diversity of therapeutic 
options, which includes CAM, that have been found to be safe, effective and informed 
by available evidence to achieve optimal health and healing”.1  A British Medical 
Journal editorial described integrated medicine similarly, as the practising of medicine 
in a way that selectively incorporates elements of CAM into comprehensive treatment 
plans alongside solidly orthodox methods of diagnosis and treatment.22  The term and 
practice of integrative medicine is controversial and has been criticised as being an ill-
conceived concept, promoting the use of unproven or disproven therapies, which is in 
conflict with the principles of both evidence-based medicine and medical ethics.23   
 
The World Health Organisation (WHO) describes CAM as inter-changeable with 
traditional medicine; “a broad set of health care practices that are not part of that 
country's own tradition and are not integrated into the dominant health care system.”  
Traditional medicine CAM is “the sum total of the knowledge, skills, and practices 
based on the theories, beliefs, and experiences indigenous to different cultures, 
whether explicable or not, used in the maintenance of health as well as in the 
prevention, diagnosis, improvement or treatment of physical and mental illness.”24   
 
CAM is explained by the British Medical Association as “those forms of treatment 
which are not widely used by the conventional healthcare professions, and the skills 
of which are not taught as part of the undergraduate curriculum of conventional 
medical and paramedical healthcare courses”.25   
 
A European research project termed CAM as a variety of different medical systems 
and therapies based on knowledge, skills and practices derived outside of 
conventional health care.  The group concluded that CAM was mainly used outside 
conventional health care, but in some European countries, certain treatments were 
being adopted or adapted by conventional health care.26   
 
Most formal definitions describe CAM as treatments and products that are not 
considered part of conventional medicine, as did academics Zollman and Vickers in 
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1999: “a group of therapeutic and diagnostic disciplines that exist largely outside the 
institutions where conventional health care is taught and provided”.2   
 
In Western countries, patients often ‘mix and match’ CAM with conventional 
medicine.  For example, in the cancer setting, a cancer patient may receive 
chemotherapy and associated conventional anti-nausea medications, but may 
additionally choose to receive acupuncture, which is CAM, to relieve chemotherapy-
associated nausea.  Or, a cancer patient may receive chemotherapy and decline 
associated conventional anti-nausea medications in favour of acupuncture (CAM).  In 
this scenario CAM is used as an alternative to relieve chemotherapy-associated 
nausea and is complementary to conventional chemotherapy.   
 
There can be some crossover of CAM products, for example, vitamin C taken 
systemically to relieve a cold is considered CAM as there is insufficient scientific 
evidence to justify its use in this context;27 however, if vitamin C is taken to treat a 
condition caused by a deficiency, such as scurvy, it is considered conventional 
medicine as there is compelling scientific evidence to support this use.28   
 
In summary, complementary and alternative medicines (CAM) cover a broad and 
diverse group of treatments and products that do not tend to be widely used by 
conventional healthcare professions.  This approach to defining  CAM by exclusion, 
i.e. describing CAM through what it isn’t rather than what it is, has been adopted by 
most prominent research organisations and academics because specific CAM 
treatments are varied and fluid.1  However, CAM treatments and products broadly fall 
into two subcategories.  Natural products such as herbs, vitamins and minerals that are 
consumed orally or applied to the body, which may or may not exhibit a biological 
effect, and mind-body practices such as acupuncture, hypnotherapy, movement 
therapies, meditation, massage and healing touch that have no evidence for biological 
activity.  
 
2.4 Prevalence of CAM use in the general population 
The first nationally representative survey in the US regarding the prevalence of CAM 
use involved a random sample of 1,539 adults who were interviewed by telephone in 
1990.  The survey reported that one in three respondents had used at least one form of 
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CAM during the past year to treat their most serious or bothersome medical 
condition(s).  The study also found that CAM was used primarily for chronic 
conditions, and in addition to rather than as a replacement for conventional medicine.  
It also found that a majority (72%) of CAM users did not inform their medical doctors 
that they used CAM.29  A national follow-up survey found an increase in CAM use by 
the American public from 33.8 percent in 1990 to 42.1 percent in 1997.29  This 
study’s findings were supported by another US study conducted through a mail survey 
of 1,035 randomly selected individuals reporting 40 percent of those responding had 
used CAM during the previous year.30   
 
A 2004 South Australian survey of over 3000 people found CAM was used by 52.2% 
of the population.  The greatest CAM usage was found in women aged 25 to 34 years, 
with higher income and education levels.  CAM providers had been visited by 26.5% 
of the population and the users of CAM reported a lower quality of life than non-
users.  More than half (57.2%) of CAM users did not report the use of CAM to their 
conventional medical doctor.31  A further 2005 study of a sample of 1067 adults from 
all Australian states and territories, found 44.1% of those interviewed used some form 
of CAM.  The most common characteristics of CAM users were age of 18 to 34 years, 
female, employed, well-educated, private health insurance coverage and higher-than-
average incomes.32  A 2010 Australian cross-sectional postal survey sent to a random 
sample of 4500 Australians aged ≥ 50 years found a CAM usage rate of 46.3% and 
that Australian women used more CAM than did Australian men.33  A critical review 
of the predictors of CAM use in Australia over a 14 year period from 2000 to 2014 
found a higher rate of use by females compared to males and that Australian female 
CAM users were more likely to be middle-aged with a higher education and annual 
income in comparison to female non-CAM users.  Australians were found more likely 
to use CAM to treat chronic conditions, including cancer.34   
 
CAM use in Australia is more likely in women with higher income and education 
levels, and most CAM users also consult conventional medical doctors, though are 
unlikely to report their CAM use to them.  In both the US and Australia, CAM users 
do not commonly reject all conventional medical care, usually taking a pluralistic 
approach to illness, with most CAM users also consulting conventional medical 
doctors.  Medical pluralism can be defined as the employment of more than one 
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medical system or the use of both conventional and CAM treatments for health and 
illness.35  It has been suggested that factors influencing medical pluralism, involving 
non-conventional medical health care such as CAM use, may be attributed to the 
peculiar attributes of patients such as personality, experience, culture, social class, 
family, and religion together with individuals’ fears, beliefs, behaviour, and the 
meanings they give to their ill-health which conventional medicine is perceived by the 
patient to not understand.36   
 
2.5 Cancer patient CAM use 
Cancer patients, as in the general population, are more likely to take CAM if they 
have higher education, are female and have higher than average income.14  The 
significance of having a higher income has not always been supported in the 
literature.8  Age has been found to be a significant factor, although evidence is 
contradictory.14  Cancer type, disease progression, fear of recurrence, race, physician 
dissatisfaction, co-morbidity, higher social status, being married, living in a 
metropolitan area, normal weight, non-smokers and prior CAM use have been shown 
to be significant factors for CAM use by cancer patients.8,37  The majority of CAM 
studies have been done in the US or other western countries14 and CAM studies done 
outside of western countries have not reproduced such consistent results. 
 
An African study on cancer patients showed high CAM use but found women less 
likely to use CAM than men and that education, income and age were not factors 
influencing CAM use.38  A study in Singapore found race, education level and prior 
CAM use to be significant predictive factors for cancer patients.39  A Mexican study 
showed that CAM users were most likely to be higher educated females with 
advanced cancer.40  An Iranian study of breast cancer patients found fear of 
recurrence and dissatisfaction with the physician the most likely causes for CAM use 
41 and in Japan, advanced cancer stage, higher education, type of cancer and a 
younger age were found to influence CAM use.42  
 
Men are less likely to take CAM than women.14  Men who select CAM to treat cancer 
or to support conventional cancer treatment may not have high regard for scientific 
evidence and they are most likely to receive their CAM information and motivation 
from female relatives or friends.43  Some men with prostate cancer, up to 39% in one 
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study,44 used CAM.  A US study of prostate cancer patients receiving curative surgery 
and radiation found a rate of 32% using CAM during treatment45 and an earlier study 
on a similar cohort of curative prostate patients measured a rate of 43%.46  Prostate 
cancer patients may also use CAM because of disease progression,47 although it is 
uncommon for men with any type of cancer to use CAM exclusively without 
conventional medical interventions.43  
 
2.5.1 Australian cancer patients 
In Australia, a significant proportion of cancer patients use CAM, with a prevalence 
measured in a recent study at 65%.6  The Australian population of cancer patients 
more likely to use CAM reflects the majority of studies, with these patients possessing 
higher education, being female and having higher than average income.6,48  A study 
on CAM use by elderly Australian women with cancer found that although their CAM 
use was less than that shown in studies involving women of all ages with cancer, they 
used CAM more than elderly women without cancer.49  
 
Aboriginal Australians are twice as likely to die from cancer as non-aboriginal 
Australians.50  Chemotherapy, which may debilitate and take an aboriginal person 
away from normal societal duties, may be seen as undesirable from an indigenous 
belief system.51  Aboriginal Australians would like to use their bush medicines and 
have these and other traditional healing practices recognised by orthodox medicine.52  
Better cancer outcomes have been shown to occur when traditional aboriginal healing 
practices (spiritual, physical and emotional) are used with adjuvant conventional 
interventions to treat cancer.52 53   
 
2.5.2 Australian CAM research and educational organisations 
Research funding in Australia for independent, rigorous scientific studies on CAM 
efficacy and safety has traditionally been difficult to obtain.  The CAM industry has 
been hesitant to support research for unpatented herbs because their competitors may 
benefit as well, and public funding from government organisations has been difficult 
to acquire as CAM research is contentious and conventional medicine research is 
prioritised.54  This situation has been overturned to some extent with the 
establishment of the National Institute of Complementary Medicine (NICM), based at 
the University of Western Sydney, and the Australian Research Centre in 
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Complementary and Integrative Medicine (ARCCIM), part of the Faculty of Health, 
University of Technology, Sydney, which have attracted industry and Australian 
government funding to aid their research.  Both organisations conduct independent 
CAM research and provide educational support for health professionals.  The NICM 
examines the safety and efficacy of complementary medicines and the ARCCIM 
researches CAM use and practice in Australia and overseas.  The University of 
Sydney has accepted industry funding to establish the Maurice Blackmore Chair in 
Integrative Medicine with the purpose of undertaking CAM research focusing on how 
CAM may interact with current standard conventional medical treatments.  
 
The National Institute of Integrative Medicine (NIIM) is a not-for-profit organisation 
involved in CAM teaching and research, and facilitates multidisciplinary clinics 
utilising conventional and CAM practitioners.  The Australasian Integrative Medicine 
Association (AIMA) is the peak medical body representing the doctors and other 
health care professionals in Australasia who practise the concept of integrative 
medicine, combining the use of evidence-based CAM and/or CAM practitioners with 
orthodox methods of diagnosis and treatment.22  The practice of integrative medicine 
has been criticised as merely a rebranding exercise for alternative medicine because 
CAM lacking in a scientific evidence base, such as chiropractic,55 is sometimes 
promoted and practised as integrative medicine.56  The teaching of integrative 
medicine in Australian universities has been criticised and cautioned by the Friends of 
Science in Medicine (FIM),57 an Australian based organisation committed to 
maintaining tertiary educational institutions free of health-related courses not based 
on science.58   
 
NPS Medicinewise (known prior to 2009 as the National Prescribing Service) is a not-
for-profit organisation whose programs are funded by the Australian government to 
provide free, independent, evidence-based information on medicines, including CAM, 
for the benefit of health professionals and consumers.59  The Cancer Council of 
Australia provides information specifically aimed at educating cancer patients who 
are considering using CAM60 and the Clinical Oncology Society of Australia (COSA) 
has produced a position statement on the use of CAM by cancer patients that provides 
guidance for health professionals involved with the treatment of cancer patients who 
are using or wish to use CAM.61   
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2.5.3 Cancer diagnosis 
Cancer diagnosis is a crucial time for CAM decision making by patients.  CAM 
selection decisions have been shown to coincide with conventional medicine 
decisions.10  Initial diagnosis and conventional medicine discussions with the treating 
oncologist are very important.  Evidence links increased CAM use to cancer patients 
who are not satisfied by the initial oncology consultation and proffered options for 
conventional treatment.62  
 
The use of CAM by patients increases after cancer diagnosis,19 20 in particular, the use 
of herbal CAM products.63  Delaying conventional care for the treatment of cancer, 
through choosing to use only CAM after cancer diagnosis, can worsen patient 
outcome.64,65  Cancer diagnosis may cause patients considerable stress, with one 
Australian study of head and neck cancer patients showing just under one-third (28%) 
developing post-traumatic stress disorder, 66 which may hinder their decision making 
and be associated with avoidance of people connected to the cancer experience.67   
 
A CAM discussion with an informed healthcare provider, particularly in regard to 
safety with conventional treatment, should be provided to cancer patients as near to 
cancer diagnosis as possible.19  Particular attention should be given to women and 
higher income individuals at diagnosis, as these populations are the most likely to 
start CAM at this time.68  Targeting populations such as these, which are most likely 
to use CAM, may be a pragmatic way to aim CAM discussion resources within a 
cancer centre.   
 
2.6 Reasons for CAM use by cancer patients  
Cancer patients may be undergoing chemotherapy treatment for palliative reasons to 
prolong life and lessen cancer disease symptoms, or to treat cancer with curative 
intent.  A Norwegian study found that cancer patients receiving chemotherapy for 
palliative or curative intent use biologically-active herbal CAM in equal number of 
products, though palliative patients take them more often.66  The more frequent use of 
biologically-active CAM by palliative patients with advanced cancer is linked to a 
wish to improve quality of life and increase hope for chances of survival.69  Curative 
cancer patients tend to use biologically-active CAM to prevent adverse reactions to 
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their chemotherapy. 66  Men with prostate cancer have been found to use CAM to treat 
or support themselves after negative experiences with conventional care.70 
 
2.6.1 Treat non-cancer conditions 
Patients receiving chemotherapy may be using CAM, regularly or occasionally, to 
treat conditions unrelated to their cancer.  For example, an acupuncturist may be 
sought regularly to treat or prevent migraine.  Glucosamine is regularly taken to treat 
osteoarthritis, and echinacea, which may be purchased at supermarkets, is taken 
occasionally to treat cold symptoms.  A consequence of taking glucosamine or 
echinacea during cancer treatment is the potential interaction with chemotherapy 
drugs.7,71,72  
 
2.6.2 Support during treatment  
Patients receiving chemotherapy may take CAM to lessen chemotherapy side effects 
or for disease symptom management.73  Evidence has been established for mind-body 
CAM to be used safely with chemotherapy for this purpose74 and is explored further 
in this review (2.14).  
 
2.6.3 Treat cancer 
Some patients receiving chemotherapy take CAM to treat their cancer.  Although 
there are published and ongoing studies on CAM use to treat cancer, definitive 
evidence to do so is lacking at this time. 11,20  A small proportion of cancer patients, 
8% in one study, 75 decide to select CAM alone to treat cancer.  Cancer patients who 
reject conventional treatment, or select CAM initially and delay conventional 
treatment, potentially sacrifice years of life, particularly if their cancer is being treated 
with curative-intent.  Two studies have found that delayed conventional treatment has 
a negative impact on breast cancer patients.65,76  
 
Cancer patients using CAM are not necessarily hostile to conventional medicine 11 
and it is logical for a person suffering from a disease, such as cancer, for which 
conventional medicine does not have all of the answers, to look to potential CAM 
benefits.  Cancer patients looking for integration would prefer to use CAM through 
their conventional providers if it were offered, 6 and cancer patients integrating CAM 
with their conventional care feel they benefit from both.77 
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2.6.4 Improving psychological well-being and control 
A British study stated, “Cancer patients receiving CAM reported being emotionally 
stronger, less anxious, and more hopeful about the future even if the cancer remained 
unchanged”.78  Cancer patients feel more in control and empowered through CAM 
consumption,10,37 though it has been proposed that any perceived benefits cancer 
patients receive from CAM use are exclusively obtained through the placebo effect.79  
 
2.7 CAM safety  
Cancer patients who take biologically-active CAM may be compromising their health 
in a number of ways: through direct adverse effects, potential drug interactions, or by 
taking poisonous CAM, or CAM that contains toxic contaminants.  
 
2.7.1 Direct adverse effects 
Direct adverse effects such as allergic reactions, gastrointestinal complaints, 
photosensitivity, skin reactions, hepatotoxicity, and neurotoxicity have been reported 
through herbal CAM use by cancer patients.11  For example, the herb, black cohosh, 
which is used to treat menopausal symptoms, has had 30 independent cases of 
reported hepatoxicity associated with its intake.80   
 
2.7.2 Adverse effects due to manufacturing quality 
The bioavailability and pharmacological activity of plant-based CAM may vary 
considerably through differing standards of practice during preparation, 81,82 and some 
CAM preparations may be contaminated with toxic impurities.83,84  For example, the 
herbal combination PC-SPES (PC=Prostate Cancer-SPES= Hope), used to treat 
prostate cancer, was found to contain varying amounts of  synthetic drugs (warfarin, 
diethylstilboestrol and indomethacin) in addition to the blend of herbal ingredients 
stated on the label.85,86  Diethylstilboestrol is a drug that has been used to treat 
prostate cancer in conventional medicine; however, due to side effects, is rarely used 
now.87  It is likely that these products were purposely adulterated, which adds the 
complication of integrity to herbal research.88  It has since been proposed that CAM 
investigators should consider using independent laboratories for quality control 
evaluations when conducting clinical trials, to ensure integrity of results.88  
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There have also been reports of substitution errors being made in CAM manufacture, 
including a Chinese medicine case report, where a cancer patient received the wrong 
herb, Stephania, which was substituted for the desired herb, Aristlochia.  
Unfortunately, the patient developed acute nephrotoxicity and later, as a direct result 
of the error, genitourinary cancer.89  
 
2.7.3 Varying distribution of active ingredients within plant tissues  
Plant constituents are not always evenly distributed or present throughout the plant.  
For example, the Ginkgo biloba leaf has differing active constituents and differing 
therapeutic activity from the fruit.  In TCM, the ginkgo fruit has been used to treat 
asthma and bronchitis from as long ago as 2600 BC.90  Presently, medicines derived 
from ginkgo leaves are used to improve cognitive function and ginkgo was the most 
frequently prescribed herbal medicine in Germany for this purpose in 2000.90  It is 
therefore important to elucidate detail of plant constituent origin when considering the 
safety of CAM.   
 
Growing conditions of plants should also be taken into consideration as the 
concentration of active compounds may vary depending on the location where a plant 
is grown and the timeliness and conditions of harvesting.91,92 
 
2.7.4 Unknown active constituents 
Herbal medicine practitioners believe that the original plant tissue is preferable to 
isolated active constituents.  Secondary constituents within the plant are viewed as 
having a positive role in the absorption, metabolism and excretion of major active 
constituents.93  Unknown secondary constituents may be problematic when 
considering conventional medicine integration because these constituents may also 
have potential to interact with chemotherapy and be undetected as the cause.12 
 
2.7.5 Government regulation of the quality and safety of ingested CAM 
The Australian Therapeutic Goods Administration (TGA) has developed a labelling 
system to identify registered medicines for supply in Australia.  Products assessed for 
safety, quality and effectiveness by the TGA are registered on the Australian Register 
for Therapeutic Goods (ARTG) and labelled with ‘AUST R’.  Medicines must have 
high-level evidence for efficacy to be registered; very few CAM are registered. 
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Medicines with low or medium level evidence for efficacy can be assessed by the 
TGA for listing on the ARTG, and these are labelled with ‘AUST L’.  Listed 
medicines are only assessed for safety and quality but not efficacy, and must be a low 
risk to the public.  Almost all biologically-active CAM, such as vitamin, mineral and 
herbal products, are listed medicines.  Some CAM is exempt from regulation by the 
TGA and so does not carry the AUST L label – these have not been evaluated by the 
TGA and safety is unknown.65  This includes products that make a generalised health 
claim rather than a medicinal claim, and do not look like a medicine, such as teas and 
nutraceuticals, as well as products that are too dilute to be of concern, such as 
homeopathic products diluted beyond 5X.94   
 
The effectiveness of the TGA’s administration of CAM has been questioned in a 
recent audit report commissioned by the Department of Health and Ageing.  The 
report concluded that the TGA’s “light touch” approach to regulating CAM has been 
a failure and that the regulation of complementary medicines has been of limited 
effectiveness.  The audit noted that up to 90% of complementary products were non-
compliant with regulatory requirements and that advertisements making misleading 
therapeutic claims were going unchallenged.  The audit acknowledged that the TGA 
had limited resources and suggested targeting serial offenders and companies that 
intentionally try to avoid regulation.95  
 
Although the TGA has strategies to provide safe and appropriately labelled 
biologically-active CAM to the Australian consumer, it is evident at this time that this 
is not always the case.  Those involved in documentation of cancer patients’ CAM 
consumption should be aware of this fact. 
 
2.8 Potential for CAM to interact with chemotherapy 
There is indirect evidence for both positive and negative effects of herbal CAM use 
with chemotherapy; however, currently there is not enough information available 
about herb-chemotherapy interactions to make definite recommendations.96  As it has 
been estimated that herbal CAM interactions are responsible for a substantial number 
of unexpected toxicities and possible sub-therapeutic treatment seen in cancer 
patients,11 this review concentrates on these potential interaction risks for cancer 
patients.   
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2.8.1 Herbs 
Ingested CAM, particularly herbs, has the potential to interact with chemotherapy 
drugs.  As cancer treatment often produces adverse effects in patients, interactions and 
any resultant adverse effects of CAM may be hidden, emphasising the importance of 
knowledge of potential mechanisms of action.  It has been estimated that in the 
population of patients receiving chemotherapy and taking CAM, at least 27% are at 
risk of a clinically relevant interaction.97  Some mechanisms of action for 
biologically-active herbal CAM with chemotherapy have been postulated to occur at 
an enzyme level, through metabolic pathways or through altering ATP binding 
cassette transporters.12  Biologically-active CAM interactions and potential 
interactions with chemotherapy are less documented than with commonly prescribed 
drugs;12 however, some have been studied and further studies are being 
undertaken.12,98-101   
 
Due to the fact that chemotherapy drugs have a narrow therapeutic target range which 
delineates maximum efficacy and tolerable toxicity, patient chemotherapy doses are 
carefully calculated by practitioners.102  The result of interactions with biologically-
active CAM may be to render chemotherapy drugs either more toxic or sub-
therapeutic, thus compromising treatment.11  It also potentially skews data from 
clinical trials if CAM with interaction potential is taken concurrent with a trial drug, 
but not adjusted for in subsequent analysis.103  
 
It has been estimated that approximately one-third of ambulatory cancer patients are 
at risk of a drug-drug interaction.104  Adding biologically-active CAM herbal 
combinations which in turn may have unknown active constituents presents a 
dilemma when considering safe integration.  
 
2.8.2 Antioxidants 
Antioxidant supplementation above normal dietary requirements has been found to be 
potentially problematic for consumers.  Antioxidants decrease the levels of cancer-
causing reactive oxygen species (ROS) that are formed during normal metabolism and 
are therefore sometimes recommended to the general population to reduce cancer risk.  
However, clinical trials evaluating health benefits of antioxidants have produced 
conflicting results with some showing an increase in cancer risk associated with 
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antioxidant supplementation.105  A large study found that men who took multivitamin 
supplements more than seven times per week had double the risk of developing fatal 
prostate cancer compared with men who had never taken multivitamin 
supplements.106  A more recent study concluded that supplementation with the 
antioxidant vitamin E significantly increased the risk of prostate cancer among 
healthy men,107 and vitamin E and beta carotene antioxidant supplementation in male 
smokers has been shown to increase the incidence of lung cancer.108 
 
In the cancer setting, two recent studies have shown that antioxidant supplementation 
accelerates the progression of tumours.  Antioxidant supplementation was 
demonstrated in animal studies to increase the proliferation of human lung cancer 
cells and tumour growth,109 and also to increase melanoma metastasis.110  
 
Cancer patients are attracted to antioxidant supplements during chemotherapy and a 
review of studies on antioxidant supplementation to reduce chemotherapy toxicity has 
found there is some potential.111  However, it has been proposed that any beneficial 
effects of antioxidant supplementation to reduce toxicity may be at the cost of 
diminishing the effectiveness of chemotherapy or radiotherapy by protecting tumour 
cells from oxidative damage.73,112-116  Indeed, cancer patients taking supplemental 
antioxidants to try to reduce side effects of adjuvant radiotherapy in a randomized 
placebo-controlled trial may have compromised radiation treatment efficacy.117  The 
primary mechanism of action of many chemotherapy agents, such as the alkylating 
agents, anthracyclines, podophyllin derivatives, platinum compounds and 
camptothecins, is the generation of reactive oxygen species (ROS), which induces 
apoptosis in cancer cells.  Antioxidants may inhibit ROS, thereby protecting the 
cancer cell from death.113,114  While a systematic literature review has proposed that 
no trials provide evidence of significant decreases in chemotherapy efficacy 
associated with antioxidant supplementation, many of the 19 included studies were 
small and underpowered, only four studies were double blinded, and presented 
survival data were premature.118  Importantly, as most of the included study subjects 
in this review had advanced or relapsed disease, the results are not applicable to 
patients with earlier, more chemo-sensitive disease such as the curative population.118  
As there is no conclusive evidence sufficient to produce clinical guidelines on safe 
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use,119 antioxidant supplements should be avoided with chemotherapy agents that 
induce oxidative stress as the mechanism for anticancer activity.  
 
2.9 CAM selection influences  
 
2.9.1 Practitioner recommendation  
It has been estimated that adult Australians visit CAM practitioners at the same rate 
they do medical practitioners.32  A small proportion of people (6%) visit only CAM 
practitioners, which suggests that a substantial number of people in the Australian 
general population who consult a medical practitioner also consult a CAM 
practitioner.32  Significantly, many medical practitioners are unaware of their patients’ 
CAM consultations.32  This has implications for CAM use as cancer patients may be 
receiving differing points of view from their CAM and medical practitioners.120 
 
2.9.1.1 Medical practitioner-recommendation  
A study has found that approximately 20% of Australian general practitioners actively 
practiced at least one form of complementary medicine or therapy, and almost 50% 
had an interest in CAM training.121  It has since been proposed that there is a trend for 
medical practitioners in Australia to incorporate CAM into their practice.122  Non-
CAM medical practitioners are more likely to refer their patients to medical 
practitioners who practise CAM than to non-medically trained CAM practitioners.123  
Medical practitioners may have varying training and/or education in the use of CAM 
and, as CAM practice is mostly unregulated, there may be a temptation to stray 
outside their field of expertise and unethically cross professional boundaries.  This 
was the case when a Queensland general practitioner was suspended from practising 
for six months in 2011 for administering sodium bicarbonate intravenously, on the 
advice of a naturopath, to treat a breast cancer patient.124  Another more extreme 
example is that of a UK medical practitioner who prescribed and promoted an 
unproven Indian Ayurvedic herbal blend “Carctol” to treat cancer.  The medical 
practitioner’s unsubstantiated endorsements such as ‘‘Since I have been putting 
people on Carctol I have seen miracles’’ appeared in the UK press.125  No studies can 
be found to support Carctol’s use.126  The conversion phenomenon has been 
postulated as a reason medical practitioners become holistic.127  This is supported by a 
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study which showed that over half of physicians attending an holistic conference had 
encountered a spiritual or religious experience.128   
 
2.9.1.2 Non-medical practitioner recommendation  
Chiropractic, acupuncture, osteopathy, and massage therapy are the most popular 
provider-based CAM therapies in Australia.32  Chiropractic, which is the leading 
CAM therapy choice, does not have robust evidence outside of treating back pain55,129 
and there is a disproportionate lack of evaluation of its safety.130  One researcher has 
concluded that the risks of chiropractic treatment by far outweigh its benefit.131  
Though chiropractic is a government-regulated profession in Australia, there has been 
criticism of the Australian Health Practitioner Regulation Agency (AHPRA) for 
inaction over complaints made to the board about chiropractic clinic websites that 
made claims likely to harm consumers.132   
 
“External” complementary therapy modalities have little chance of interacting with 
chemotherapy drugs; however, there are occasions when CAM practitioners may stray 
out of their expertise.  For example, non-medically trained acupuncturists in the UK 
advised patients about conventionally prescribed medicines, which led in some cases 
to adverse health consequences for their patients.133  In 2002, a large proportion of 
chiropractors in the UK advised parents against the measles-mumps-rubella 
vaccination for their patients’ children.134  
 
With the exception of chiropractors, osteopaths and TCM practitioners, CAM 
practitioners in Australia are not government-regulated professions,135 although there 
are a number of voluntary CAM associations.136  This exemplifies the great variety of 
education, background and views that may be expressed within each CAM discipline.   
 
Naturopaths, herbalists, TCM practitioners and sometimes chiropractors137 
recommend the use of biologically-active CAM.  As naturopaths and western herbal 
CAM practitioners are not government regulated in Australia, there may be great 
variation in practitioner quality and practice.138,139  The variation of standards and 
levels of training for naturopaths and other CAM providers has given an opportunity 
for manufacturers of biologically-active CAM, such as herbs and vitamins, to provide 
unchallenged product information.  Practising naturopaths in Australia receive over 
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90% of their continuing professional education directly from CAM manufacturers and 
a substantial amount of undergraduate naturopathic education is also supplied directly 
from CAM manufacturers.138,140  
 
Pseudoscience is defined as “claims presented so they seem scientific even though 
they lack supporting evidence and credibility”.141  The pseudoscience known as “live 
blood analysis” is practised by many CAM practitioners in Australia; especially 
naturopaths and sometimes chiropractors, to determine vitamin and mineral 
deficiencies.142,143  Unfortunately, general practitioners sometimes use and advertise 
live blood analysis as part of their clinic services.144 
 
Live blood analysis originates from the work of a German researcher Gunther 
Enderlein, who in 1925 used darkfield microscopy to observe blood phenomena not 
able to be seen in stained samples.  He postulated, among other things, that microbes 
he observed caused particular illnesses.145  Enderlein’s theory has since been 
disproven through further microbial and molecular research.146  A more recent study 
concluded that live blood analysis is difficult to standardise and diagnostic reliability 
is low.145  Further, a specific study looking at cancer diagnosis concluded that live 
blood analysis cannot reliably detect cancer. 147  Of concern is the fact that live blood 
analysis apparatus is sold by companies which make and market the minerals and 
vitamins for which the results of the test are likely to detect deficiencies.137  Edzard 
Ernst, Emeritus Professor of Complementary Medicine at the Peninsula Medical 
School at the Universities of Exeter and Plymouth, described how patients receiving 
live blood analysis consultations are cheated three times over, “ by being diagnosed a 
condition they don’t have, by being subjected to lengthy and expensive treatment, and 
by resubmitting to the test to receive news of improvement “.148   
 
Homoeopaths often recommend oral treatment using homoeopathic remedies.  As 
dosages of constituents are infinitesimal,149 homoeopathy is highly likely to not 
interfere with chemotherapy.  It should be noted; however, that non-medically trained 
homoeopaths have recommended ‘‘homoeopathic vaccinations’’ for which no reliable 
evidence exists, instead of conventional vaccination.134 
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Pharmacists have been accused of putting profits over professionalism by acting more 
like shopkeepers who stock products that will sell, rather than have proven ethical 
health applications.150  Pharmacists have not always followed ethical instruction from 
their professional societies in this regard.  The Royal Pharmaceutical Society of Great 
Britain, for example, has raised concerns over pharmacists selling homeopathic 
products and has called for homoeopathic products in pharmacies to state that there is 
no scientific evidence to support efficacy beyond placebo.151 
 
CAM recommendations may be supplied from uninformed or at least not suitably 
trained people working in a professional-looking environment.  Shop assistants who 
work in health food stores may take it upon themselves to give unsound CAM advice 
to patients.  A Canadian study found a health food store assistant advising a breast 
cancer patient to stop her prescribed anti-cancer drug tamoxifen.152  Pharmacy 
assistants may have the same potential to give unsound advice and potentially confuse 
the cancer patient undergoing conventional treatment. 
 
2.9.1.3 Psychopathic practitioner recommendation 
Quack health practitioners who promote borderline belief systems in medicine often 
do so due to having a psychopathic personality.127  Psychopaths have a cognitive 
defect which prevents feeling sympathy or remorse.  The following psychopathic 
traits are described by Canadian psychologist, Dr Robert Hare, in his “Psycopath 
Checklist”:153 lack the capacity to feel compassion, exhibit grandiosity and superficial 
charm, are pathological liars, employ conning/manipulative behaviour and lack guilt 
and empathy.  The psychopathic traits of grandiosity, superficial charm and 
pathological lying, when exhibited by a quack practitioner giving cancer patients the 
very words they want to hear (such as “cancer cure”),154 can lead the vulnerable 
patient to believe the rhetoric.  Psychopathic health practitioners may range from 
having no training at all to being among recognised professions such as medical 
practitioners or dentists.127  
 
2.9.2 Non-practitioner recommendation  
Most biologically-based CAM is self-selected by patients and influenced from a wide 
variety of sources and recommendations.  An American study showed that the 
majority of patient use of herbs was for reasons outside of evidence-based 
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indications.155  Evidence has been established for certain CAM used in cancer 
treatment supportive care, for example, ginger, which has been shown to significantly 
reduce chemotherapy-induced nausea compared with placebo.156  However, selection 
data points to the likelihood of cancer patients consuming CAM, with no evidence or 
even disproven evidence, which may potentially interfere with conventional medicine 
and cause harm.155  Non-practitioner based CAM selection is a grey area in the case of 
patients visiting professional-looking websites, taking online CAM practitioners’ 
advice, and selecting CAM based on that guidance. 157  
 
Cancer patients may not value scientific evidence158 and many believe that CAM will 
benefit their cancer even if studies have not proved efficacy of the CAM selection.6  
In the general population a study found the majority of patients selected CAM outside 
evidence.155  Cancer patients may confuse evidence-based CAM with CAM proven to 
be not efficacious or even dangerous.  Flawed CAM, marketed with pseudoscientific 
assertions, may be very appealing to the cancer patient looking for alternatives.  The 
sheer volume of CAM information may be very confusing to the cancer patient and 
cause considerable anxiety.10 
 
2.9.2.1 Significant others  
Cancer patients’ decisions for taking CAM are likely to be influenced by significant 
others: family, friends, spouse, and even casual acquaintances met in waiting rooms 
and support groups.  This influence may range from encouraging and supporting the 
patient's decision through to making the decisions for the patient.6,10,16  Men who 
select CAM to treat or support cancer mainly receive their CAM information and 
motivation from female relatives or friends.43  Family and friends who influence 
cancer patients' CAM decisions feel that the patient does not have the ability to make 
their own CAM decisions, and can be particularly insistent and persuasive to the 
patient when they regard themselves as having CAM knowledge or expertise.16 
 
2.9.2.2 Media information 
Although the internet has many reputable, informative cancer sites, unscrupulous 
promoters of pseudoscience now have a platform which the uninformed may find 
seductive.11,159-161  Additionally, newspaper reports of CAM cancer treatments have 
been found to mislead.162  An Australian study found that reports of biologically-
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active treatments are the CAM cancer treatments most published in newspapers.  
Australian newspapers have also been shown to play down potential side effects 
whilst embellishing potential benefits of CAM, with two-thirds of articles describing 
CAM use in the context of a cure.163   
 
Pseudoscientific CAM options in any media advertising are presented for the 
layperson, consequently statements and assertions are not referenced.  It convinces 
vulnerable patients by appealing to faith or by promoting fear.  Pseudoscience 
peddlers may be evangelical in their attempts to convert and there is often conflict of 
interest between the information base and the person promoting it. 141,164  Sellers of 
pseudoscience may recommend CAM only, and can be very effective at demonising 
conventional medicine.161  Some pseudo-scientists may also masquerade as 
practitioners, practising without qualifications or evidence base.165  As most cancer 
patients seeking CAM have expressed a preference to receive it as part of their 
hospital care,6 advocates with CAM knowledge are needed within the conventional 
care setting to at least guide people away from pseudoscience in their CAM 
choice.7,10,166 
 
2.10 Dietary modification 
After diagnosis, many cancer patients wish to make dietary modification to include 
more healthy food choices.  Supplemental dietary variations such as vegetable juices 
often make the patient (and family) feel better and are mainly harmless.  It is when the 
misconception that “diseases can be cured by eating the ‘right’ foods”167 results in a 
cancer patient changing their diet to an extreme, such as “carrot juice only”, that 
dietary modification may be detrimental to the patient’s health.  Pseudoscience, 
misconceptions and myths of the cancer disease process may lead to anxiety-causing 
statements such as “cancer loves sugar”.168  Pseudoscience claims such as this can be 
difficult to counter as it often has some tenuous basis in truth.169  The saying, "cancer 
loves sugar" has been around since 1927 when the cell biologist Otto Warburg 
hypothesised the prime cause of cancer is the replacement of the respiration of oxygen 
in normal body cells by a fermentation of sugar and this early scientific work is 
misinterpreted and misquoted as "cancer loves sugar".168,170  Perhaps another 
explanation for the persistence in the belief that “cancer loves sugar” is that too much 
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carbohydrate is consumed in western diets, leading to obesity which is known to be a 
significant co-morbidity in cancer outcome.171  
 
2.11 Spontaneous regression of cancer 
Over the last one hundred years, there have been documented reports of spontaneous 
regression of cancer.172  Dubious case reports of miracle cures due to CAM do not 
acknowledge this phenomenon.  Although spontaneous regression has been reported 
in all types of human cancer, the types of cancer most reported were nephroblastoma, 
renal cell carcinoma, melanoma and lymphoma.173  Postulated mechanisms of action 
of spontaneous regression are varied; however, it is agreed that further elucidation 
would improve cancer treatment.174 
 
2.12 The placebo/ nocebo effect 
The word placebo originates from the Latin “I shall please,” and the placebo effect is 
often assumed to be only psychological.  The placebo effect is, in fact, far more 
complex and is not constant; differing placebos invoke a greater effect than others for 
the same condition and patient belief in an intervention produces a greater placebo 
response.175  The placebo effect is greater in certain types of diseases and a positive 
placebo response has been measured in up to 50% of patients suffering depression, 
pain or Parkinson’s disease.176  Physiological mechanisms of action such as dopamine 
release (Parkinson's disease) and endogenous opioid release (pain) caused by placebo 
interventions have been measured.177,178  The placebo effect becomes greater in 
proportion to the patient’s number of visits and other interactions with health 
professionals 179 and is also linked to previous positive responses from clinical 
interventions.180  More recently it has been found that an individual’s response to 
placebo treatment may be genetically linked.  Studies have shown individual genetic 
variation in the synthesis, signalling and metabolism of the dopaminergic, opioid, 
cannabinoid, and serotonergic neurotransmitter pathways, contribute to differences in 
placebo treatment response.181  
 
Cancer patients, through belief in a certain CAM and/or CAM practitioner, will 
experience a placebo benefit whether the intervention works or not, and are not easily 
swayed by evidence to the contrary.158  This may be problematic for the cancer 
specialist, particularly when trying to guide a patient away from potentially harmful 
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CAM, as patient CAM choices may also dictate engagement with conventional 
care.166   
 
The “nocebo effect” has been described as a phenomenon directly opposite to the 
placebo effect.  A nocebo effect occurs when verbal suggestions of negative outcomes 
result in a patient expecting and actually experiencing clinical worsening of the 
condition.182  It would seem logical that if a cancer patient is told by a significant 
person that chemotherapy will diminish their cancer outcome, there is a possibility of 
the nocebo effect worsening that patient's response to chemotherapy. 
 
2.13 Declaration of CAM use to conventional health providers 
CAM consumption by cancer patients is often not revealed to their conventional 
treatment professionals, particularly if the patient is not asked, and many cancer 
patients who consider CAM to be harmless do not necessarily volunteer use even 
when they are specifically asked to give this information.11  Cancer patients would 
prefer their health care providers to initiate discussions regarding CAM, 15 perhaps 
due to anticipation of a negative response, in order to avoid risking their relationship 
with their oncologist. 183  An explanation may be that a neutral or indifferent response 
may be interpreted wrongly by the patient as a negative response.  This indifference 
may be that the conventional providers view CAM as harmless, at most having only 
mild interaction potential, and not worthy of consideration.184  As CAM may interact 
with chemotherapy leading to adverse effects and potential treatment failure,97 skilled 
interview techniques are required.  Actively asking, being non-judgemental and 
explaining potential negative consequences may help extract CAM use information 
from the patient.185 
 
2.14 Obtaining CAM evidence 
Evidence-based medicine is defined as the process of systematically reviewing, 
appraising and using clinical research findings to aid the delivery of optimum clinical 
care.186  Conventional research is hypothesis driven, seeking to answer questions of an 
intervention to a specific symptom or disease, whereas CAM treatment may involve 
multiple herbs and treatment modalities.  It has therefore been suggested that CAM 
should be studied as a whole and not limited to conventional scientific research.187  
The concept of “black box” study design, which allows traditional CAM practitioners 
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to use complex modalities to treat patients in a trial 188 has limitations, as outcomes 
are too broad for meaningful conclusions and may not constitute evidence of scientific 
value.187 
 
Conventional clinical trials normally involve three phases: Phase I looks at safety and 
dosage on a small population of patients, Phase II trials test efficacy and, in the cancer 
setting, efficacy for cancer type, and Phase III studies use large numbers of preferably 
randomized participants to compare the new substance to current standard treatments.  
There have been very few Phase III trials done on unpatented botanicals due to the 
complexity and high cost of this level of research.187  Phase IV studies examine side 
effects, risks and benefits when the substance is used by a large number of consumers 
after the treatment has been approved for use.189 
 
Using herbs in the cancer setting, either singularly or in combination with 
conventional treatment, has design challenges when considering safety and 
appropriate dose.  CAM biological treatments often use treatment history as proof of 
safety; however, this does not constitute safety when used concurrently with 
chemotherapy.  
 
CAM dose is rarely determined through the conventional trial method of dose 
escalation187 and dose response may not be linear.  This is the case of the anti-tumour 
mushroom Grifola frondosa, which showed reduced anti-tumour activity at higher 
dose.190  The Sloan Kettering Cancer Center researchers have found and published 
ways to obtain Phase I safety, dosage and efficacy data for botanicals to treat cancer 
whilst maintaining scientific integrity.191 
 
In the cancer setting, the use of a full placebo arm is considered unethical and 
therefore pragmatic trial methods are used, for example comparing standard care to 
standard care plus new treatment.192  Although placebos are unethical to use by 
themselves in cancer trials, they are still required when using best existing care plus 
or minus the trial intervention.  The formation of an appropriate placebo and blinding 
of patients is often difficult when trying to measure CAM interventions.193  Many 
herbs have distinctive taste, smell and appearance and are hard to duplicate; however, 
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when volume is not an issue, encapsulation has been used successfully to enable a 
matching trial placebo.187,191 
 
R.B. Bausell, a former Director of Research for the University of Maryland’s Centre 
of Complementary and Alternative Medicine, postulates that all beneficial CAM 
effects are due to the placebo response.175  Bausell contends that no methodologically 
sound CAM studies have been shown to be superior to placebo and that only flawed 
studies have shown CAM results to be superior to placebo results.  In support of this 
contention, Bausell cites Cochrane Collaboration database studies which found only 
5% of ninety-eight legitimate randomised and controlled published CAM studies 
showed greater than placebo effect.194-196  There is inherent bias and ignorance of 
clinical trial methodological issues such as the placebo effect, natural disease history 
and statistics in clinicians involved in CAM studies.  No CAM has scientific 
validation of mechanism of action beyond that of placebo, and there is a lack of 
understanding of parsimony, the elimination of variables,197 leaving the way open in 
trials for positive effects to be wrongly attributed to CAM.175  
 
2.15 CAM with evidence to treat cancer  
Anecdotal evidence and encouraging case studies for CAM, as pointed out by 
Bausell,175 have not been able to be repeated in more rigorous study settings.  When 
tested in rigorous clinical trials, no CAM cancer treatments alone has shown benefit 
beyond placebo175 and the use of CAM concurrently with conventional care has not 
yet been shown definitively to alter overall survival for the better.198  There have, 
however, been some encouraging studies for certain CAM when used as adjuvants 
with standard cancer interventions to treat cancer. For example, fish oil 
supplementation was found in a study to increase first-line chemotherapy efficacy in 
patients with advanced non-small cell lung cancer199 and polysaccharide K (PSK), a 
commercial extract of the mushroom Coriolus versicolor, has shown promise when 
used concurrently with chemotherapy to treat leukaemia, colorectal and gastric 
cancers.200  
 
2.16 CAM with evidence for cancer supportive care  
Ginger has been shown in a randomized, double-blinded trial to significantly reduce 
chemotherapy-induced nausea compared with placebo156 (Table 2.1) but this is the 
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only biologically-active CAM that has solid evidence for efficacy in cancer patients.  
Many cancer patients take a variety of biologically-active CAM, especially 
antioxidants, vitamins and minerals, to try to lessen chemotherapy side effects or to 
boost immunity; up to 80% of breast cancer women take antioxidants during cancer 
treatment for this reason.73  Robust human studies examining which antioxidants 
should be used, in what specific dose, for which chemotherapy and cancer type, are 
lacking at this time.  As antioxidant supplementation may reduce effectiveness of 
chemotherapy treatment, and in some circumstances hasten cancer growth and 
metastasis, they should not be recommended for use by patients receiving 
chemotherapy.73 
 
Table 2.1 Oral CAM with evidence for chemotherapy supportive care 
Symptom 
description 
Complementary medicine and evidence Reference 
Chemotherapy-
induced nausea 
Ginger 
• Significantly reduced chemotherapy-induced 
nausea compared with placebo in a randomized, 
double-blinded trial 
156 
Chemotherapy-
induced diarrhoea 
Probiotics/Yoghurt 
• Decreased fluorouracil chemotherapy-induced 
diarrhoea without toxicity 
201 
• Case report of death in a non-cancer, immune-
deficient patient receiving chemotherapy and 
steroids to treat an autoimmune disease. The 
patient ate self-selected supermarket yoghurt 
and succumbed to the Lactobacillus rhamnosus 
probiotic infection. 
202 
• Case report of sepsis infection by probiotic 
lactobacillus acidophilus in a patient with mantle 
cell lymphoma undergoing hematopoietic stem 
cell transplant. 
203 
Cachexia Fish oil supplement 
• Provided benefit over standard care to patients 
with non-small cell lung cancer through 
maintenance of weight and muscle mass during 
chemotherapy administration 
204 
 
Mind–body CAM can significantly reduce stress, enhance immunity and quality of 
life, and may increase length of survival for cancer patients74 (Table 2.2).  Mind–body 
therapy includes relaxation, meditation, imagery, hypnosis, biofeedback, self-
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expression, mild exercise, massage and acupuncture.  Although study evidence for the 
efficacy of mind–body therapies has been questioned due to the difficulty of 
producing, and often the lack of, study placebo controls,175 benefit over standard care 
is proven and mind–body CAM therapies are safe to use as adjuvants with 
chemotherapy.74  Also, certain mind-body CAM may be received at little or even no 
cost to the cancer patient, who may be experiencing financial difficulties.205 
 
Significant stress has been shown, in an animal study, to stimulate tumour growth 
through higher levels of cortisol and adrenaline diminishing immune function.206  
Stress is observed more in cancer patients who perceive themselves as helpless 
victims than those who see the disease as a challenge or opportunity to find what 
really matters in their lives.207  Mind-body CAM, which give cancer patients an 
opportunity to participate in their own care, may alter the patients’ view of their 
cancer to allow them to better deal with the stress cancer diagnosis brings.74  Cancer 
patients respond best to individualised mind-body CAM which caters for individual 
needs and preference.208 
 
Integration of massage therapy is advanced and is now an established subspecialty 
with published integration guidelines and training programs.209,210  Training of family 
members in safe and gentle massage may be a cost-effective option for patients and 
has been studied.211  Massage therapies which enhance cancer patients’ wellbeing are 
Swedish massage, aromatherapy massage, reflexology, acupressure and manual 
lymphatic drainage.212  
 
Acupuncture, part of TCM, has been practised for thousands of years in China and is 
defined as the insertion of one, or several, needles into the skin at particular sites 
called acupuncture points, for therapeutic purposes.  Acupuncture points may also be 
stimulated by variations within acupuncture: moxisbution (heat), acupressure, 
electroacupuncture and laser acupuncture.213  Acupuncture is integrated into 
conventional cancer care at institutions such as Memorial Sloan Kettering Cancer 
Center and M.D. Anderson Cancer Center.214 
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Table 2.2 Mind–body CAM with evidence for chemotherapy supportive care 
Mind–body CAM  Supportive care use Reference 
Acupuncture • Benefit for chemotherapy-induced 
acute vomiting 
215 
Acupressure (acupuncture 
points stimulated by 
pressure) 
• Benefit for chemotherapy-induced 
nausea and vomiting 
216 
Moxibustion (acupuncture 
points stimulated by heat) 
• Benefit for chemotherapy-induced 
acute vomiting 
217 
Mild exercise • Reduces fatigue and enhances life 
satisfaction 
• Yoga has been shown to be a useful 
practice for women recovering from 
breast cancer treatments to reduce 
stress, improve quality of life and well-
being, and to reduce persistent post-
treatment fatigue 
218 
219 
220 
Hypnosis • Decreased chemotherapy-induced 
nausea and vomiting 
221 
Imagery and relaxation 
(e.g. imagining immune 
cells as powerful medieval 
knights or big brooms 
dispatching cancer cells) 
• Modulates immune functioning during 
treatment 
222 
Massage • Decreased chemotherapy-induced 
nausea and vomiting 
223 
• Reflexology decreased anxiety during 
chemotherapy 
224 
Meditation • Shown to alter immune patterns by 
decreasing stress 
225 
• Decreases anxiety and depression 226 
Music • Reduces chemotherapy-induced anxiety 227,228 
Self-expression (includes 
written or verbal 
expression, artwork, 
humour and movement) 
• Written emotional expression has 
shown a positive effect on outlook and 
decreased dark feelings in patients with 
breast cancer 
229 
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2.17 Conclusion – where are the gaps in the literature? 
There are significant gaps in the literature on CAM efficacy, safety and potential to 
interact with chemotherapy. Cancer patients may be receiving CAM advice, which is 
not evidence-based, to use CAM at the time of receiving chemotherapy. Additionally, 
there is often a communication gap on CAM use between cancer patients and their 
conventional cancer care providers, especially cancer doctors, as cancer patients are 
reluctant to declare their CAM use (or intention to use) and expect their cancer doctor 
to ask them for this information.  
 
Cancer patients’ consumption of CAM may vary considerably over the duration of 
their cancer journey, and consideration is needed on what CAM is taken by cancer 
patients at the crucial time of receiving chemotherapy. This is particularly the case for 
patients being treated with curative intent for whom the accuracy of each dose is 
pivotal in providing treatment efficacy.  Beneficial effects of CAM may be attributed 
to the placebo effect175 and therefore a better understanding of the potential benefits 
of the placebo effect may enhance the cancer patient’s conventional therapy outcome.  
Similarly, the nocebo effect should be acknowledged and better understood, as 
negative comments directed at conventional medicine, if believed by the patient, may 
lessen the effectiveness of conventional interventions, or lead patients away from 
conventional medicine altogether.  Consideration should be given to how a potentially 
harmful biologically-active CAM that exhibits a positive placebo effect on a patient 
may be substituted with either biologically-active CAM with evidence for safety or 
with safe mind-body CAM to achieve the same beneficial effects. Better 
understanding of why cancer patients select CAM at this time may prepare 
conventional professionals to ask the right questions, have appropriate resources and, 
if needed, to effectively dissuade patients from biologically active CAM that may be 
detrimental to their treatment. 
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Chapter 3 
Research Questions,  
Aims, Objectives and Methods 
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3.1 Research questions 
The major research questions addressed in Chapter 4 focus on those people most at 
risk of compromising a potentially curative treatment, asking:  
1. to what extent do adult cancer patients receiving curative-intent chemotherapy 
potentially compromise their treatment and/or safety by using CAM,  
2. who influences adult cancer patients in their decisions to use complementary 
and alternative medicine (CAM) at the time of receiving chemotherapy,  
3. whether there is evidence of a need for an educational intervention to guide 
cancer patients on the safe use of CAM chemotherapy. 
Following on from this, as a suitable educational tool could not be located a brochure 
was designed as described in Chapter 5 and, using this brochure, Chapter 6 considers 
the question:  
4. To what extent is the potential for medical doctor recommendation and patient 
acceptance of a purpose designed patient educational brochure on the safe use 
of CAM with chemotherapy  
Finally, following dissemination of the brochure within one hospital cancer facility, 
Chapter 7 asked the question: 
5. To what extent does the availability of a purpose-designed brochure within a 
cancer service aid doctors’ discussions with their patients on CAM use and 
assist patients to understand the effects of CAM during their chemotherapy 
treatment? 
The major study described in this thesis (Chapter 4) is an observational study of CAM 
use by cancer patients receiving curative intent chemotherapy for the first time.  This 
is followed by the design and development of an information brochure (Chapter 5) 
and two quality assurance audit studies conducted during the development of the 
information brochure educational intervention (Chapter 6) and post-implementation 
(Chapter 7).  All studies were conducted at the Sunshine Coast Cancer Care Services 
Day Unit, Nambour Hospital, Queensland, Australia. These chapters have been 
published in peer-reviewed journals, and the methods for each study are contained in 
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the methods section of Chapters 4, 6 and 7.  The section that follows discusses the 
decisions involved in designing the studies in greater depth than contained in the 
relevant chapters. 
 
The overarching consideration during study design revolved around the findings of a 
meta-analysis of 30 years of study surveys of CAM use by cancer patients.  This 
found a variance in results explained by three basic methodological factors; whether 
the participants were interviewed face-to-face or had self-completed questionnaires, 
whether participants were provided with predefined lists of different CAM treatments 
or had to recall them without being prompted, and whether surveys restricted or 
expanded CAM use to certain CAM categories.230   
3.2 Chapter 4  
Aim  
To establish CAM use in a population sample of cancer patients commencing 
curative-intent chemotherapy. 
Objectives 
• Measure the number of study participants using CAM at the commencement 
of chemotherapy treatment. 
• Determine whether CAM assessed as having potential to interact with 
prescribed chemotherapy was used 
• Investigate CAM use by patients prior to cancer diagnosis 
• Determine whether patients used CAM for supportive care reasons or with the 
intention of treating their cancer. 
• Understand whether patients’ CAM decision making was influenced by advice 
from others 
• Consider whether CAM advisers were in favour of chemotherapy treatment. 
• Explore patient requirements for educational information on the safe use of 
CAM with chemotherapy  
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Methods 
A semi-structured interview method was used in preference to a self-completed 
questionnaire.  The self-completed questionnaire mode of data collection has a higher 
rate of missing responses and also reports a lower percentage of CAM use than 
interview-based surveys231 so a semi-structured interview performed at patients’ 
chair-side by the investigator on the day of the patient receiving chemotherapy was 
thought to assure greater accuracy.  The semi-structured interview method, using a 
trained, motivating interviewer can also increase item response rates, clarify 
ambiguous questions, and jog respondents’ memories for aiding recall of events and 
behaviour.230  The semi-structured interview method also enables the interviewer to 
better record CAM use by study participants, as patients’ conception of CAM may 
sometimes be different from that of health care professionals.232   
 
A limitation of the method used in the study in Chapter 4 was that interviewer-guided 
interviews on CAM may be biased by social desirability.  Studies suggest that 
respondents give more positive and socially desirable responses in interview surveys 
than in self-administration.233  For example, study participants may have assumed the 
interviewer to be in favour of CAM and bias their response accordingly.  However, 
this may not necessarily be the case for cancer patients using CAM, interviewed by a 
pharmacist, as it could also be argued that within a setting of conventional oncology, 
respondents are probably less willing to reveal CAM use fearing that this might be 
regarded as undesirable.230  With reference to this phenomenon, participants were 
informed through the patient consent form (Appendix A) and during interview that 
their study participation, and the findings on their CAM use, had absolutely no impact 
on their subsequent treatment or interaction with the cancer centre.  
 
Studies using a self-completed questionnaire to survey CAM use by cancer patients 
report a higher rate of CAM use when participants choose CAM treatments from a 
presented or prompted list rather than with free recall.230  This is consistent with 
questionnaire design on the recall of pharmacological treatments.234  Surveys that 
restrict CAM use to certain categories or treatments yield lower prevalence 
estimates235 and studies that include prayer as CAM substantially increase the CAM 
usage rate.236  It was therefore decided to perform the study using a semi-structured 
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interview method using a constructed questionnaire (Appendix B) that contained 
prompt lists from the standard clinical pharmacy medication history list (Appendix C) 
and a list developed from previous CAM research studies (Appendix B).  Prayer was 
excluded as CAM. 
 
The study in Chapter 4 was approved for commencement by Queensland Government 
Human Research Ethics Committee, The Prince Charles Hospital (Appendix D) and 
The University of Queensland School of Pharmacy Ethics Committee (Appendix E).  
National Low Risk Ethics Single Site Approval and local hospital governance 
approval was granted after signing of a legal agreement between the Sunshine Coast 
Hospital and Health Service and The University of Queensland (Appendix F). 
3.3 Chapters 6 and 7 
Quality assurance audit studies were conducted during the development of the 
information brochure educational intervention (Chapter 6) and post-implementation 
(Chapter 7). 
Aims 
Chapter 6: To investigate, using study samples of chemotherapy prescribers and 
patients receiving chemotherapy, key aspects of recommendation, content choice and 
acceptance of a purpose designed patient educational brochure on the safe use of 
CAM with chemotherapy. 
Chapter 7: To establish whether a purpose-designed educational tool used within a 
cancer service aided doctors’ discussions with their patients on CAM use and assisted 
patients to understand the effects of CAM during their chemotherapy including safe 
use. 
Objectives 
Chapter 6: 
• Determine cancer care doctors’ perception of the brochure’s need, potential 
recommendation and to which patient group/s  
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• Explore whether cancer patients receiving chemotherapy accept the 
educational interventional intervention information as relevant, easy to read 
and understand and whether it answered their CAM questions  
Chapter 7: 
• Determine whether cancer care doctors perceived a need for the patient 
educational tool, and recommended the brochure to their patients 
• Investigate whether doctors thought the brochure made it easier for them to 
discuss CAM with their patients 
• Consider whether doctors believed that the intervention saved them time 
during patient consultations 
• Explore whether cancer patients thought the brochure had enough information 
to answer their CAM questions  
• Examine whether patients thought the information was easy to read and 
understand 
Methods 
The studies in Chapters 6 and 7 assess the patient educational brochure intervention 
document work up (Appendix G) and post publication (Appendix H) implementation 
respectively.  These studies both contain two study participant population samples, 
health professionals and cancer patients, who were recruited to the study in the same 
way.  All prescribers of chemotherapy at the Sunshine Coast Cancer Care Services 
Day Unit, Nambour Hospital, Queensland, Australia were asked to participate, and 
consecutive cancer patients attending the unit were asked to participate.  One 
prescriber was excluded as he was a collaborator in this research.  As both studies 
were conducted at a single site, they have the limitation that cancer patients attending, 
and cancer doctors practising, at the Sunshine Coast Cancer Care Service may not be 
representative of patients and cancer consultants at other sites.  Indeed, Nambour 
hospital treats patients living on the Sunshine Coast of Queensland which is 
recognised to have a disproportionate population of alternative-thinking people as, in 
2012–13, the Sunshine Coast recorded the highest percentage of conscientious 
objection to vaccination in Australia for children aged 5 years, at 7.1%.237   
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Quantitative survey research methods were used in both studies, focusing on the 
collection and analysis of subjective data gained in the form of opinions self-reported 
in questionnaires by study participants.  While evidence from survey research is not as 
inherently strong as evidence from experimental research,238 this method was adopted 
for the studies in Chapters 6 and 7 to obtain meaningful quantitative assessments of 
subjective factors.  Another option may have been to use qualitative research methods 
through, for example, gathering cancer patient participants together in groups, or as 
one-on-one interviews either in person or via the telephone, to discuss , develop and 
extract thoughts from narrative explanations.238  The reason a qualitative approach 
was not adopted was for pragmatic reasons.  Prescribers are inherently extremely busy 
and so are difficult to schedule at a given time, so a tick and flick questionnaire to 
complete when they could and then to follow up, was felt most likely to ensure 
maximum participation and compliance with the return of their answers.  Similarly, a 
distributed questionnaire was thought most appropriate for patients due to them 
receiving chemotherapy treatment and having to contend with other associated 
medical interventions and appointments.   
 
For cancer patient participants in both studies, a self-completed questionnaire mode of 
data collection was used, in the form of a validated Health Service consumer testing 
feedback form (Appendix I).  The form was distributed to patient participants and 
they were given the option of either completing the feedback form at the day unit or 
returning the form by mail using a supplied prepaid envelope. For the health 
professional chemotherapy prescriber participants in both studies, a self-completed 
questionnaire mode of data collection was adopted, using questionnaires designed to 
obtain data that met the studies’ aims (Appendices J and K).  The questionnaire was 
distributed to staff participants and asked to return the completed form to the 
investigator personally, through postal mail or through email attachment.   
 
The Chapter 6 study was granted ethics exemption for publication by the Queensland 
Government Human Research Ethics Committee, The Prince Charles Hospital 
(Appendix L) and the Chapter 7 study was granted ethics exemption for publication 
by Queensland Government Human Research Ethics Committee, The Prince Charles 
Hospital and The University of Queensland School of Pharmacy Ethics Committee 
(Appendices M and N).  
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Complementary and alternative 
medicine use by patients receiving 
curative-intent chemotherapy 
 
 
The content of this chapter has been published as: 
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alternative medicine use by patients receiving curative-intent chemotherapy. Asia-
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4 Complementary and alternative medicine use by patients receiving curative-
intent chemotherapy  
 
Abstract 
Aim: To determine which types of complementary and alternative medicine (CAM) 
are being used by cancer patients commencing curative-intent chemotherapy, whether 
the CAM taken has the potential to affect treatment efficacy, the reasons for patients’ 
decisions to use CAM and whether these patients would like information on CAM 
safety with chemotherapy.  
 
Methods: 75 solid tumour malignancy patients receiving curative-intent treatment 
attending a cancer care day unit were interviewed about their CAM use on the day of 
receiving their first dose of chemotherapy. 
 
Results: 60% of study participants were using CAM at the start of chemotherapy 
treatment.  Biologically active CAM assessed as having potential to interact with 
prescribed chemotherapy was ingested by 27% of patients, all of whom had routinely 
used CAM prior to cancer diagnosis.  CAM was used by 51% of patients for 
supportive care reasons and by 28% of patients with the intention of treating their 
cancer. Patients’ CAM decision-making was influenced by advice from family and 
friends, practitioners, and from casual acquaintances.  13% of patients were told by a 
CAM advice-giver not to have chemotherapy.  The majority of patients (84%) would 
have liked to receive information on which CAM is safe to use with chemotherapy 
before treatment commenced.   
 
Conclusion: Patients being treated with curative intent, particularly those with a 
history of CAM use, may be taking biologically-active CAM with potential to 
compromise their chemotherapy treatment.  These patients want cancer-care health 
professionals to provide them evidence-based information on safe CAM use with 
chemotherapy and may be contending with alternative health advice to not have 
chemotherapy. 
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4.1 Introduction  
Complementary and alternative medicine (CAM) is defined as a broad and diverse 
group of treatments and products that are not widely used by conventional healthcare 
professions.78  CAM includes mind-body medicine such as meditation, massage and 
acupuncture, and biologically-active products such as herbs and vitamin supplements.  
Cancer patients, as in the general population, are most likely to use CAM if they have 
higher education, are female and have higher than average income.239  The majority of 
patients receiving chemotherapy will consider using CAM,6 and are likely to be 
receiving CAM advice from a variety of sources who may be particularly insistent 
and persuasive when they regard themselves as having CAM expertise, including 
family, friends, practitioners and even casual acquaintances.6,15,16  Many cancer 
patients take biologically-active CAM such as antioxidants with the intention of 
lessening side effects from chemotherapy or to “boost” immunity, with up to 80% of 
women with breast cancer taking antioxidants during cancer treatment,73 and curative-
intent patients may take herbal CAM in the hope of preventing adverse side-effects 
from their chemotherapy.66  In Australia, a significant proportion of cancer patients 
use at least one form of CAM, more often biologically based, with overall prevalence 
measured at 65%.6   
 
Curative treatment of most tumour types is based on the administration of multiple 
cycles of regularly scheduled chemotherapy.  Chemotherapy dose intensity, a function 
of dose and frequency of administration, has been shown to correlate with outcome 
for various tumour types in prospective clinical studies.240  For this reason, 
granulocyte-colony stimulating factor support is standard treatment in most curative 
treatments of breast cancer as it enables dose intensity to be kept constant, which 
significantly improves disease-free and overall survival.241  Conversely, anything that 
compromises dose intensity may reduce chemotherapy effectiveness.  Orally ingested 
herbal CAM may be able to affect cytochrome P450 enzymes and drug transporters 
which are involved in the metabolism of many anticancer drugs, and herbal CAM 
interactions with chemotherapy have been suggested to be responsible for a 
substantial number of unexpected toxicities and under-treatment seen in cancer 
patients.11,12  Few clinical studies have been performed to elucidate the effects of 
herbal CAM on the pharmacokinetics of anticancer drugs, and potential interactions 
are difficult to calculate as herbal supplements are often taken as complex mixtures of 
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biologically active constituents.13  For these reasons, it has been proposed that herbal 
CAM should be considered contraindicated for use by patients undergoing active 
treatment with conventional chemotherapeutic agents.116  Antioxidants are another 
group of products that are commonly used by cancer patients, but it has been 
proposed that any beneficial effects of antioxidant supplementation to reduce 
toxicity111 may be at the cost of diminishing the effectiveness of chemotherapy or 
radiotherapy by protecting tumour cells from oxidative damage.73,112-116  Indeed, 
cancer patients taking supplemental antioxidants to try to reduce side effects of 
adjuvant radiotherapy in a randomized placebo-controlled trial may have 
compromised radiation treatment efficacy.117  The primary mechanism of action of 
many chemotherapy agents, such as the alkylating agents, anthracyclines, podophyllin 
derivatives, platinum compounds and camptothecins, is the generation of reactive 
oxygen species (ROS), which induces apoptosis in cancer cells; antioxidants may 
inhibit ROS, thereby protecting the cancer cell from death.113,114  While a systematic 
literature review has proposed that no trials provide evidence of significant decreases 
in chemotherapy efficacy associated with antioxidant supplementation, most of the 
subjects had advanced or relapsed disease so this review is not applicable to patients 
with earlier, more chemo-sensitive disease such as in the curative population.118  To 
date, there is not sufficient evidence to determine whether antioxidants exert a 
positive or a negative effect with adjuvant cancer treatment.242  As there is no 
conclusive evidence sufficient to produce clinical guidelines on safe use,119 
antioxidant supplements should be avoided with chemotherapy agents that induce 
oxidative stress as the mechanism for anticancer activity.   
 
Considering the narrow therapeutic window of anticancer drugs, relatively small 
changes in dose intensity due to antioxidant activity or herbal interactions may 
compromise treatment effectiveness.  This is especially important in the curative-
intent patient population, as diminishment of chemotherapy dose may reduce effective 
dose intensity and hence adversely affect disease-free and overall survival.  This study 
aimed to elucidate which CAM are being used in a study sample of cancer patients 
entering curative-intent chemotherapy treatment, the influences on their decisions to 
use CAM and to identify, using the literature available, CAM taken which may 
compromise chemotherapy treatment.   
 
 62 
4.2 Methods 
4.2.1 Participants 
The study was conducted during the 12 month period from March 2013 to February 
2014, using adult patients attending the Sunshine Coast Cancer Care Services Day 
Unit.  To be eligible for the study, patients were diagnosed with a solid tumour 
malignancy and were receiving their first chemotherapy with curative intent.  Patients 
were excluded if they had previously commenced curative-intent chemotherapy 
elsewhere or were under 18 years of age.  Consecutive eligible patients were asked to 
participate in this study over the 12 month time period.  75 patients were eligible and 
agreed to participate.  One eligible patient (female, breast cancer) declined the study.  
19 eligible patients (14 female and 5 male; 12 breast, 5 colorectal, 1 testicular and 1 
oesophageal) were missed due to interviewer leave (Figure 4.1).  Each patient took 
part in the interview with the cancer pharmacist investigator immediately before 
chemotherapy administration and all patients gave written informed consent.  The 
study was approved by Human Research Ethics Committees at Queensland Health 
(The Prince Charles Hospital) and The University of Queensland.  A legal project 
agreement was signed between the Sunshine Coast Hospital and Health Service and 
The University of Queensland as a requirement for local hospital governance 
approval.   
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Figure 4.1: Patient recruitment during study period 
 
4.2.2 Interview procedure 
A purpose-designed interview guideline was developed based on previous literature to 
enable semi-structured patient interviews.  Questions identified participants’ socio-
demographic background (including marital status, household gross income, and 
educational level), previous CAM use and frequency, current CAM use (including 
ingested CAM use documented as part of the standard clinical pharmacy medication 
history service for day patients), CAM use declaration to conventional cancer health 
professionals, expected benefits from CAM use, side effect expectation from CAM 
use and source of influence on the CAM selected for use.  Study participants were 
asked whether the person giving CAM selection advice was in favour of them 
receiving chemotherapy.  Study participants were also asked whether they wished to 
receive information on which CAM is safe to use with chemotherapy.  Information 
regarding participants’ cancer type and stage, chemotherapy treatment, co-morbidities 
and any concurrent conventional cancer treatment information was obtained from 
existing hospital treatment records.  
Eligible patients 
(n = 95) 
 
Declined study 
(n = 1) 
 
Study participants 
(n = 75) 
 
Investigator leave 
(n = 19) 
 
Female 
(n = 53) 
 
Male 
(n = 22) 
 
Breast 
(n = 49) 
 
Colorectal 
(n = 4) 
 
Colorectal 
(n = 11) 
 
Testicular 
(n = 9) 
 
Oesophageal 
(n = 2) 
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4.2.3 Statistical methods 
The data were organised and where appropriate, trends were reported using simple 
descriptive statistics (mean (SD), median (IRQ) or proportions).  Continuous data 
were checked for normality using the Shapiro-Wilk test.  Binary comparisons were 
undertaken using either a standard unpaired t-test for normally distributed data or a 
Mann Whitney U-test for unpaired non-parametric or non-normal data.  One way 
ANOVA was used where three or more subgroups were present.  Logistic regression 
was employed to examine the relationship between the explanatory variable current 
CAM use and the predictor variables age, sex, marital status, educational standard, 
gross income, malignancy, tumour stage, the presence or otherwise of co-morbid 
disease and the prior use of CAM. A backwards elimination model was employed and 
interaction terms were inserted where necessary.  The significant results were 
expressed as the regression coefficient (β) and the associated P-value. 
Statistical analysis was performed using a propriety statistical package (STATA 
version 12.0) and the level of significance was taken as P < 0.05 throughout. 
 
4.3 Results 
4.3.1 Patient characteristics  
The majority of patients interviewed were female (71%) and breast was the most 
prevalent cancer type (65%), with 71% having a stage 1 or 2 cancer.  Ages ranged 
from 22 to 82 years with a mean of 54 and median of 55 years, 56% were married and 
71% had completed education at high school level or above.  There were a 
significantly higher proportion of females, married and high income participants in 
the CAM use group (Table 4.1). 
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Table 4.1 Demographic and clinical characteristics for all study patients and for 
those who used some form of complementary and alternative medicine (CAM) at 
the time of commencing chemotherapy treatment and those who did not.  
Characteristic n No CAM use (%) CAM use 
(%) 
P-value 
Total 75 30 (40.0) 45 (60.0)  
Prior CAM use    <0.001 
 yes 44 9 (30.0) 35 (77.8)  
 no 31 21 (70.0) 10 (22.2)  
Age (years) #  56.4 (12.5) 52.9 (11.4) 0.21 
 20-29 1 0 1  
 30-39 8 2 6  
 40-49 19 8 11  
 50-59 21 10 11  
 60-69 20 7 13  
 70-79 5 2 3  
 80-89 1 1 0  
Sex    0.03 
 Female 53 17(56.7) 36(80.0)  
 Male 22 13 (43.3) 9 (20.0)  
Marital status    0.02 
 Married  42 13 (43.3) 29 (64.4)  
 Defacto 7 1 (3.3) 6 (13.3)  
 Single 26 16 (53.3) 10 (22.2)  
Highest Education    0.08 
 Primary 7 4 (13.3) 3 (6.7)  
 Secondary year 10 14 8 (26.7) 6 (13.3)  
 Secondary 30 11 (36.7) 19 (42.2)  
 Secondary + TAFE 8 3 (10.0) 5 (11.1)  
 Tertiary 14 3 (10.0) 11 (24.4)  
 Post grad  2 1 (3.3) 1 (2.2)  
Household income (gross, AUD)   0.001 
 0-30 29 18 (60.0) 11 (24.4)  
 31-59 22 8 (26.7) 14 (31.1)  
 60-100 9 2 (6.7) 7 (15.6)  
 Over 100 15 2 (6.7) 13 (28.9)  
Malignancy    0.29 
 Breast 49 16 (53.3) 33 (73.3)  
 Colorectal 17 9 (30.0) 6 (13.3)  
 Oesophageal 2 1 (3.3) 1 (2.2)  
 Testicular 7 4 (13.3) 5 (11.1)  
Tumour Stage    0.34 
 I 14 7 (23.3) 7 (15.6)  
 II 39 10 (33.3) 29 (64.4)  
 III 22 13 (43.3) 9 (20.0)  
Co-morbidities    0.59 
 yes 45 18(60.0) 27 (60.0)  
 no 30 12 (40.0) 18 (40.0)  
 
# Age was normally distributed and is presented as mean (SD). 
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4.3.2 CAM use with chemotherapy  
60% (45/75) of study participants engaged in CAM use at the time of commencing 
chemotherapy treatment, of which most (41/45) orally ingested CAM (Table 4.2).  
Two variables were identified as significant to CAM use with chemotherapy: income 
(β = +0.76, P = 0.007) and routine prior use of CAM (β= +2.01, P < 0.001).  Patients 
ingesting CAM when starting chemotherapy consumed between 1 and 15 different 
CAM products with a median of 3 and mean of 4 products taken per patient.  Mind-
body CAM such as massage, meditation and acupuncture was used by 29% of all 
study patients for support (Table 4.2).  Only one patient expected to experience side-
effects from CAM use and this was weight loss through dietary alteration. 
 
Table 4.2 The number (and %) of patients using orally ingested and mind-body 
CAM at the time of commencing chemotherapy treatment, with potential effect 
or interaction indicated for each type based on information in the literature.  
 Type of CAM Number (%) 
of patients 
Comment 
Orally ingested CAM (n = 41)   
 vitamin supplements 23 (56%) potential decrease in therapeutic response 112 
 mineral supplements 19 (46%) - 
 herbal products  14 (34%) potential for interaction 11,13 
 fish/krill oil 13 (32%) potential chemo-resistance effect 243 
 probiotics 10 (24%) - 
 CoQ10 7 (17%) potential decrease in therapeutic response 112 
 turmeric 6 (15%) potential decrease in therapeutic response 244 
 medicinal mushrooms  4 (10%) - 
 ginger 3 (7%) may reduce chemotherapy-induced nausea 156 
 homeopathic preparations 3 (7%) - 
 glutamine 2 (5%) - 
 apricot kernels 2 (5%) potentially toxic 245 
 other:  
lemon/ sodium bicarbonate/ 
proprietary “alkaline” water, 
diluted sodium chlorite 
7 (17%) - 
Mind-body CAM (n = 22)   
 massage/ reflexology† 14 (64%) †benefit over standard care for chemotherapy 
treatment support 17,246   meditation† 7 (32%) 
 acupuncture/acupressure† 4 (14%) 
 yoga†  1 
 aromatherapy  4 (14%)  
 crystal healing 2  
 bowen therapy 1  
 reiki 1  
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Supplementary vitamins were taken for reasons other than treating a medical 
deficiency by 23 patients.  Of these, 3 patients took a single standard multivitamin 
daily for non-cancer reasons without further supplementation;  as in previous 
studies116,247,248 these patients were not assessed as having chemotherapy interaction 
potential, although any supplementation above normal dietary intake should be 
regarded with suspicion until further research proves safety.114  The other 20 patients 
(16 female, 4 male) were taking antioxidant supplements (vitamins A, C, E, beta 
carotene and coenzyme Q10) with potential to diminish their prescribed 
chemotherapy effect by protecting tumour cells from oxidative damage.112  All 20 
patients were taking antioxidant supplements with chemotherapy agents that induce 
oxidative stress for anticancer activity: alkylating agents, anthracyclines, podophyllin 
derivatives, and/or platinum compounds114 (Table 4.3).  
 
Table 4.3 The study patients who were at risk of diminished effectiveness of their 
chemotherapy through taking oral antioxidant supplements at the same time 
Cancer 
type 
F M Stage 
l 
Stage 
ll 
Stage 
lll 
Chemotherapy 
treatment  
Chemotherapy with 
potential for 
diminished dose 
intensity from 
antioxidant 
supplementation 
Breast 4 - 1 3 - AC;   4 cycles  
(+/- paclitaxel 
x 12) 
cyclophosphamide, 
doxorubicin 
Breast 4 - 1 3 - TC    4 cycles cyclophosphamide 
Breast 7 - - 6 1 FEC-D  6 
cycles   
(+ /- 
trastuzumab) 
epirubicin, 
cyclophosphamide 
Colorectal  1 3 - - 4 mod Folfox6  
12 cycles 
oxaliplatin 
Testicular  - 1 - - 1 BEP 5   4 
cycles 
etoposide, cisplatin 
Total 16 4 2 12 6   
 
The population of 20 patients taking antioxidant supplements with chemotherapy 
agents that induce oxidative stress encompassed all 14 patients who additionally 
ingested biologically-active herbal CAM (Table 4.4) in combinations for which it is 
difficult to predict potential chemotherapy interactions.13  Two of these patients 
undergoing platinum chemotherapy ingested fish oil supplements, which has induced 
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platinum chemo-resistance in mice243 and two additionally ingested potentially toxic 
apricot kernels.245   
 
Table 4.4 Details of the study patients found at risk of chemotherapy interaction 
through antioxidant and other biologically-active CAM ingestion, with their 
routine CAM use prior to cancer diagnosis 
Sex Malignancy Stage Biologically-active CAM 
ingestion  
at chemotherapy 
commencement 
Routine CAM use prior 
to cancer diagnosis 
f breast l vitamin A 
vitamin C 
vitamin E  
vitamin B 
complex 
melatonin 
homeopathy, chiropractor, 
bowen therapy, 
acupuncture 
regular vitamin/herbal 
supplements  
f breast l vitamin C 
vitamin E  
betacarotene 
resveratrol   
flaxseed  
hemp oil 
glutamine 
probiotic  
naturopaths  
regular vitamin/herbal 
supplements  
f breast ll vitamin C 
selenium  
sheep sorrel 
herb robert 
milk thistle 
astragalus  
cat’s claw 
burdock 
naturopaths  
regular vitamin/herbal 
supplements 
f breast ll vitamin C 
vitamin E  
bue-green 
algae  
milk thistle 
horny goat 
weed 
ashwagandha  
goldthread  
turmeric  
hawthorn  
grape seed  
boswellia  
flaxseed 
ginseng, 
panax  
quercetin  
bacopa  
hu zhang  
regular vitamin/herbal 
supplements (purchased 
through internet 
multilayer marketing 
scheme)  
f breast ll vitamin C 
vitamin E  
CoQ10  
beta-
sitosterol 
astragalus  
grape seed 
hu zhang  
turmeric  
coriolus 
mushroom 
maitake 
mushroom   
vitamin D 
folinic acid 
perilla 
chiropractor, naturopath, 
acupuncture, iridology  
regular vitamin/herbal 
supplements 
f breast ll CoQ10 
lycopene  
turmeric  
hu zhang 
ginseng, 
panax 
quercetin 
naturopath 
regular vitamin/herbal 
supplements 
f breast ll vitamin A 
vitamin C 
papain 
green tea 
chiropractor, acupuncture, 
naturopath  
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vitamin E 
betacarotene  
betaine  
liquorice 
fish oil 
regular vitamin/herbal 
supplements 
f breast ll vitamin C 
rosehips 
 
 
 
 
acupuncture  
chiropractor  
regular vitamin/herbal 
supplements (from friend 
through internet 
multilayer marketing 
scheme) 
f breast ll vitamin C  
CoQ10 
barley grass 
fish oil 
probiotic 
regular self administered 
herbs/teas, and special 
diets  
f breast ll vitamin C   
CoQ10  
chlorella  
bue-green 
algae  
turmeric 
vitamin D 
calcium 
zinc 
magnesium 
probiotic 
naturopath 
regular vitamin/herbal 
supplements 
f breast ll vitamin C 
vitamin E  
fish oil  
potassium 
vitamin D 
chiropractors  
acupuncture 
regular vitamin 
supplements 
f breast ll vitamin C  
reishi 
mushroom  
turmeric  
green tea 
apricot 
kernels 
homeopath  
chiropractor  
f breast ll vitamin C 
vitamin E  
coriolus 
mushroom 
shiitake 
mushroom 
reishi 
mushroom  
cordyceps 
mushroom  
bupleurum  
ginseng, 
panax   
zizyphus  
pinellia  
ginger 
green tea 
liquorice 
andrographis  
white 
soapwort 
picrorhiza  
lycopene  
turmeric 
scullcap 
osteopath,  naturopath,  
acupuncture,  homeopathy  
regular herbal 
supplements 
f breast ll vitamin A 
vitamin C 
vitamin E  
reishi 
mushroom  
shiitake 
mushroom 
coriolus 
mushroom 
bromelain 
green tea 
papain 
diosmin 
rutin 
quercetin 
chlorophyll  
aloe vera 
turmeric 
reiki, acupuncture, 
naturopath 
rebirthing practitioner 
regular vitamin/herbal 
supplements 
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f breast lll vitamin C  regular vitamin 
supplements  
m colorectal lll vitamin C 
vitamin E 
betacarotene 
CoQ10 
apricot 
kernels  
celery  
green tea 
fish oil 
bowen therapy, 
reflexology,  
chiropractor  
bach flower  
m colorectal lll vitamin C 
betacarotene 
CoQ10 
lycopene  
pau d’arco  
astaxanthin  
naturopath  
regular vitamin/herbal 
supplements  
f colorectal lll vitamin C  
bue-green 
algae  
 homeopathy naturopath  
regular vitamin 
supplements 
m colorectal lll vitamin C  
betacarotene 
CoQ10 
 
chiropractor  
acupuncture  
 
m testicular III vitamin C  
selenium 
“many” 
herbs  
(undeclared) 
vitamin B 
complex 
vitamin D 
magnesium 
fish oil 
regular vitamin/herbal 
supplements 
 
 
4.3.3 Motivation for CAM use  
CAM was used for supportive care reasons by 51% (38/75) of patients at 
commencement of chemotherapy treatment, the most popular being to try to improve 
the immune system (Figure 4.2).  Other supportive care motivations were to reduce 
stress, lessen chemotherapy side effects, improve chemotherapy effectiveness, feel in 
control, boost energy, and help sleep.  CAM was used by 21% (16/75) of patients to 
treat existing conditions unrelated to their cancer of which fish or krill oil (13/16) was 
the most popular.  Many patients altered their diet (41%) with the aim of living a 
healthier lifestyle and to ensure their cancer did not return after treatment.  Dietary 
modulation to eat more healthily was adopted by study participants through dietary 
advice from their CAM adviser/s, through self-motivation, or both. 
 
Cancer treatment was the reason for CAM use by 28% of study patients (21/75); 13 
patients used vitamin C, 4 patients took medicinal mushrooms and 2 patients took 
apricot kernels.  7 patients tried to treat their cancer by drinking lemon, sodium 
bicarbonate and/or proprietary “alkaline” water to try to change systemic pH or by 
taking diluted sodium chlorite labelled “liquid oxygen”.  Some patients altered their 
diet with the intention to treat or slow their cancer, with 13 patients stopping sugar 
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due to a belief that the removal of dietary sugar would “starve” cancer cells 
selectively and arrest cancer progression.  
0% 5% 10% 15% 20% 25% 30% 35%
improve immune system
live a healthy l ifestyle
treat cancer
treat unrelated condition
reduce stress 
lessen chemotherapy side effects
feel in control
improve chemotherapy effectiveness
boost energy
help sleep
manage disease symptoms
Percentage of all  patients
 
Figure 4.2 Reasons given by study patients for their CAM use at the time of 
commencing chemotherapy treatment  
 
4.3.4 CAM decision-making  
Patients’ CAM decision-making was influenced by advice from family and friends, 
practitioners (CAM and conventional) either formally or informally, and from casual 
acquaintances met in person or on the Internet.  Of the patients who engaged in CAM 
use, most were advised by friends (19/45) and/or CAM practitioners (19/45) of which 
most (13/19) were naturopaths.  Other patients were self-motivated (15/45); had 
received CAM advice from a general practitioner (7/45); were influenced by partners 
(7/45), the internet (6/45), books/magazines (5/45), cancer support groups (2/45) and 
3 patients received CAM advice from strangers; 2 randomly met in person and 1 on 
the internet. 
 
Ten (13%) of the patients were advised not to have chemotherapy treatment (Table 
4.5).  In some cases this advice was given by CAM practitioners (naturopaths, 
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chiropractors, aromatherapist), and other patients received this advice from a friend 
who relayed CAM advice from her naturopath, a de facto partner, a breast cancer 
friend who had surgery but rejected chemotherapy, a Facebook friend never met in 
person, and another by a friend who was self-treating his own prostate cancer (Table 
4.5).  
 
Table 4.5 The study patients who received advice not to have chemotherapy, 
showing their previous CAM use, treatment completion and CAM advice-giver 
Age Sex Malignancy Stage CAM advice-
giver against 
chemotherapy 
treatment 
Routine 
CAM use 
prior to 
cancer 
diagnosis 
Completed 
all cycles of 
chemotherapy 
47 f breast I friend yes yes 
47 f breast I naturopath yes yes 
62 f breast I naturopath yes yes 
39 f breast II facebook friend no yes 
45 f breast II friend yes yes 
56 f breast II aromatherapist yes yes 
65 f breast II chiropractor yes no 
70 f breast II naturopath and 
chiropractor 
yes no  
49 m testicular  II friend no yes 
67 m testicular III partner (defacto) yes yes 
 
4.3.5 CAM use declaration  
Of those patients taking oral CAM, 63% (26/41) declared their CAM use to a 
conventional health care provider relevant to their cancer care prior to study 
interview; 17 patients did so because they were asked, 6 didn’t want their CAM to 
interfere with chemotherapy, 1 patient to “make sure CAM would assist 
chemotherapy”, 1 patient because she wanted to know which other CAM could be 
recommended, and another patient because the cancer care patient booklet given in 
the nurse clinic recommended to do so.  Reasons for patients not declaring their oral 
CAM use was because about half (7/15) thought it harmless, one-third (5/15) because 
they were not asked, 2 because of perceived rejection and lack of interest by 
conventional health providers and 1 patient because he had been told not to as the 
CAM was banned in Australia.   
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4.3.6 Previous CAM use  
CAM was used routinely prior to cancer diagnosis by 61% (46/75) of patients, 
ranging from self-selected oral CAM, to regular visits to CAM practitioners such as 
chiropractors (13/75) and/or naturopaths (10/75) for CAM treatment and advice.  
Motivation for regular previous CAM use was to treat prior medical problems or for 
perceived maintenance of good health.  The remaining 39% of study patients had 
never or only rarely used CAM or consulted a CAM practitioner previously.  Routine 
prior use of CAM significantly predicted the use of potentially harmful biologically-
active CAM with chemotherapy (β= +3.13, P = 0.003).  The total number of 20 
patients who ingested CAM of concern with chemotherapy during the study had 
routinely used CAM before cancer diagnosis and treatment.  Conversely, none of the 
patients (0/29) who never or only rarely used CAM prior to cancer diagnosis were 
using CAM that was assessed as having the potential to modify chemotherapy 
effectiveness.  Routine prior use of CAM predicted the use of potentially harmful 
biologically-active CAM with chemotherapy (β= +3.13, P = 0.003). 
 
4.3.7 Patient CAM educational requirements  
The majority of study patients (84%) would have liked to receive specific information 
on which CAM is safe to use with chemotherapy, before treatment commencement.  
Most (55/63) preferred this information as a referenced guide, 7 of these patients 
wanted additional verbal advice and another 7 patients identified they would prefer 
sole verbal advice.  Patients wished to receive CAM safety information with 
chemotherapy at their initial oncologist consultation (46/55), either directly from their 
oncologist during the consultation (16/46), or either from their oncologist or other 
cancer care health professional (30/46) at that time. 
 
4.4 Discussion 
This is the first study the authors are aware of to examine CAM use exclusively in the 
adjuvant curative-intent patient population at the time of commencing chemotherapy 
treatment and to find that the routine use of CAM previous to cancer diagnosis is a 
predictor of the use of adjuvant CAM with potential to interact with chemotherapy.  
Study methods were aligned as much as possible to literature recommendations for 
CAM study survey quality230 and the study patients’ CAM ingestion was recorded by 
a recognised expert (pharmacist) using validated processes.249,250   
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Limitations of this study were the small sample size and that it was conducted at a 
single regional site, the Sunshine Coast Cancer Care Centre, so the validity of results 
may not necessarily be reflective of cancer patients from other day cancer centres.  In 
2012–13, fully immunised children aged 5 years living in the Sunshine Coast area was 
88% compared to the national average of 91.5%, and the Sunshine Coast recorded the 
highest percentage of conscientious objection to vaccination in Australia for children 
aged 5 years, at 7.1%.237  This may have implications for this study’s findings, as a 
negative association has been found between vaccination rates with patient care by 
CAM providers.251  Also, the study included a high proportion of female patients 
(71%) who are more likely than men to use CAM.239  Further external multiple site 
studies encompassing a broader population are required to substantiate the results. 
The prevalence of CAM use found in this study of 75 solid tumour cancer patients 
commencing curative-intent chemotherapy was 60%.  This is similar to the prevalence 
of CAM use in a general cancer patient population (65%) previously measured in a 
2010 Australian study.6  27% of patients in this study were taking biologically-active 
CAM which may have compromised  their chemotherapy treatment, a similar 
proportion to that found in a 2004 North American study on a mixed population of 76 
curative and non-curative adult cancer patients which identified 28% of patients at 
risk.97  A 2013 study of patients with ovarian cancer estimated 40% were at risk of an 
interaction between the CAM they were taking and their prescribed chemotherapy.116  
This higher rate may be due to all patients being female and to the inclusion of 
patients with progressive disease who have different motivation for CAM use 
compared to the curative-intent study population, such as taking CAM to improve 
quality of life and taking more CAM risks to try to increase chances of survival.69 
 
Prior CAM use has been significantly linked to CAM use with conventional cancer 
treatment39 and our study replicated theses results.   Indeed, all 20 patients found at 
risk of compromising chemotherapy effectiveness through CAM use in this study had 
routinely used CAM before cancer diagnosis and treatment and none of the patients 
who reported little or no previous CAM did so.  These results were found to be 
significant, which suggests there is an association between previous CAM use and the 
use of CAM of concern with chemotherapy.  This result may help cancer health 
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professionals better anticipate and preference CAM educational resources to previous 
routine CAM users. 
 
Motivation for CAM use by study participants was predominantly for supportive care 
reasons.  Mind-body CAM, mostly massage, meditation and acupuncture, was used 
by half of the study patients using CAM for supportive care treatment, showing that a 
significant proportion of patients seeking CAM are receptive to mind-body 
chemotherapy support.  Although mind-body CAM evidence has been questioned due 
to the difficulty of producing, and often the lack of, placebo controls,175 there is 
demonstrated benefit over standard care,74,246 and when applied by appropriately 
trained therapists using reasonable patient-specific precautions, is safe to integrate 
with chemotherapy.17  Mind-body CAM may therefore be an alternative option to 
effectively guide patients away from potentially harmful interactions from 
biologically-active CAM. 
 
CAM was being used to treat cancer by 28% of study participants.  This result, in a 
curative-intent population study sample, may reflect that some patients have an 
unrealistic expectation from CAM use and/or are not confident that their conventional 
treatment will be effective.  The most popular CAM for cancer treatment was oral 
vitamin C supplementation which does not have efficacy 252 and may compromise 
chemotherapy effectiveness.115  Apricot kernels, taken by two patients, are also 
without efficacy to treat cancer and potentially toxic.245  CAM used by patients for 
pseudoscientific reasons to treat cancer such as drinking squeezed lemons in water or 
taking sodium bicarbonate to treat cancer by attempting to change systemic pH, 
drinking liquid oxygen (sodium chlorite in water), or stopping sugar with the aim of 
selectively “starving” cancer cells may not be harmful in their own right; however, 
using exclusively to delay or forgo chemotherapy in the curative setting is the greatest 
danger to patients.   
 
Prior to commencing their chemotherapy treatment, 13% of study patients had 
received alternative health advice against having chemotherapy and to use CAM 
exclusively to treat their cancer.  A stage ll testicular seminoma patient was advised 
by a prostate cancer friend to reject chemotherapy and instead use a pseudoscientific 
cancer “cure” product (sodium chlorite in water) found on the internet.  Early stage 
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seminoma is a highly curable disease with conventional treatment.  Fortunately this 
patient did not follow his friend’s misguided advice and received the curative 
chemotherapy treatment.  This occurrence exemplifies how cancer type and stage 
difference may be misunderstood or discounted by cancer patients and people 
influencing them, and that curative-intent patients may be contending with alternative 
treatment advice that counters evidence-based information on cancer treatment and 
outcome expectation.   
 
The majority of patients taking oral CAM declared their use to a conventional health 
care provider when asked.  Only 15% were motivated to volunteer oral CAM use 
because they were unsure whether it would interfere with their chemotherapy.  This 
result is comparable to previous work that has shown cancer patients do not 
necessarily volunteer CAM consumption unless asked,11 and that cancer patients 
prefer their health care providers to initiate discussions regarding CAM use.15   
 
84% of all study participants, including some that were not taking CAM, indicated 
they would have liked to receive specific information on which CAM is safe to use 
with chemotherapy before treatment commencement, and most preferred this 
information as a referenced guide.  A recent US survey revealed that many 
oncologists do not initiate CAM discussions, even with their curative-intent patients, 
due to their perception of having inadequate CAM knowledge.247  Previous work 
indicates cancer patients would discontinue their CAM use or ask their consultant for 
advice if a detrimental chemotherapy interaction was suspected97 and patients 
receiving chemotherapy in a day unit readily stopped CAM that was identified to be 
problematic on the advice of their cancer pharmacist.253  Our study has shown that 
curative-intent patients (particularly those with a history of CAM use) may be taking 
CAM at risk of chemotherapy interaction and need to be educated that taking 
antioxidant supplements and/or herbal combinations with chemotherapy may 
compromise the effectiveness of their treatment.  Patient focussed CAM-
chemotherapy safety information resources may be an effective way for oncologists to 
explore CAM use with patients and disseminate this information.254 
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5 Patient brochure development  
Cancer patients require clear direction on CAM use integration to avoid biologically-
active CAM potentially interfering with the effectiveness of their chemotherapy 
treatment.  The curative-intent cancer patient study cohort (Chapter 4) reported that 
they would have liked to receive specific CAM-chemotherapy information, preferably 
in a written handout form, before commencement of chemotherapy treatment.  In an 
attempt to provide this information to all cancer patients receiving chemotherapy, 
including those with progressive disease, an evidence-based educational brochure was 
developed. 
 
5.1 Defining the content 
In order to make it an effective educational tool the brochure’s content required 
information acceptable to conventional cancer care professionals (especially 
prescribers of chemotherapy) for use in consultations, as well as information 
acceptable to patients.255  The brochure was formulated following guidelines for 
developing patient education handouts developed in the US by Tom Lang 
Communications and from the Health Literacy Checklist for Written Consumer 
Resources, developed by Melbourne Primary Care Network in Australia.255,256  These 
guidelines recommend that patient educational handouts be attractive to patients, not 
offend, be logically organised, visually appealing, use personal pronouns, contain 
awareness information rather than just facts, explain principles on why something 
works (or doesn’t), contain strong topic sentences, use illustrations, include simple 
tables and lists and provide additional readings on the topic.255  To reliably match 
patient educational tools with individuals, it is recommended that measuring the 
understanding of the actual target population is more acceptable than relying on 
readability formulas.257 Therefore, the brochure was developed, using recommended 
guidelines, with the intent to assess readability and acceptance through surveying a 
representative sample of cancer patients receiving chemotherapy, using an established 
consumer feedback form (Appendix I). 
 
The brochure was required to be brief, in order to not overwhelm patients already 
burdened by handout information, and to be as neutral as possible (neither supportive 
of, or against CAM use) to avoid alienating potential CAM users who may be 
receiving alternative CAM advice.258  It was decided to provide patients with 
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evidence-based guidance on CAM safety with chemotherapy, focussing on promoting 
patients’ CAM disclosure rather than arguing the limitations of biological CAM 
efficacy.  A statement was included advising that no CAM has efficacy to treat cancer 
and that delaying conventional treatment by using CAM first may compromise cancer 
outcome. In this way, a neutral, unbiased tone was imparted while retaining 
information with an evidence base. 
 
Mind-body CAM such as acupuncture, massage and meditation have efficacy, at least 
above standard care, to support patients during their chemotherapy treatment.  As 
mind-body therapies are able to be integrated with chemotherapy safely using 
appropriate patient specific precautions,17 they were recommended to patients in the 
brochure with the proviso that some (acupuncture, hypnosis and massage) need to be 
administered by trained practitioners.  In keeping with neutrality, other mind-body 
therapies safe to use with chemotherapy, but without an evidence base, were stated in 
the brochure as safe to use, but were not specifically recommended.  The same 
approach was taken for ingested CAM without biological activity, such as 
homeopathy.  It was important to mention CAM without compelling evidence, but 
considered safe to use with chemotherapy, as the positive response achieved through 
the placebo effect when treating conditions such as pain and depressive conditions, 
from which cancer patients commonly suffer, can be up to 50%.176  The rate of 
depression in cancer patients is three to five times higher than the general population 
and depression has been associated with increased mortality in breast cancer 
patients.259  
 
The only two biologically-active CAM products recommended in the final brochure 
publication were ginger, which has placebo-controlled trial evidence for 
chemotherapy supportive care to prevent nausea,156 and probiotics, which improved 
chemotherapy-induced diarrhoea in a randomised study of colorectal cancer 
patients.201  The probiotic recommendation included a warning for use, as there have 
been case studies of patients (severely immunocompromised) developing serious 
probiotic infections.202,260  Originally, fish oil was included as a recommendation due 
to its positive effect on countering cachexia in a lung cancer study,204 but was 
removed from the final brochure publication because of a study recommending 
avoidance of fish oil during chemotherapy due to its potential chemo-resistance 
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effect.243  In keeping with the evidence base, other biologically-active CAM were 
discussed in a “potential interactions” table, to explain to patients why these products 
may interact with chemotherapy and also to explain why they should not be used 
during chemotherapy treatment, or at least be considered with caution.  To capture 
patients who are going to take biologically-active CAM anyway, for example in the 
circumstance when conventional chemotherapy options offer little benefit, the 
brochure explains how patients should provide conventional providers with 
information on what CAM they are taking, to enable best care for them.  
 
The consumption of antioxidant supplements by cancer patients during chemotherapy 
treatment is popular but potentially problematic.  The brochure discusses antioxidant 
supplementation with chemotherapy, identifies it as a potential problem and provides 
explanations as to why it may diminish chemotherapy effectiveness.  It also points out 
that antioxidant-containing foods ingested in a normal diet are safe with 
chemotherapy.  
 
The brochure’s brief was to be short and concise and to put doubt into patients’ minds 
regarding the safety of biologically-active CAM, but not to address specific CAM 
products.  For patients requiring extra, more specific explanations on particular CAM 
products, the brochure included evidence-based CAM information internet resources, 
such as the Memorial Sloan Kettering Cancer Center and the National Cancer 
Institute, to guide them to safe, evidence-based sites.  
 
The layout of the brochure was intended to maximise the inclusion of information in 
easy to read tabular form, with the intention of providing CAM recommendations and 
precautions in an easily accessed format.  An evaluation study was performed before 
the brochure went to print (Chapter 6), and minor alterations were made to 
accommodate doctor and patient feedback.   
 
5.2 Publication process 
After the brochure evaluation study, the brochure information transferred neatly into 
an eight page, A5 booklet.  The Sunshine Coast Hospital and Health Service 
(SCHHS) publishing unit added typeset and design features in neutral and calming 
colour schemes, with author consultation (Appendix H).  Before the publishing 
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process began, required approvals were gained through completion of relevant 
documentation including a publication request approved by the Clinical Director of 
Cancer Care and the Medical Service Director at the Sunshine Coast Hospital and 
Health Service, Queensland, Australia.  In September 2014, 300 copies of the 
brochure were printed for use at the Sunshine Coast Cancer Care Service (Nambour 
Hospital, Queensland, Australia).  Due to its popularity, both with health professional 
staff and patients in the unit and other interested parties (for example, private 
clinicians, academics and community cancer care organisations), a further 800 have 
been printed to date.  
 
The brochure is now available as an online resource on the Queensland Health 
intranet.  Other health and hospital services have shown interest in using the brochure 
in their cancer centres.  It is possible for these districts to liaise with the SCHHS for 
permission to print the brochure with their own health service logo added to the front 
cover. 
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6 Evaluation of a patient CAM-with-chemotherapy educational brochure  
 
Abstract 
Biologically-active CAM may detrimentally interfere with chemotherapy treatment, 
so cancer patients require targeted, evidence-based information on chemotherapy-
CAM integration consequences. The object of this study was to investigate the 
potential for medical doctor recommendation and patient acceptance of a purpose 
designed patient educational brochure on the safe use of CAM with chemotherapy.  
Cancer care doctors (n=17) were provided a draft version of a patient educational 
brochure developed by the authors and completed a structured feedback form.  Cancer 
patients receiving treatment (n=12) were provided with the brochure and completed 
the local health service consumer testing feedback form. All 17 doctors perceived a 
need for the brochure and all would recommend the brochure to their patients. 
Approximately 59% of doctors indicated they would recommend the brochure to all 
patients receiving chemotherapy and 41% preferred that only patients using CAM or 
who enquired about CAM be given the brochure.  Cancer patients receiving 
chemotherapy reported the brochure information answered their questions and was 
easy to understand. This evidence-based CAM-chemotherapy patient brochure may be 
a useful adjunct for use by cancer care health professionals to educate patients on the 
potential dangers of biologically active CAM use with chemotherapy and to provide 
patients with safe CAM alternatives.  
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6.1 Introduction 
The majority of patients receiving chemotherapy will consider taking complementary 
and alternative medicine (CAM)6 at some time during their treatment.  CAM is 
defined as a broad and diverse group of treatments and products that do not tend to be 
widely used by conventional healthcare professions.78  Biologically-active CAM have 
the potential to interact with conventional medicines, including anti-neoplastic 
treatments11 and herbal CAM interactions with chemotherapy have been estimated to 
be responsible for a substantial number of unexpected toxicities and possible under 
treatment of some cancers.12  Studies on patients receiving chemotherapy have 
concluded that one-quarter of patients taking biologically-active herbal and/or vitamin 
supplemental CAM are at risk of a clinically relevant interaction.97,261  
 
Mind-body CAM has shown efficacy in supportive care for patients receiving 
chemotherapy and when applied by appropriately trained therapists, using reasonable 
patient specific precautions, is safe to use at that time.17  Mind-body therapy CAM is 
a safe option for cancer patients who wish to use CAM during chemotherapy. 
 
Patients would like to receive specific information on which CAM is safe to use with 
chemotherapy before their treatment commences.261  The purpose of this study was to 
evaluate the acceptance by doctors and consumers of an evidence-based brochure 
designed to provide answers to common questions chemotherapy patients have about 
CAM use with chemotherapy.  
 
6.2 Methods 
An educational brochure was developed by the authors (Appendix G) with the aim of 
providing a tool for use by cancer care doctors and associated cancer health 
professionals to give evidence-based guidance to patients on CAM use with 
chemotherapy.  Eighteen doctors at the Sunshine Coast Cancer Care Service 
(Nambour Hospital, Queensland, Australia) were asked to provide feedback 
concerning the draft patient brochure through completing a structured feedback form.  
One doctor did not return the feedback form.  Six oncologists, two oncology training 
registrars, five haematologists, two haematology training registrars and two general 
rotational hospital registrars gave written feedback. Following doctor feedback, the 
draft brochure was submitted to the local health service publishing unit for 
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publication.  The relevance, clarity, presentation, readability and acceptance of the 
brochure were tested through distribution to 12 chemotherapy patients (Table 6.1) 
who each completed the Sunshine Coast Hospital and Health Service consumer 
testing feedback form.  
 
Table 6.1 Demographic characteristics of the chemotherapy patients surveyed 
(n=12). 
Characteristics n 
Age, years  
 31-40 1 
 41-50 4 
 51-60 2 
 61-70 5 
Sex  
 F 7 
 M 5 
Highest level of education  
 Left school before year 10 1 
 Secondary (year 10) 4 
 Secondary (year 12) 3 
 Tertiary 4 
 
6.3 Results 
6.3.1. Doctor feedback 
All 17 doctors thought there was a need for the brochure and responded that they 
would recommend the brochure to their patients (Table 6.2).  Approximately 59% of 
doctors said they would recommend the brochure to all patients receiving 
chemotherapy but 41% preferred that only patients using CAM or asking about CAM 
be given the brochure.  Two doctors preferred to personally give the educational 
CAM brochure to the patient, seven at nurse education clinic, three by the doctor or at 
nurse clinic and five by doctor, nurse clinic or other cancer care health professional.  
No doctors sought to limit the brochure to early stage/ curative intent patients.  
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Table 6.2 Doctor feedback with breakdown in terms of medical specialty. 
 Oncologist 
n= 6 
Haematologist 
n= 5 
Oncology 
Registrar 
n= 2 
Haematology 
Registrar 
n= 2 
Rotational 
Registrar 
n= 2 
Total 
n= 17 
 Yes No Yes No Yes No Yes No Yes No Yes No 
Do you think there is a need 
for this brochure? 6 - 5 - 2 - 2 - 2 - 17 - 
Would you recommend this 
brochure to your patients?  6 - 5 - 2 - 2 - 2 - 17 - 
Which patients receiving chemotherapy would you recommend this brochure to? (more than one answer if required) 
All patients 4 3 1 2 1 10 
Patients /carers who ask 
about CAM or using CAM 
3 2 1 0 1 7 
Only early stage/curative 
intent patients 
- - - - - - 
Other (specify) - - - - - - 
Who should give this brochure to the patient?  (more than one answer if required) 
Treating consultant/ 
registrar 
4 2 2 0 1 9 
Nurse clinic  4 5 2 2 2 14 
Other cancer care 
professional (specify) 
1 
(pharmacist) 
1 
(any) 
1 
(pharmacist) 
0 1 
(any) 
4 
General practitioner   0 0 0 0 1 1 
Other (specify) 1 
(any health 
practitioner 
that finds out 
patient using 
CAM) 
0 0 1 
(with other 
handouts in 
patient pack) 
0 2 
 
Feedback received from doctors on the brochure wording and/or phrasing, when 
thought appropriate by the authors, was incorporated into the brochure. A 
haematologist indicated that it “May be worth noting that “invasive” mind-body 
techniques (eg acupuncture) could be an issue in [a] setting of low platelets etc” but 
did note the limitation for such details within the brochure’s scope and intended broad 
message.  Another clinician was concerned “some fish oils have antiplatelet effect 
and could be an issue with haematology patients with low platelets”.  A fish oil 
caution was not included in the brochure because at risk patients are closely 
monitored, the antiplatelet effect is not great (10 g of fish oil per day has less effect on 
platelet function than 100 mg of aspirin given intravenously262) and dietary fish oil 
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may be consumed in amounts similar to standard supplements.  One doctor sought 
inclusion of B group vitamins and vitamin E for the treatment of peripheral 
neuropathy; however, a 2008 Cochrane review concluded insufficient evidence for the 
use of vitamin B,263 and vitamin E may have chemotherapy interaction 
complications.114  Another prescriber’s suggestion of adding grapefruit prohibition 
was not considered within the brochure brief. 
 
Doctors were generally positive when optional extra feedback was given: Some 
comments are presented here: 
“I think it is just right- short and balanced” 
“Overall, great idea and good brochure” 
“Good amount of writing. Messages are clear” 
“Well put together brochure. Definitely useful” 
“Excellent idea. I liked it. So many patients ask questions which this brochure 
is going to answer.” 
“Definitely a topic poorly understood by many patients and doctors/ health 
care professionals. Patients often ask about the benefits/risks associated with 
CAMs during chemo. This brochure will help.” 
One doctor criticized the brochure for being too academic; “Needs editing for 
English-it’s written in academic English, needs to be properly edited for patient 
reading”. However the brochure was considered to be appropriate by the authors and 
so few changes were made; the brochure was instead submitted for publication and 
subsequent consumer testing to determine if it was understandable. 
 
6.3.2 Patient feedback 
Patients were generally enthusiastic about the brochure and all 12 found the 
information clear and easy to understand.  All patients thought the information was 
relevant to them and that the brochure contained enough information to answer their 
CAM questions (Table 6.3). 
“It’s a great little book- a good size that you would read because it is not 
over- involved. It’s matter-of-fact and gives you what you need to know in an 
easily understandable read. I think I would’ve found this booklet very 
beneficial when I started my regime.” 
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“To all concerned with the research of the publication of this information- 
well done” 
“I found it a great and informative book: clear and to the point, thank you” 
 
Additional patient feedback indicated that the main messages in the brochure, that 
biologically active CAM may interact with chemotherapy and should be declared to 
conventional health professionals, were understood: 
“I would certainly ask more questions of the nursing staff/GP/specialist “ 
“Just check with your specialist first to make sure it’s not going to have adverse 
reaction with the chemo” 
 “Talk to your doctor, ask questions about CAM, tell your doctor if you are taking any 
CAM” 
“I was unaware that using “natural” remedies antioxidant, herbs could be counter 
productive.” 
 
The brochure was also effective in making patients aware that CAM therapies are 
effective and safe to use for support during chemotherapy treatment: 
“Complementary therapies can work” 
“Good to know about the yoga and other things which won’t affect the chemo 
but could be substantially helpful with your wellbeing” 
“Would certainly look into more of the massage, reflexology etc, also the 
meditation and yoga” 
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Table 6.3 Patient feedback, with breakdown in terms of gender and patient 
malignancy (Haem = Haematology; Oncol = Oncology), and numbers indicating 
those who answered yes (Y), no (N) or did not answer the question (na). 
 Total 
n=12 
Female 
n=7 
Male 
n=5 
Haem 
n=4 
Oncol 
n=8 
Y N/na Y N/na Y N/na Y N/na Y N/na 
Did you find the information 
clear, easy to read and 
understand?  
12 0/0 7 0/0 5 0 4 0/0 8 0/0 
Was there enough 
information to answer your 
questions?  
12 0/0 7 0/0 5 0 4 0/0 8 0/0 
Did the information explain 
medical terms well? 
12 0/0 7 0/0 5 0 4 0/0 8 0/0 
Do you believe this 
information is relevant to 
you? 
12 0/0 7 0/0 5 0 4 0/0 8 0/0 
Is the content culturally 
sensitive and appropriate? 
10 0/2 5 0/2 5 0 3 0/1 7 0/1 
Is the design appropriate and 
appealing? 
12 0/0 7 0/0 5 0 4 0/0 8 0/0 
Is the design clear, 
uncluttered, and easy to 
follow? 
12 0/0 7 0/0 5 0 4 0/0 8 0/0 
Is the print large and clear 
enough? 
12 0/0 7 0/0 5 0 4 0/0 8 0/0 
Did the photos and 
illustrations help you 
understand the information? 
11 0/0 6 1/0 5 0 3 1/0 8 0/0 
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6.4 Discussion 
The evidence-based educational brochure was designed to be brief and as neutral as 
possible; neither supportive of, or against CAM use.  The authors deemed this 
necessary to not alienate potential CAM users who may be receiving alternative CAM 
advice.17  Chemotherapy patients are likely to be contending with CAM advice from a 
variety of sources including family, friends, practitioners and even casual 
acquaintances, who may be particularly insistent and persuasive when they regard 
themselves as having CAM expertise.6,10,16,261  Conventional health practitioners need 
to provide evidence based CAM information to chemotherapy patients to counter 
CAM misconceptions patients may have and to guide patients away from taking CAM 
which may be potentially detrimental to their treatment.   
 
All cancer care doctors indicated they would use the brochure for their patients.  A 
proportion of doctors wanted only patients asking about or using CAM to receive the 
brochure.  These doctors were concerned that giving CAM information to patients 
may be misconstrued as being promotional of CAM use with chemotherapy and one 
patient did report she would look into more mind-body CAM and supplements that 
may help if she were able to take them, as a result of reading the brochure.  If only 
patients who ask about CAM were offered the brochure, patients in need of CAM 
guidance with chemotherapy may be missed; cancer patients do not necessarily 
volunteer their CAM consumption unless asked,11 prefer their health care providers to 
initiate discussions regarding CAM use,15 want safety information regarding CAM 
with chemotherapy before they start treatment,261 and make CAM decisions at the 
same time as standard medical decisions.10  
 
Though there are existing general information resources on CAM use, chemotherapy 
patients want to receive specific evidence-based information on CAM use at the time 
of receiving chemotherapy.261  This small population study demonstrated that a 
brochure showed promise in providing cancer patients’ educational requirements on 
the safe use of CAM with chemotherapy and may be a useful tool for use by cancer 
care health professionals to educate patients on potential dangers of biologically 
active CAM use with chemotherapy and to provide patients with safe CAM 
alternatives if required.  
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7 The use of a brochure to enable CAM-with-chemotherapy patient education 
 
Abstract 
The majority of cancer patients receiving chemotherapy will consider taking 
complementary and alternative medicine (CAM) during their treatment.  As 
biologically-active CAM may detrimentally interfere with chemotherapy treatment, 
cancer patients require evidence-based information on chemotherapy-CAM 
integration consequences.  This study aimed to assess if the availability of a purpose-
designed brochure within a cancer service aided doctors’ discussions with their 
patients on CAM use and helped patients understand the effects of CAM during their 
chemotherapy treatment.  Cancer care doctors consulting in an adult day unit 
completed a structured post-intervention feedback survey form (n=17), and cancer 
patients receiving chemotherapy treatment were provided the brochure and completed 
the local health service consumer testing feedback form (n=30).  All cancer care 
doctors perceived a need for the brochure, and recommended the brochure to their 
patients.  All doctors thought the brochure made it easier for them to discuss CAM 
with their patients and 59% believed that it saved them time during patient 
consultations.  90% of cancer patients reported the brochure had enough information 
to answer their CAM questions and all patients thought the information was easy to 
read and understand.  An evidence-based CAM-with-chemotherapy patient brochure 
was perceived to have enabled cancer care doctors to discuss CAM with their patients 
and to have answered patients’ CAM questions. 
 
7.1 Introduction 
A recent US survey revealed that less than half of oncologists initiate complementary 
and alternative medicine (CAM) discussions with their patients, mainly due to a 
perception of having inadequate CAM knowledge.264  CAM is defined as a broad and 
diverse group of treatments and products that are not widely used by conventional 
healthcare professions.2  The term CAM is used for the purpose of this study; 
however, of note is that The National Center for Complementary and Alternative 
Medicine (NCCAM) has changed its name to National Centre for Complementary and 
Integrative Health (NCCIH) and uses the term “integrative” in preference to 
“alternative”.  The majority of patients receiving chemotherapy will consider utilizing 
CAM at some time during their treatment6 and even curative-intent patients, who 
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require assured dose intensity for best outcomes,240 may be using CAM with potential 
to compromise the effectiveness of their chemotherapy treatment.258  As one-quarter 
of patients taking herbal and/or vitamin supplemental CAM are at risk of a clinically 
relevant interaction with their chemotherapy,97 it is important that patients receive 
evidence-based information on the potential consequences of chemotherapy-CAM 
integration. 
 
Cancer patients may be contending with pseudoscientific alternative treatment advice, 
from family, friends or CAM practitioners, that counters evidence-based information 
on cancer treatment and outcome expectation.258  Cancer care health professionals 
should therefore openly discuss CAM with their patients and ensure evidence-based 
CAM information is offered to them.265  Though there are existing general 
information resources for cancer patients on CAM use, targeted education addressing 
CAM use during active treatment is required.  Over 80% of curative-intent cancer 
patients indicated that, before treatment commences, they would like specific 
information on which CAM is safe to use with chemotherapy.258   
 
In an endeavour to provide CAM-chemotherapy information to cancer patients, an 
evidence-based educational brochure was developed based on current evidence.  
Information needed to be acceptable to both conventional cancer care professionals 
(especially prescribers of chemotherapy) and also to cancer patients, to make it an 
effective educational tool.255  The brochure was also required to be brief, to not 
overwhelm patients already burdened by handout information, and to be as neutral as 
possible, neither supportive or against CAM use, to avoid alienating potential CAM 
users who may be receiving alternative CAM advice.  To keep the brochure concise, it 
was decided to provide patients with evidence-based guidance on CAM safety with 
chemotherapy; to promote caution and CAM disclosure rather than argue the 
limitations of biological CAM efficacy.  A statement was included to the effect that 
no CAM has efficacy to treat cancer and that delaying conventional treatment by 
using CAM first may compromise cancer outcome.  In this way, a neutral, unbiased 
tone was imparted while retaining information with an evidence base. 
 
Mind-body CAM therapies such as acupuncture, massage and meditation have 
efficacy, at least above standard care, to support patients during their chemotherapy 
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treatment.17  As mind-body CAM therapies are able to be integrated with 
chemotherapy safely, when applied by appropriately trained therapists using 
reasonable patient specific precautions, they were recommended to patients in the 
brochure.  Other mind-body CAM safe to use with chemotherapy but without an 
evidence base were listed in the brochure as safe to use with chemotherapy, but were 
not specifically recommended.  The same approach was taken for ingested CAM 
without evidence for biological activity such as homeopathy.  In this way, CAM that 
is without compelling evidence but is safe to use with chemotherapy was included in 
the brochure because patients who wish to use it may benefit from a placebo effect; 
the positive response achieved by placebo when treating conditions such as pain and 
depression, from which cancer patients commonly suffer, can be as high as 50%.176   
 
The only two biologically-active CAM products included in the final brochure as 
recommendations were ginger, which has placebo-controlled trial evidence for 
chemotherapy supportive care to prevent nausea,156 and probiotics, which improved 
chemotherapy-induced diarrhoea in a randomised study of colorectal cancer 
patients.201  The probiotic recommendation in the brochure included a warning to not 
use if very ill as there are case studies of patients (severely immunocompromised) 
developing serious infections associated with probiotic use.202,260  Originally, fish oil 
was included as a recommendation due to its positive effect on countering cachexia in 
a lung cancer study,204 but was removed from the brochure because of a recent study 
recommending fish oil be avoided during chemotherapy due to its potential chemo-
resistance effect,243 though more research is required to support this associative 
study’s negative finding.  Other biologically-active CAM were included in a 
“potential interactions” table, to explain to patients why these products may interact 
with chemotherapy and also to explain why they should not be used or at least be 
considered with caution.  The consumption of antioxidant supplements during 
chemotherapy treatment is popular but potentially problematic.112  The brochure 
identifies antioxidant supplementation with chemotherapy as a potential problem and 
provides an explanation why it may diminish chemotherapy effectiveness.  To capture 
patients who are going to take biologically-active CAM anyway, for example in the 
circumstance of conventional chemotherapy options offering little benefit, the 
brochure explains in a final statement that patients should provide their cancer 
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specialist or pharmacist with information on any CAM they are taking to ensure the 
best care can be provided for them.   
 
The layout of the brochure was intended to maximise the inclusion of information in 
easy to read tabular form, with the intention of providing CAM recommendations and 
precautions in an easily accessed format.  The design, content and potential, 
acceptance of the first edition of the brochure was assessed prior to 
implementation,254 and a second edition incorporating minor changes was then 
published and distributed.  In the present study we describe cancer doctors’ 
acceptance and use of the brochure in an adult day cancer centre and assess whether 
the brochure helped cancer patients understand the effects of CAM use during their 
chemotherapy treatment. 
 
7.2 Methods 
A published educational brochure (Appendix H) in use at the Sunshine Coast Cancer 
Care Service (Nambour Hospital, Queensland, Australia) for 6 months was assessed 
in April 2015 by cancer care doctors who prescribe chemotherapy (oncologists, 
haematologists and registrars) and adult patients receiving chemotherapy in the cancer 
day unit.  All cancer doctors were asked to provide feedback concerning their use of 
the patient brochure through completing a structured feedback form.  Questions 
included whether the brochure is needed, was being recommended by them to 
patients, whether the brochure made it easier for them to discuss CAM with patients 
and whether the brochure saved them time during consultations.  Doctors were also 
asked whether all or just certain populations of their patients receiving chemotherapy 
were offered the brochure.  Other questions to doctors elicited their opinion on who 
should distribute the brochure to patients, recommended changes to the brochure and 
any other feedback.  The relevance, clarity, presentation, readability and acceptance 
of the brochure were tested through distribution to consecutive day unit cancer 
patients receiving chemotherapy, who completed the Sunshine Coast Hospital and 
Health Service consumer testing feedback form.  Participants were given the option of 
either completing the feedback form in the day unit or through returning the form by 
mail using a supplied prepaid envelope.  The study was granted ethics exemption for 
publication by Human Research Ethics Committees at The Prince Charles Hospital 
and The University of Queensland.   
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7.3 Results 
7.3.1 Doctor feedback 
Six oncologists, 2 training oncology registrars, 6 haematologists, 3 haematology 
registrars (1 training and 2 general) gave written feedback.  One doctor (general 
registrar) did not return the feedback form.  All 17 cancer care doctor participants 
thought there was a need for the brochure, reported that they recommend the brochure 
to their patients, and thought the brochure made it easier to discuss CAM with their 
patients (Table 1).  Over half (59%) reported that it saved them time during patient 
consultations, however 29% disagreed and two were not sure whether it saved 
consultation time as they had not used the brochure enough.  Of those that disagreed, 
one oncologist commented that, “checking specific medications or supplements 
requires a review of more detailed/ specific information on the product which is not in 
the scope of the booklet”, and another oncologist thought the brochure took more 
consultation time because it “has led to discussion which previously patients may not 
have raised with the medical team”. Only 35% of doctors indicated that they 
recommend the brochure to all patients receiving chemotherapy, preferring to provide 
it to patients that they were aware were taking CAM (59%) or patients/carers who 
asked about CAM (70%).  Almost all of the doctors (88%) believed the treating 
doctor should give the brochure to their patients, though most doctors (70-76%) 
thought a variety of sources would be appropriate to distribute the brochure to their 
patients, including nurses and pharmacists involved in providing care, and displaying 
the brochure in the clinic waiting area.  The clinic education nurse received the most 
votes (53%) as the preferred person to distribute the brochure to patients (Table 7.1).  
No doctors sought to limit the brochure to early stage/ curative-intent patients.  
Additional written doctor feedback is listed in Supplementary Table 7.1. 
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Table 7.1 Doctor feedback with breakdown in terms of medical specialty and numbers 
indicating those who answered yes (Y), no (N) or did not answer the question (na)  
 Oncologist 
 
n= 6 
Haematologist 
 
n= 6 
Oncology 
Registrar 
n= 2 
Haematology 
Registrar 
n= 3 
Total 
 
n= 17 
 Y N Y N/na Y N Y N/na  Y N/na 
Do you think there is a need 
for this brochure? 6 - 6 - 2 - 3 -  17 0 
Do you recommend this 
brochure to your patients? 6 - 6 - 2 - 3 -  17 0 
Do you think the brochure 
makes it easier for you to 
discuss CAM with your 
patients? 
6 - 6 - 2 - 3 -  17 0 
Has the brochure saved you 
time during patient 
consultations?  
5 3 4 1/1 2 - 1 1/1  10 5/2 
all patients receiving 
chemotherapy 
    2      3     0     1          6 
patients you know are using 
CAM 
    3      4     2     1        10 
patients/carers who ask about 
CAM  
    5      3     2     2        12 
only early stage/curative intent 
patients 
     -      -      -     -          0 
I wouldn’t recommend it to 
any patients 
     -      -      -     -          0 
other       -       1      -     -          1 
treating consultant/ registrar      6       5      2     2        15 
nurse at clinic education      5       4      2     1        12 
any nurse in  cancer care day 
unit 
     5       5      1     1        12 
cancer pharmacist      5       5      2     1        13 
any health professional in 
cancer care day unit  
     2       6      1     3        12 
displayed in day unit waiting 
room (for anyone to take) 
     5       5      2     1        13 
general practitioner        1       4      1     1          7 
other (specify)      0       0      0     0          0 
treating consultant/ registrar      1        -      1     1          3 
nurse at clinic education      5        3      -     1          9 
any nurse in  cancer care day 
unit 
     -        -      -     -          0 
cancer pharmacist      -        2      1     -          3 
any health professional in 
cancer care day unit  
     -        -      -     1          1 
displayed in day unit waiting 
room (for anyone to take) 
     -        1      -     -          1 
general practitioner        0        -      -      -          0 
other (specify)      0        -      -      -          0 
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7.3.2 Patient feedback 
40 day unit chemotherapy patients were asked to participate in the study of which 30 
(demographic characteristics listed in Table 7.2) completed the Sunshine Coast 
Hospital and Health Service consumer testing feedback form.  7 patients did not 
return the form and 3 patients declined the study.  All patient participants (n=30) 
found the information clear and easy to understand, the design appealing and the print 
large and clear enough.  97% of patients found the brochure easy to follow.  90% of 
patients thought the information was relevant to them and 90% also thought the 
brochure contained enough information to answer their CAM questions (Table 7.3).  
Additional written patient feedback is listed in Supplementary Table 7.2. 
 
Table 7.2 Demographic characteristics of patient participants (n=30) 
Characteristics n 
Age, years  
 21-30 1 
 31-40 1 
 41-50 5 
 51-60 5 
 61-70 12 
 71-80 4 
 81-90 2 
Sex  
 F 17 
 M 13 
Highest level of education  
 Left school before year 10 6 
 Secondary (year 10) 7 
 Secondary (year 12) 4 
 Secondary + TAFE 7 
 Tertiary 4 
 Tertiary + Post grad 2 
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Table 7.3 Patient feedback, with breakdown in terms of gender and 
numbers indicating those who answered yes (Y), no (N) or did not answer 
the question (na) 
 Total 
n= 30 
Female 
n= 17 
Male 
n= 13 
 Y N/na Y N/na Y N 
Did you find the information 
clear, easy to read and 
understand?  
30 0/0 17 0/0 13 0 
Was there enough information 
to answer your questions?  
27 2/1 14 2/1 13 0 
Did the information explain 
medical terms well? 
30 0/0 17 0/0 13 0 
Do you believe this information 
is relevant to you? 
27 3/0 16 1/0 11 2 
Is the design appropriate and 
appealing? 
30 0/0 17 0/0 13 0 
Is the design clear, uncluttered, 
and easy to follow? 
29 1/0 17 0/0 13 0 
Is the print large and clear 
enough? 
30 0/0 17 0/0 13 0 
 
7.4 Discussion 
All cancer care doctors participating in this study recommend the brochure to some or 
all of their patients and find the brochure makes it easier to discuss CAM with their 
patients.  Cancer patients do not necessarily volunteer their CAM consumption unless 
asked,11 and prefer their health care providers to initiate discussions regarding CAM 
use.15  The brochure’s recommendation and distribution during the cancer care 
consultant clinics is timely as cancer patients make CAM decisions at the same time 
that they make standard medical decisions.10  Patients may not reveal their CAM 
consumption if they anticipate a negative response or do not wish to risk their 
relationship with their oncologist183 and patients report higher satisfaction with their 
clinic visit when CAM is discussed.266  The brochure’s existence and recommendation 
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implies an interest in patients’ CAM use, which was welcomed; “that complementary 
practices are understood and valued by this hospital”, “it is appreciated that staff at 
Nambour Hospital are available to discuss these issues and patient queries and 
concerns”. 
 
Most doctors recommend the brochure to patients who ask about CAM, “Yes, 
informative and well-presented brochure. I would have no hesitation in giving 
brochure to patients who enquired about the use of CAM in cancer care”.  However, 
discussion around CAM consumption is not always initiated by the patient265 and a 
haematologist commented as such: “If it is given out routinely (to all patients) would 
promote patients discussing CAM if not prepared to raise it themselves”.  To ensure 
no patients that are utilizing CAM, or may consider commencing CAM use, are 
missed, all patients should receive the brochure at the start of chemotherapy 
treatment.  Only 35% of cancer care doctors recommended the brochure to all patients 
receiving chemotherapy, which indicates that some chemotherapy patients do not 
receive the brochure and associated explorative conversation during their initial 
consultation from their consultant, their preferred CAM information source, at the 
time they are likely to be making CAM decisions.265  76% of cancer care doctors 
identified they were happy for the brochure to be displayed in the waiting area for 
anyone to take, which would enable access to patients who are taking CAM but don’t 
otherwise ask; however, further education of cancer doctors is required to encourage 
better anticipation and information provision to patients who are considering using 
CAM with chemotherapy but do not reveal their intention. 
 
Cancer patients are likely to be influenced in their decision-making by significant 
others to take CAM: family, friends and even casual acquaintances met in waiting 
rooms and support groups.6,10  Some patients used the brochure as a talisman to ward 
off well-meaning but potentially dangerous advice.  One patient commented he would 
“share the info with my carers and those, with the best intent, urging me to take this 
and that,” another; “friends constantly tell one that such & such is great, But…”. 
 
Some patients indicated that they would like to have seen more detailed information, 
and a haematologist gave feedback, ”?additional interaction eg velcade(bortezomib)/ 
green tea”, though the interaction significance of bortezomib and green tea has been 
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challenged in a preclinical study.267  The brochure’s intent was to provide patients 
with evidence-based guidance on CAM safety and to promote caution and CAM 
disclosure rather than provide specific information on individual products.  The 
brochure contains a recommendation for patients to visit internet sites with evidence-
based CAM information resources such as the Memorial Sloan Kettering Cancer 
Center and the National Cancer Institute for further CAM information.  It is important 
to try and guide cancer patients away from pseudoscientific internet cancer product 
merchandisers whose arguments may be seductive.11  Patients should also be made 
wary of what they read as, for example, two-thirds of articles in Australian 
newspapers describe CAM cancer treatments in the context of a cure.163  The brochure 
was effective in making patients cautious about using CAM “be careful, consult with 
doctor before indulging in CAM”, “the unproven benefits of CAM, the interactions of 
various CAM with my treatment regime”, “there has not been enough research on 
medicine based CAM”.   
 
Cancer patients feel better about themselves and their treatment when empowered to 
make their own decisions,10 and the majority of patients (90%) in this study thought 
the brochure contained enough information to answer their questions.  An oncologist 
commented that the brochure was able to "promote patients on to an evidence-based 
path”.  This small post-intervention quality assurance study found the availability of a 
purpose-designed CAM brochure within a cancer service aided discussions between 
doctors and their patients on the effects of CAM, helped patients understand the 
potential effects of CAM during their chemotherapy treatment and may save doctor 
consultation time.  As the study was conducted at a single site, it has the limitation 
that cancer patients attending, and cancer doctors practicing, at the Sunshine Coast 
Cancer Care Service may not be representative of patients and cancer consultants at 
other sites.  Further studies at different cancer centres are required to substantiate the 
positive reception for the educational CAM-with-chemotherapy brochure established 
in this study. 
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Supplementary Table 7.1 Additional written doctor feedback 
Do you think the brochure makes it easier for you to discuss CAM with your patients? 
Oncologists • Reminder to discuss CAM/ non-prescribed meds 
• Offers a starting point which actually clarifies the initial questions patients have 
• It is easy to read and follow. Patients often ask about alternative treatment 
Oncology registrar • clear, easy to follow 
Haematologists • If it is given out routinely (to all patients) would promote patients discussing CAM 
if not prepared to raise it themselves. 
• Provides good summary of medicine and non-medicine based CAM 
Haematology registrar • Should a patient express an interest in CAM, I would be very happy to give them 
this brochure [if] not prepared to raise it themselves. 
• I think this is important to discuss CAM with chemo patients as practically 
speaking, quite a few pts are inclined towards CAM & it’s very important to tell 
them the interactions of herbal/ chinese meds with chemo meds. 
Has the brochure saved you time during patient consultations? 
Oncologists • Most of the time is consumed discussing/ checking specific medications or 
supplements and this requires a review of more detailed/ specific information on the 
product which is not in the scope of the booklet 
• It is easier to refer patients to the brochure if there is less time 
• has led to discussion which previously patients may not have raised with the 
medical team 
• Have not used it enough. Generally should help. 
Haematologists • haven’t used yet but believe it will 
• not used it yet but I imagine it would 
Haematology registrar • patients (to date) have not mentioned CAM in my clinics 
• I found it very useful. I think it should be discussed with all patients receiving 
chemo. 
• Some patients may not reveal their inclination towards CAM & therefore it’s 
important to discuss with them 
Extra feedback and/or suggested additions or omissions for the next brochure edition 
Oncology registrar • Yes, informative and well-presented brochure.  I would have no hesitation in giving 
brochure to patients who enquired about the use of CAM in cancer care. 
Haematologists • I think this is valuable to promote patients onto an evidence based path if they are 
considering alternative therapy 
• I have given a few to my husband’s (GP) clinic 
• I would try and publish something about it in the LMA (local medical association) 
newsletter 
• ?additional interaction eg velcade/ green tea 
Haematology registrar • I find the brochure very helpful as the majority of patients enquire about issues such 
as alternative medicine, life style, sports and meditation 
• I suggest a strong emphasis be made in the brochure that although following a 
healthy diet or life style is good to keep the patient in a better performance status,  
this is not an alternative to specific cancer directed therapy 
• I think it’s important that all the registrars, particularly the ones doing clinic, should 
go through the brochure and discuss with the patient (about to start chemo) the 
important aspects about CAM 
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Supplementary Table 7.2 Additional written patient feedback 
Did you find the information clear, easy to read and understand? 
• I think it’s a very good publication 
• very well set out 
• well set out, easy to understand language 
• liked summaries 
• references should be on same page as the reference number 
• provides valuable background information 
• was pretty straight forward, easy to understand 
• subtopics limited to a paragraph makes reading easy and able to remain attentive to subject 
• yes, well set out and easy to read 
Was there enough information to answer your questions? 
• wasn’t overwhelming but very informative 
• bit more info on vitamins, when you can and can’t take them  
• would it be useful mentioning other supplements such as glucosamine, lysine, other joint and arthritis supplements, 
sleep supplements etc if there is a possibility that they could also be harmful 
• no specifics on doses of vitamins/ herbal ,mixtures etc. How much is too much? 
• dispel the myths of alternative treatment. Good intentions doesn’t necessarily correlate with a treatment regimen 
• yes, some new info in pamphlet 
What were the main messages? 
• the unproven benefits of CAM. The interactions of various CAM with my treatment regime 
• do not mix CAM with chemo treatment 
• that mind-body therapy CAM seems very good 
• that mind-body CAM is the most important when looking for complementary cancer care. That all other 
medication (CAM) should be checked with doctor 
• that you can do other treatments on chemotherapy 
• don’t use alternative medicines with your chemo unless you consult your doctor first 
• that complementary practices are understood and valued by this hospital 
• is not worth the risk of interfering with chemotherapy effectiveness 
• herbs etc might interact with chemo, not enough research  
• discuss what you are taking with your doctor 
• that mind-body therapy CAM was safe and helpful when having chemotherapy 
• there has not been enough research on medicine based CAM, which can potentially reduce the effectiveness of 
chemo and cause side-effects 
• safe for mind-body therapies 
• risk of ineffective treatment outcome if CAM used 
• refer to doctor before undertaking alternative or complementary medicines 
• very helpful regarding herbal medicines, excellent 
• provides clarity re CAM and relationship with conventional treatment 
• to use common sense and enable decision for your well being  
• what CAM is safe with chemo 
• advise if you are taking any supplements 
• how to care for yourself 
• some things are definitely good- others not sound 
• be careful, consult with doctor before indulging in CAM 
• food and alternative medicines which have potential to impact on chemo 
• mind/body therapy is beneficial during chemotherapy, CAM may interact in a negative way during chemo 
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What do you feel you should do as a result of reading this resource? 
• share the info with my carers and those, with the best intent, urging me to take this and that. 
• complete the chemo treatment I am on at the moment 
• keep on doing what my oncologist suggested 
• continue with Tai Chi daily, keep up my painting, walking, reading, social activities 
• look into complementary and alternative medicine more 
• consider all options, practice more mind-body therapies 
• take no other products or treatments until chemotherapy is completed 
• feel confident with usage of some complementary treatments 
• be careful what you take with chemo 
• stop using any potentially harmful CAM and check with the hospital pharmacy if any other  
medications I am taking could react with chemotherapy 
• look at suggested websites for more information 
• nothing CAM 
• valuable education tool for treatment plan 
• check (CAM) with chemist beforehand 
• nothing I already have been doing; exercise, meditation, visualization 
• be careful of what I take 
• should have read this book properly a lot earlier through my treatment 
• keep it handy 
• nothing, I have not used any CAM 
• helpful to receive this information at the time I have chemo 
• avoid those foods and alternative medications that may affect chemotherapy 
Are there any other comments or suggestions that you would like to make? 
• perhaps a list of food groups which may complement diet whilst receiving chemotherapy 
• perhaps a little more detail about physical activities (ie: yoga, walking etc) 
• Thank you! Perhaps some info re super food trend, if there is an interaction   
• an easy to follow guide that would be good for all patients undergoing chemotherapy 
• it is appreciated that staff at Nambour Hospital are available to discuss these issues and patient queries and 
concerns 
• unfortunately hospital treatments are focused on your surgery, chemo, radiation with a small space for dietician 
and psychology support. I am much more than my body, so therapies (CAM) that help with emotional and spiritual 
side are important too. You want to complement your treatment, not interfere with it. 
• I thought you were supposed to exercise, pamphlet says mild exercise. My mild exercise might be just about 
nothing 
• perhaps mention of time frame for when after treatment finished it would be safe to continue CAM for existing 
conditions or for assisting recovery 
• well presented and easy to follow 
• a very good idea because friends constantly tell one that such &such is great, But… 
• good arrangement of information, colour scheme of brochure good and appealing 
• good size -enough info without over info to make it confusing 
• use of tables gives clear understanding 
• can’t find fault with brochure- very good 
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8 Discussion 
The aims of this thesis were to establish what extent adult cancer patients receiving 
curative-intent chemotherapy potentially compromise their treatment and/or safety by 
using complementary and alternative medicine (CAM) and to identify which cancer 
patients use CAM at this time, why they use it, and who are most at risk.  
Additionally, it aimed to establish whether there was a need for an educational 
intervention to guide cancer patients on the safe use of CAM with chemotherapy, 
develop and publish the educational intervention and to evaluate the effectiveness of 
the intervention through surveying cancer patients and cancer care professionals, 
particularly doctors. 
 
The literature review of CAM use during chemotherapy treatment (Chapter 2) found 
that the cohort of cancer patients most at risk from taking biologically-active CAM 
with adjuvant chemotherapy treatment were those being treated with curative intent.  
The subsequent study on a consecutive sample of curative-intent cancer patients at the 
Sunshine Coast Cancer Care Services Day Unit, Nambour Hospital, Queensland, 
Australia (Chapter 4) found 60% of study patients commencing curative-intent 
chemotherapy were using CAM at the time of receiving chemotherapy which is a 
similar rate to 65% measured in a previous Australian study of cancer patients.6  This 
figure is not as high as found in a 2014 Australian study on CAM use by a mixed 
population of cancer patients receiving radiation treatment (78% when prayer was 
excluded as CAM use).268  In the present study (Chapter 4), answering research 
question 1, one-quarter (27%) of patients were taking biologically-active CAM that 
may have compromised their chemotherapy treatment.  This is a similar proportion to 
that found in the US for a mixed population of curative and non-curative adult cancer 
patients that identified 28% of patients at risk.97   
 
The motivation for CAM use by study participants was predominantly for supportive 
care reasons.  Mind-body CAM, which may be used safely with adjuvant 
chemotherapy, was used by half of the study patients using CAM for supportive care 
treatment.  Over a quarter of study participants were trying to treat their cancer using 
CAM that has no evidence for efficacy.  Answering research question 2, it was found 
study participants’ CAM decision-making was influenced by advice from family and 
friends, practitioners and casual acquaintances.   
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Resolving research question 3, the study (Chapter 4) identified a clear need for an 
educational intervention, finding that over three-quarters of the patient participants 
wanted specific safety information on CAM integration with chemotherapy, 
preferably as a written handout. An educational tool, designed to advise cancer 
patients how to navigate CAM-chemotherapy integration safely, was developed for 
use and distribution by cancer care professionals (Chapter 5). To answer research 
question 4, the educational tool was evaluated in a quality assurance study (Chapter 
6), which showed potential for medical doctor and patient use and feedback from 
target populations was incorporated into the brochure. After implementation and use 
within the Sunshine Coast Cancer Care Service, Nambour Hospital, Queensland, 
Australia, a further quality assurance study (Chapter 7) found the brochure 
intervention to be effective in aiding discussions between doctors and their patients on 
the effects of CAM, and helped patients understand the potential effects of CAM 
during their chemotherapy treatment, answering research question 5.  The findings for 
the thesis research questions and aims and objectives achieved are further discussed in 
the following key thesis results. 
 
8.1 Key thesis results  
 
In a population sample of curative-intent cancer patients, one quarter were 
taking biologically-active CAM that theoretically may have altered the dose 
intensity of their adjuvant chemotherapy treatment.   
 
To date there is not sufficient evidence to determine whether biologically-active CAM 
antioxidants taken by 27% of the study population (Chapter 4) exert a positive or a 
negative effect with adjuvant cancer treatment.242  However, considering the narrow 
therapeutic window of anticancer drugs, relatively small changes in dose intensity that 
may occur due to antioxidant activity have the potential to compromise treatment 
effectiveness.  Antioxidant supplements are often used by cancer patients with the 
motivation to reduce chemotherapy side effects, but their efficacy to ameliorate 
chemotherapy side effects is yet to be determined.242  It has been proposed that the use 
of antioxidant supplementation by cancer patients to reduce toxicity may be at the 
cost of diminishing the effectiveness of chemotherapy by protecting tumour cells 
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from oxidative damage.112  A randomized, placebo-controlled trial of cancer patients 
taking supplemental antioxidants to reduce side effects of adjuvant radiotherapy 
demonstrated that these patients had worse survival outcomes after their radiation 
treatment. 117  As the primary mechanism of action of many chemotherapy agents is 
similar to radiotherapy, through the generation of reactive oxygen species (ROS), it is 
reasonable to equate these results.  A more recent general review of the use of 
antioxidants with adjuvant cancer treatment concluded it was difficult to determine 
whether antioxidants affect treatment outcomes but cautioned that for curative 
regimens, it is important not to inhibit therapy in any way.242 
 
One quarter of the study sample of curative-intent cancer patients (Chapter 4) took 
antioxidants, placing them at risk of diminishing their cancer treatment outcome 
through reducing their effective adjuvant chemotherapy dose intensity.  70% of these 
patients additionally took herbal combinations that had the potential to interact with 
chemotherapy (positively or negatively) but not enough is known to allow any 
predictions to be made.13  Herbal CAM interactions have previously been attributed to 
a substantial number of unexpected toxicities and under-treatment seen in cancer 
patients receiving adjuvant chemotherapy.11,12  
 
There is a significant association between cancer patient routine use of CAM 
prior to cancer diagnosis and their use of biologically-active CAM at risk of 
compromising chemotherapy effectiveness  
 
Prior CAM use has been significantly linked to CAM use with conventional cancer 
treatment in a study of 403 mixed curative and palliative adult cancer patients treated 
at an ambulatory treatment unit in Singapore.39  Though this study captured oral CAM 
usage, it did not specify prior CAM use or estimate the significance of the prior CAM 
use with chemotherapy treatment.  All curative-intent patients (Chapter 4) found to be 
at risk of compromising their chemotherapy effectiveness through biologically-active 
CAM use had routinely used CAM before cancer diagnosis and treatment.  This 
significant result suggests an association between previous CAM use and CAM use of 
concern with adjuvant chemotherapy.  This routine CAM use prior to cancer 
diagnosis was self-selected oral CAM and/or involved regular visits to CAM 
practitioners, such as chiropractors and/or naturopaths, for CAM treatment and 
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advice.  Motivation for regular previous CAM use was to treat prior medical problems 
or for perceived maintenance of good health.  This finding of an association between 
previous CAM use and the use of CAM of concern with chemotherapy may help 
cancer health professionals better anticipate and preference CAM educational 
resources to previous routine CAM users. 
 
Cancer patients receiving curative-intent chemotherapy treatment may be 
receiving advice from CAM advisers not to have chemotherapy  
 
Thirteen percent of study participants (Chapter 4) were advised by CAM practitioners, 
family members, friends and strangers not to have chemotherapy treatment.  This is 
concerning, as timely adjuvant chemotherapy treatment in the curative-intent cancer 
patient population correlates positively with their disease-free and overall survival.241  
These study participants were contending with alternative treatment advice to use 
only CAM to treat their cancer, which counters evidence-based information on cancer 
treatment and outcome expectation.  This result, in the patient group who presented 
for their chemotherapy treatment despite being advised not to, points to the possible 
existence of unseen patients who may have delayed or even rejected chemotherapy 
treatment on the recommendation of CAM advisers.  
 
CAM advisers may also demonise conventional cancer treatment, and this may have a 
nocebo effect.160,161  A nocebo effect occurs when verbal suggestions of negative 
outcomes result in a patient expecting and actually experiencing clinical worsening of 
the condition.182  It would seem logical that the group of study participants (13%) who 
were advised by CAM practitioners, family members, friends and strangers not to 
have chemotherapy treatment faced the possibility of the nocebo effect actually 
worsening their response to chemotherapy. 
 
Cancer patients want to receive information on which CAM is safe to use 
adjuvant with chemotherapy, before treatment commencement 
 
Most (84%) of study participants (Chapter 4) indicated they would have liked to 
receive specific information on which CAM is safe to use with chemotherapy before 
the commencement of their treatment.  Most preferred to receive this information in a 
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referenced guide, from conventional cancer professionals, especially their cancer care 
doctor.  
 
Some patients were receiving advice from CAM information providers that conflicted 
with conventional care.  This advice extended to encouraging cancer patients to 
choose biologically-active CAM that may have risked both patient safety and 
chemotherapy treatment effectiveness.  Cancer patients require evidence-based 
information to enable them to make informed decisions on which CAM can be used 
safely with adjuvant chemotherapy.   
 
An evidence-based CAM-with-chemotherapy patient brochure may be a 
useful adjunct for use by cancer care health professionals to educate patients 
on the potential dangers of biologically-active CAM use with chemotherapy 
and to provide patients with safe CAM alternatives.  
 
In the post-intervention brochure study (Chapter 7), it was shown that specific 
information on CAM use with chemotherapy contained in a purpose-designed, 
evidence-based patient brochure proved effective in being able to answer most cancer 
patients’ CAM information needs.  The brochure also provided cancer professionals 
with an effective CAM information tool they were happy to provide to their patients.   
 
This brochure enables a united, evidence-based voice on CAM information 
dissemination from all health professionals working in cancer care.  It has been 
observed where patient and medical perspectives diverge, cancer care nurses have 
aligned with patients and have also given contradictory advice.269  Use of such a 
brochure in the cancer care setting may avoid the possibility of health professionals 
reinforcing non evidence-based CAM advice and potentially adding to patients’ 
confusion and anxiety about what to do about CAM integration. 
 
Any contradictions in their CAM advice may cause cancer patients considerable 
anxiety, particularly when they are making conventional treatment decisions, as their 
disease is often treated quickly, with little time for consideration and debate.  In this 
context the brochure can be used to show patients that conventional cancer care 
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professionals know about CAM and can guide cancer patients on how to integrate 
CAM safely with their chemotherapy if they wish to do so.   
 
The brochure has brought consistency to the evidence-based message patients receive 
from cancer care professionals at the Sunshine Coast Cancer Care Service.  
Additionally, cancer care professionals who were not surveyed in the thesis studies 
have welcomed the educational tool.  Cancer pharmacists use it in conjunction with 
the taking of patients’ medication histories and nursing staff and allied health 
professionals, including psychologists, dieticians and social workers, use it in their 
practice at the cancer care service unit.  The brochure is also used outside its original 
domain.  Copies have been taken from the Sunshine Coast Cancer Care Service and 
displayed in private cancer clinic waiting rooms on the Sunshine Coast and in 
Brisbane, it is used in community cancer care organisations on the Sunshine Coast, 
and university academics have used the brochure for teaching purposes.  
 
Other Queensland government health service district cancer care centres have shown 
interest in using the brochure.  A further post-evaluation study involving these 
centres, as well as other interstate and international cancer service centres, would be 
useful to gauge whether the brochure translates to cancer centres which may have a 
different patient and health professional demographic.  The brochure may also 
translate for use by general practitioners and other community-based health 
professionals.  Studies to evaluate this use may also be worthwhile. 
 
8.2 Limitations  
A limitation of the thesis was that all of the included studies were conducted using 
population samples of cancer patients attending, and cancer doctors practising, at a 
single site, the Sunshine Coast Cancer Care Service, Nambour Hospital, Queensland, 
Australia. The validity of results may not necessarily be reflective of cancer patients 
and doctors from other day cancer centres and further external multiple site studies 
encompassing a broader population are required to substantiate the results.  That said, 
the study methods were aligned as much as possible to literature recommendations for 
CAM study survey quality,230 and study limitations were discussed in the respective 
discussion sections.  For example, a confounding factor for the curative-intent study 
(Chapter 4), conducted on a sample of cancer patients attending the Sunshine Coast 
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Cancer Care Service, may not be representative of patients at other sites due to the 
fact that the Sunshine Coast area recorded the highest percentage of conscientious 
objection to vaccination in Australia for children aged 5 years,237 and there is a 
negative association between vaccination rates with patient care given by CAM 
providers.251   
 
The studies in this thesis followed public hospital patients, the majority of which have 
no private health insurance.  It has been shown that patients with private health 
insurance are significantly more likely than those without private health insurance to 
consult CAM practitioners in Australia.270   
 
The quality assurance brochure development and post intervention studies (Chapters 6 
& 7) were also conducted at the single site (Sunshine Coast Cancer Care Service).  
This has the limitation that the surveyed cancer patients and cancer doctors may not 
be representative of patients and cancer doctors at other sites.  Further studies at 
different cancer centres are required to substantiate the positive reception for the 
educational CAM-with-chemotherapy brochure established in this thesis. 
 
8.3 Future research  
People that are commencing curative-intent treatment are arguably the most important 
demographic of oncology patients.  These are the people with the greatest potential to 
have their cancer eradicated and return to normal life.  Therefore, these people 
deserve continued emphasis in research studies, and continued effort in providing 
education about the best way to optimise treatment outcomes.  The data in this thesis 
is interesting, and indicates future work with greater participant numbers and at other 
cancer centres would provide valuable information as to whether they are 
representative of other sites with different patient and health professional 
demographics.   
 
The major thesis study (Chapter 4) found that a proportion of cancer patients (13%) 
being treated with curative-intent chemotherapy were advised not to have 
chemotherapy adjuvant treatment.  This raises the question of what happens to 
patients, not captured by the study, that accepted this advice and did not present for 
curative-chemotherapy treatment.  A research study to quantify to what extent this 
 113 
may be occurring and reasons why, would be worthwhile.  A longitudinal study of a 
cohort of these patients may elucidate long term survival difference, whether these 
patients accepted other forms of conventional interventions such as surgery and/or 
radiotherapy, whether these patients accept chemotherapy treatment after their cancer 
has progressed or whether they never accept conventional treatment.  The answer to 
these questions may better prepare conventional cancer providers to provide 
appropriate support to these patients who are at high risk of diminishing their long-
term survival.65   
 
8.4 Conclusions 
In the absence of strong evidence otherwise, biologically-active CAM should be 
considered to be contraindicated with curative-intent treatment, as diminishment of 
chemotherapy dose through biologically-active CAM interaction can correlate with 
worse disease-free and overall survival outcomes for this cohort of cancer patients.11-
13,112,241  
 
Cancer patients in this demographic should be informed and dissuaded from taking 
biologically-active CAM at the same time as adjuvant chemotherapy, particularly as 
they may be receiving advice to take biologically-active CAM with adjuvant 
chemotherapy from practitioners, family, friends, and casual acquaintances.  A 
communication bridge is required to disseminate this information because of the 
additional complication that cancer patients do not necessarily volunteer their CAM 
consumption, preferring their cancer doctor to initiate discussions regarding CAM 
use, but most cancer doctors do not initiate CAM discussions with their patients. 
 
An evidence-based CAM-with-chemotherapy patient brochure purpose-designed for 
use by cancer patients at the time of receiving chemotherapy may provide the 
communication bridge required to enable cancer care health professionals to educate 
patients on the potential dangers of biologically-active CAM use with chemotherapy 
and to provide patients with safe CAM alternatives. 
 
 114 
 
 
 
 
 
 
 
 
 
 
References 
 115 
References  
 1. Gaboury I, April KT, Verhoef M: A qualitative study on the term 
CAM: is there a need to reinvent the wheel? BMC Complement Altern Med 12:131, 
2012 
 2. Zollman C, Vickers A: ABC of complementary medicine: What is 
complementary medicine? BMJ 319:693-6, 1999 
 3. NCCIH: Terms Related to Complementary and Integrative Health 
[Internet] 2016 [updated 2016 Feb 19; cited 2016 Jun 25]. Available from: 
https://nccih.nih.gov/health/providers/camterms.htm  
 4. Ernst E: Homeopathy: what does the "best" evidence tell us? Med J 
Aust 192:458-60, 2010 
 5. Mosby's Medical Dictionary 10th ed. Elsevier: St Louis: Mosby; 2016. 
Biological activity; p.210 
 6. Oh B, Butow P, Mullan B, et al: The use and perceived benefits 
resulting from the use of complementary and alternative medicine by cancer patients 
in Australia. Asia Pac J Clin Oncol 6:342-9, 2010 
 7. Werneke U, Earl J, Seydel C, et al: Potential health risks of 
complementary alternative medicines in cancer patients. Br J Cancer 90:408-13, 2004 
 8. Pedersen CG, Christensen S, Jensen AB, et al: Prevalence, socio-
demographic and clinical predictors of post-diagnostic utilisation of different types of 
complementary and alternative medicine (CAM) in a nationwide cohort of Danish 
women treated for primary breast cancer. Eur J Cancer 45:3172-81, 2009 
 9. Sparreboom A, Cox MC, Acharya MR, et al: Herbal remedies in the 
United States: potential adverse interactions with anticancer agents. J Clin Oncol 
22:2489-503, 2004 
 10. Balneaves LG, Weeks L, Seely D: Patient decision-making about 
complementary and alternative medicine in cancer management: context and process. 
Curr Oncol 15 Suppl 2:S94-100, 2008 
 11. Tascilar M, de Jong FA, Verweij J, et al: Complementary and 
alternative medicine during cancer treatment: beyond innocence. Oncologist 11:732-
41, 2006 
 12. Meijerman I, Beijnen JH, Schellens JH: Herb-drug interactions in 
oncology: focus on mechanisms of induction. Oncologist 11:742-52, 2006 
 116 
 13. Goey AK, Beijnen JH, Schellens JH: Herb-drug interactions in 
oncology. Clin Pharmacol Ther 95:354-5, 2014 
 14. Bishop FL, Lewith GT: Who Uses CAM? A Narrative Review of 
Demographic Characteristics and Health Factors Associated with CAM Use. Evid 
Based Complement Alternat Med 7:11-28, 2010 
 15. Richardson MA, Sanders T, Palmer JL, et al: 
Complementary/alternative medicine use in a comprehensive cancer center and the 
implications for oncology. J Clin Oncol 18:2505-14, 2000 
 16. Ohlen J, Balneaves LG, Bottorff JL, et al: The influence of significant 
others in complementary and alternative medicine decisions by cancer patients. Soc 
Sci Med 63:1625-36, 2006 
 17. Smith PJ, Clavarino A, Long J, et al: Why do some cancer patients 
receiving chemotherapy choose to take complementary and alternative medicines and 
what are the risks? Asia Pac J Clin Oncol 10:1-10, 2014 
 18. Boon HS, Olatunde F, Zick SM: Trends in complementary/alternative 
medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. 
BMC Womens Health 7:4, 2007 
 19. Vapiwala N, Mick R, Hampshire MK, et al: Patient initiation of 
complementary and alternative medical therapies (CAM) following cancer diagnosis. 
Cancer J 12:467-74, 2006 
 20. Hardy ML: Dietary supplement use in cancer care: help or harm. 
Hematol Oncol Clin North Am 22:581-617, vii, 2008 
 21. Wieland LS, Manheimer E, Berman BM: Development and 
classification of an operational definition of complementary and alternative medicine 
for the Cochrane collaboration. Altern Ther Health Med 17:50-9, 2011 
 22. Rees L, Weil A: Integrated medicine. BMJ 322:119-20, 2001 
 23. Ernst E: Integrative medicine: more than the promotion of unproven 
treatments? Med J Aust 204:174, 2016 
 24. World Health Organisation: WHO traditional medicine strategy: 2014-
2023 [Internet]. 2013, [cited 2016 Jun 27]. Available from: 
http://www.who.int/medicines/publications/traditional/trm_strategy14_23/en/ 
 25. House of Lords: Science and Technology-Sixth Report, [Internet] 2000 
[updated 2000 Nov 21; cited 2016 Jun 29]. Available from: 
http://www.publications.parliament.uk/pa/ld199900/ldselect/ldsctech/123/12301.htm 
 117 
 26. Falkenberg T, Lewith G, Roberti di Sarsina P, et al: Towards a pan-
European definition of complementary and alternative medicine--a realistic ambition? 
Forsch Komplementmed 19 Suppl 2:S6-8, 2012 
 27. Douglas RM, Hemila H, Chalker E, et al: Vitamin C for preventing 
and treating the common cold. Cochrane Database Syst Rev:CD000980, 2007 
 28. Beaune G, Martin C, Martin D, et al: [Vitamin C measurements in 
vulnerable populations: 4 cases of scurvy]. Ann Biol Clin (Paris) 65:65-9, 2007 
 29. Eisenberg DM, Kessler RC, Foster C, et al: Unconventional medicine 
in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328:246-52, 
1993 
 30. Astin JA: Why patients use alternative medicine: results of a national 
study. JAMA 279:1548-53, 1998 
 31. MacLennan AH, Myers SP, Taylor AW: The continuing use of 
complementary and alternative medicine in South Australia: costs and beliefs in 2004. 
Med J Aust 184:27-31, 2006 
 32. Xue CC, Zhang AL, Lin V, et al: Complementary and alternative 
medicine use in Australia: a national population-based survey. J Altern Complement 
Med 13:643-50, 2007 
 33. Morgan TK, Williamson M, Pirotta M, et al: A national census of 
medicines use: a 24-hour snapshot of Australians aged 50 years and older. Med J Aust 
196:50-3, 2012 
 34. Reid R, Steel A, Wardle J, et al: Complementary medicine use by the 
Australian population: a critical mixed studies systematic review of utilisation, 
perceptions and factors associated with use. BMC Complement Altern Med 16:176, 
2016 
 35. Wade C, Chao M, Kronenberg F, et al: Medical pluralism among 
American women: results of a national survey. J Womens Health (Larchmt) 17:829-
40, 2008 
 36. Helman CG: Limits of biomedical explanation. Lancet 337:1080-3, 
1991 
 37. Stratton TD, McGivern-Snofsky JL: Toward a sociological 
understanding of complementary and alternative medicine use. J Altern Complement 
Med 14:777-83, 2008 
 118 
 38. Ezeome ER, Anarado AN: Use of complementary and alternative 
medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, 
Nigeria. BMC Complement Altern Med 7:28, 2007 
 39. Shih V, Chiang JY, Chan A: Complementary and alternative medicine 
(CAM) usage in Singaporean adult cancer patients. Ann Oncol 20:752-7, 2009 
 40. Gerson-Cwilich R, Serrano-Olvera A, Villalobos-Prieto A: 
Complementary and alternative medicine (CAM) in Mexican patients with cancer. 
Clin Transl Oncol 8:200-7, 2006 
 41. Montazeri A, Sajadian A, Ebrahimi M, et al: Factors predicting the use 
of complementary and alternative therapies among cancer patients in Iran. Eur J 
Cancer Care (Engl) 16:144-9, 2007 
 42. Hyodo I, Amano N, Eguchi K, et al: Nationwide survey on 
complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 
23:2645-54, 2005 
 43. Evans M, Shaw A, Thompson EA, et al: Decisions to use 
complementary and alternative medicine (CAM) by male cancer patients: 
information-seeking roles and types of evidence used. BMC Complement Altern Med 
7:25, 2007 
 44. Nam RK, Fleshner N, Rakovitch E, et al: Prevalence and patterns of 
the use of complementary therapies among prostate cancer patients: an 
epidemiological analysis. J Urol 161:1521-4, 1999 
 45. Hall JD, Bissonette EA, Boyd JC, et al: Motivations and influences on 
the use of complementary medicine in patients with localized prostate cancer treated 
with curative intent: results of a pilot study. BJU Int 91:603-7, 2003 
 46. Lippert MC, McClain R, Boyd JC, et al: Alternative medicine use in 
patients with localized prostate carcinoma treated with curative intent. Cancer 
86:2642-8, 1999 
 47. Ponholzer A, Struhal G, Madersbacher S: Frequent use of 
complementary medicine by prostate cancer patients. Eur Urol 43:604-8, 2003 
 48. Kremser T, Evans A, Moore A, et al: Use of complementary therapies 
by Australian women with breast cancer. Breast 17:387-94, 2008 
 49. Sibbritt D, Adams J, Easthope G, et al: Complementary and alternative 
medicine (CAM) use among elderly Australian women who have cancer. Support 
Care Cancer 11:548-50, 2003 
 119 
 50. Lowenthal RM, Grogan PB, Kerrins ET: Reducing the impact of 
cancer in Indigenous communities: ways forward. Med J Aust 182:105-6, 2005 
 51. McMichael C, Kirk M, Manderson L, et al: Indigenous women's 
perceptions of breast cancer diagnosis and treatment in Queensland. Aust N Z J Public 
Health 24:515-9, 2000 
 52. Shahid S, Bleam R, Bessarab D, et al: "If you don't believe it, it won't 
help you": use of bush medicine in treating cancer among Aboriginal people in 
Western Australia. J Ethnobiol Ethnomed 6:18, 2010 
 53. Maher P: A review of "traditional" Aboriginal health beliefs. Aust J 
Rural Health 7:229-236, 1999 
 54. Bensoussan A, Lewith GT: Complementary medicine research in 
Australia: a strategy for the future. Med J Aust 181:331-3, 2004 
 55. Ernst E: Chiropractic: a critical evaluation. J Pain Symptom Manage 
35:544-62, 2008 
 56. McLachlan JC: Integrative medicine and the point of credulity. BMJ 
341:c6979, 2010 
 57. Marron, L. Friends of Science in Medicine: "Integrative medicine" has 
no place in universities. Australasian Science [Internet] 2015 Jul/Aug [cited 2016 Jul 
16];36 (6): 46. Available from: 
http://search.informit.com.au/documentSummary;dn=536894564249506;res=IELAP
A. 
 58. Friends of Science in Medicine, Commitments and principles [Internet] 
2016, [cited 2016 Jun 29]. Available from: 
http://www.scienceinmedicine.org.au/index.php?option=com_content&view=section
&layout=blog&id=47&Itemid=151 
 59. NPS MEDICINEWISE: Using complementary medicines, [Internet] 
2012 [updated 2012 Oct 25; cited 2016 Jun 29]. Available from: 
http://www.nps.org.au/topics/how-to-be-medicinewise/using-complementary-
medicines 
 60. Cancer Council Australia: Complementary and alternative therapies, 
[Internet] 2016 [updated 2016 Jun 22; cited 2016 Jun 30]. Available from: 
http://www.cancer.org.au/about-cancer/treatment/complementary-therapies-and-
cancer.html 
 120 
 61. Cassileth BR, Deng G: Complementary and alternative therapies for 
cancer. Oncologist 9:80-9, 2004 
 62. Hann D, Allen S, Ciambrone D, et al: Use of complementary therapies 
during chemotherapy: influence of patients' satisfaction with treatment decision 
making and the treating oncologist. Integr Cancer Ther 5:224-31, 2006 
 63. Molassiotis A, Fernadez-Ortega P, Pud D, et al: Use of complementary 
and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655-63, 
2005 
 64. Malik IA, Gopalan S: Use of CAM results in delay in seeking medical 
advice for breast cancer. Eur J Epidemiol 18:817-22, 2003 
 65. Han E, Johnson N, DelaMelena T, et al: Alternative therapy used as 
primary treatment for breast cancer negatively impacts outcomes. Ann Surg Oncol 
18:912-6, 2011 
 66. Engdal S, Steinsbekk A, Klepp O, et al: Herbal use among cancer 
patients during palliative or curative chemotherapy treatment in Norway. Support 
Care Cancer 16:763-9, 2008 
 67. NationalCancerInstitute: Post-traumatic Stress Disorder. [Internet] 
2011 [updated 2015 Jul 7; cited 2016 Jun 30]. Available from: 
http://www.cancer.gov/about-cancer/coping/survivorship/new-normal/ptsd-pdq 
 68. Kim SG, Park EC, Park JH, et al: Initiation and discontinuation of 
complementary therapy among cancer patients. J Clin Oncol 25:5267-74, 2007 
 69. Correa-Velez I, Clavarino A, Eastwood H: Surviving, relieving, 
repairing, and boosting up: reasons for using complementary/alternative medicine 
among patients with advanced cancer: a thematic analysis. J Palliat Med 8:953-61, 
2005 
 70. Boon H, Brown JB, Gavin A, et al: Men with prostate cancer: making 
decisions about complementary/alternative medicine. Med Decis Making 23:471-9, 
2003 
 71. Yun J, Tomida A, Nagata K, et al: Glucose-regulated stresses confer 
resistance to VP-16 in human cancer cells through a decreased expression of DNA 
topoisomerase II. Oncol Res 7:583-90, 1995 
 72. Luettig B, Steinmuller C, Gifford GE, et al: Macrophage activation by 
the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea 
purpurea. J Natl Cancer Inst 81:669-75, 1989 
 121 
 73. Greenlee H, Hershman DL, Jacobson JS: Use of antioxidant 
supplements during breast cancer treatment: a comprehensive review. Breast Cancer 
Res Treat 115:437-52, 2009 
 74. Gordon JS: Mind-body medicine and cancer. Hematol Oncol Clin 
North Am 22:683-708, ix, 2008 
 75. Cassileth BR, Lusk EJ, Strouse TB, et al: Contemporary unorthodox 
treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann 
Intern Med 101:105-12, 1984 
 76. Chang EY, Glissmeyer M, Tonnes S, et al: Outcomes of breast cancer 
in patients who use alternative therapies as primary treatment. Am J Surg 192:471-3, 
2006 
 77. Eisenberg DM, Kessler RC, Van Rompay MI, et al: Perceptions about 
complementary therapies relative to conventional therapies among adults who use 
both: results from a national survey. Ann Intern Med 135:344-51, 2001 
 78. Zollman C, Vickers A: ABC of complementary medicine. 
Complementary medicine and the patient. BMJ 319:1486-9, 1999 
 79. Hunter M: Alternative dietary therapies in cancer patients. Recent 
Results Cancer Res 121:293-5, 1991 
 80. Mahady GB, Low Dog T, Barrett ML, et al: United States 
Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 
15:628-38, 2008 
 81. Kressmann S, Muller WE, Blume HH: Pharmaceutical quality of 
different Ginkgo biloba brands. J Pharm Pharmacol 54:661-9, 2002 
 82. Schulz V HR, Blumenthal M Tyler VE. Rational Phytotherapy; A 
reference guide for physicians and pharmacists. Berlin: Springer; 2004 
 83. De Smet PA: Health risks of herbal remedies: an update. Clin 
Pharmacol Ther 76:1-17, 2004 
 84. Koh HL, Woo SO: Chinese proprietary medicine in Singapore: 
regulatory control of toxic heavy metals and undeclared drugs. Drug Saf 23:351-62, 
2000 
 85. Sovak M, Seligson AL, Konas M, et al: Herbal composition PC-SPES 
for management of prostate cancer: identification of active principles. J Natl Cancer 
Inst 94:1275-81, 2002 
 122 
 86. Guns ES, Goldenberg SL, Brown PN: Mass spectral analysis of PC-
SPES confirms the presence of diethylstilbestrol. Can J Urol 9:1684-8; discussion 
1689, 2002 
 87. Marselos M, Tomatis L: Diethylstilboestrol: I, Pharmacology, 
Toxicology and carcinogenicity in humans. Eur J Cancer 28A:1182-9, 1992 
 88. White J: PC-SPES--a lesson for future dietary supplement research. J 
Natl Cancer Inst 94:1261-3, 2002 
 89. Cosyns JP: Aristolochic acid and 'Chinese herbs nephropathy': a 
review of the evidence to date. Drug Saf 26:33-48, 2003 
 90. Diamond BJ, Shiflett SC, Feiwel N, et al: Ginkgo biloba extract: 
mechanisms and clinical indications. Arch Phys Med Rehabil 81:668-78, 2000 
 91. Ghasemnezhad A, Honermeier, B.: Yield, oil constituents, and protein 
content of evening primrose (Oenothera biennis L.) seeds depending on harvest 
time, harvest method and nitrogen application. Industrial Crops and Products 28:17-
23, 2008 
 92. Couceiro MA, Afreen, F., Zobayed, S.M.A., Kozai, T.: Variation in 
concentrations of major bioactive compounds of St. John’s wort: Effects of harvesting 
time, temperature and germplasm. Plant Science 170:128-134, 2005 
 93. Spinella M: The importance of pharmacological synergy in 
psychoactive herbal medicines. Altern Med Rev 7:130-7, 2002 
 94. TGA: Australian regulatory guidelines for complementary medicines 
[Internet] 2015 [updated 2015 Jul 31; cited 2015 Nov 30]. Available from: 
https://www.tga.gov.au/publication/australian-regulatory-guidelines-complementary-
medicines-argcm 
 95. Rowlands D, Masters, M., Zehetner, A., Ioannou, T: Therapeutic 
Goods Regulation: Complementary Medicines, Department of Health and Aging 
[Internet] 2011 [cited 2015 Nov 30]. Available from: 
https://www.anao.gov.au/sites/g/files/net616/f/201112%20Audit%20Report%20No%
203.pdf  
 96. Cheng CW, Fan W, Ko SG, et al: Evidence-based management of 
herb-drug interaction in cancer chemotherapy. Explore (NY) 6:324-9, 2010 
 97. McCune JS, Hatfield AJ, Blackburn AA, et al: Potential of 
chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 12:454-
62, 2004 
 123 
 98. Mathijssen RH, Verweij J, de Bruijn P, et al: Effects of St. John's wort 
on irinotecan metabolism. J Natl Cancer Inst 94:1247-9, 2002 
 99. Frye RF, Fitzgerald SM, Lagattuta TF, et al: Effect of St John's wort 
on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76:323-9, 2004 
 100. van Erp NP, Baker SD, Zhao M, et al: Effect of milk thistle (Silybum 
marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 11:7800-6, 2005 
 101. Golden EB, Lam PY, Kardosh A, et al: Green tea polyphenols block 
the anticancer effects of bortezomib and other boronic acid-based proteasome 
inhibitors. Blood 113:5927-37, 2009 
 102. Gurney H: How to calculate the dose of chemotherapy. Br J Cancer 
86:1297-302, 2002 
 103. Dy GK, Bekele L, Hanson LJ, et al: Complementary and alternative 
medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 22:4810-5, 
2004 
 104. Riechelmann RP, Del Giglio A: Drug interactions in oncology: how 
common are they? Ann Oncol 20:1907-12, 2009 
 105. Goodman M, Bostick RM, Kucuk O, et al: Clinical trials of 
antioxidants as cancer prevention agents: past, present, and future. Free Radic Biol 
Med 51:1068-84, 2011 
 106. Lawson KA, Wright ME, Subar A, et al: Multivitamin use and risk of 
prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J 
Natl Cancer Inst 99:754-64, 2007 
 107. Klein EA, Thompson IM, Jr., Tangen CM, et al: Vitamin E and the risk 
of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). 
JAMA 306:1549-56, 2011 
 108. The effect of vitamin E and beta carotene on the incidence of lung 
cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene 
Cancer Prevention Study Group. N Engl J Med 330:1029-35, 1994 
 109. Sayin VI, Ibrahim MX, Larsson E, et al: Antioxidants accelerate lung 
cancer progression in mice. Sci Transl Med 6:221ra15, 2014 
 110. Le Gal K, Ibrahim MX, Wiel C, et al: Antioxidants can increase 
melanoma metastasis in mice. Sci Transl Med 7:308re8, 2015 
 124 
 111. Block KI, Koch AC, Mead MN, et al: Impact of antioxidant 
supplementation on chemotherapeutic toxicity: a systematic review of the evidence 
from randomized controlled trials. Int J Cancer 123:1227-39, 2008 
 112. Lawenda BD, Kelly KM, Ladas EJ, et al: Should supplemental 
antioxidant administration be avoided during chemotherapy and radiation therapy? J 
Natl Cancer Inst 100:773-83, 2008 
 113. D'Andrea GM: Use of antioxidants during chemotherapy and 
radiotherapy should be avoided. CA Cancer J Clin 55:319-21, 2005 
 114. Ladas E, Kelly KM: The antioxidant debate. Explore (NY) 6:75-85, 
2010 
 115. Heaney ML, Gardner JR, Karasavvas N, et al: Vitamin C antagonizes 
the cytotoxic effects of antineoplastic drugs. Cancer Res 68:8031-8, 2008 
 116. Andersen MR, Sweet E, Lowe KA, et al: Dangerous combinations: 
Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer. 
J Altern Complement Med 19:714-20, 2013 
 117. Bairati I, Meyer F, Gelinas M, et al: Randomized trial of antioxidant 
vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer 
patients. J Clin Oncol 23:5805-13, 2005 
 118. Block KI, Koch AC, Mead MN, et al: Impact of antioxidant 
supplementation on chemotherapeutic efficacy: a systematic review of the evidence 
from randomized controlled trials. Cancer Treat Rev 33:407-18, 2007 
 119. Greenlee H, Kwan ML, Ergas IJ, et al: Changes in vitamin and mineral 
supplement use after breast cancer diagnosis in the Pathways Study: a prospective 
cohort study. BMC Cancer 14:382, 2014 
 120. Ernst E: Advice offered by practitioners of complementary/ alternative 
medicine: an important ethical issue. Eval Health Prof 32:335-42, 2009 
 121. Pirotta MV, Cohen MM, Kotsirilos V, et al: Complementary therapies: 
have they become accepted in general practice? Med J Aust 172:105-9, 2000 
 122. Cohen MM: CAM practitioners and "regular" doctors: is integration 
possible? Med J Aust 180:645-6, 2004 
 123. Cohen MM, Penman S, Pirotta M, et al: The integration of 
complementary therapies in Australian general practice: results of a national survey. J 
Altern Complement Med 11:995-1004, 2005 
 125 
 124. Hurst D: Bicarb soda used to treat cancer. Brisbane Times [Internet]. 
2011 [cited 2015 Oct 26]; Available from: 
http://www.brisbanetimes.com.au/queensland/bicarb-soda-used-to-treat-cancer-
20110509-1efj1.html 
 125. Marks N: PR Coup for herbal cancer drug. BMJ 329:804, 2004 
 126. Ernst E: Carctol: Profit before Patients? Breast Care (Basel) 4:31-33, 
2009 
 127. Jarvis WT: Why Health Professionals Become Quacks [Internet] 1998 
[cited 2015 Mar 28]. Available from: 
http://www.quackwatch.com/01QuackeryRelatedTopics/quackpro.html 
 128. Goldstein MS, Jaffe, D. T., Sutherland, C.,: Physicians at a holistic 
medical conference: "Who and Why?". Health Values 10:3-13, 1986 
 129. Ernst E: Chiropractic treatment for fibromyalgia: a systematic review. 
Clin Rheumatol 28:1175-8, 2009 
 130. Gouveia LO, Castanho P, Ferreira JJ: Safety of chiropractic 
interventions: a systematic review. Spine (Phila Pa 1976) 34:E405-13, 2009 
 131. Ernst E: Deaths after chiropractic: a review of published cases. Int J 
Clin Pract 64:1162-5, 2010 
 132. Harvey K, Vickers M: Chiropractic board in firing line. MJA Insight 
[Internet]. 2016 Jan [cited 2016 Feb 15]. Available from: 
http://www.doctorportal.com.au/mjainsight/2016/1/ken-harvey-and-malcolm-vickers-
chiropractic-board-in-firing-line 
 133. Macpherson H, Scullion A, Thomas KJ, et al: Patient reports of 
adverse events associated with acupuncture treatment: a prospective national survey. 
Qual Saf Health Care 13:349-55, 2004 
 134. Schmidt K, Ernst E: MMR vaccination advice over the Internet. 
Vaccine 21:1044-7, 2003 
 135. Weir M: Regulation of Complementary and Alternative Medicine 
Practitioners. Law in Context 23:171-199, 2005 
 136. Canaway R: A Culture of Dissent: Australian Naturopath's 
Perspectives on Practitioner Regulation. Complement Health Pract Rev 14:136-152, 
2009 
 137. Metagenics: Find a practitioner [Internet] 2016 [cited 2016 Jul 29]. 
Available from: https://www.metagenics.com.au 
 126 
 138. Lin v, McCabe, P., Bensoussan, A., Myers, S. P., Cohen, M., Hill, S., 
& Howse, G.: The practice and regulatory requirements of naturopathy and western 
herbal medicine in Australia. Risk Manag Healthc Policy 2:21-33, 2009 
 139. Wardle J: Unregulated naturopaths putting lives at risk, [Internet] 2010 
Oct 21 [cited 2016 Feb 15]. Available from: http://www.abc.net.au/news/2010-10-
21/unregulated_naturopaths_putting_lives_at_risk/40276 
 140. Wardle J: TGA submission on CAM advertising [Internet] 2010 Aug 
10 [cited 2016 Feb 17]. Available from: 
https://www.tga.gov.au/sites/default/files/consult-advertising-arrangements-101028-
submission-wardle.pdf 
 141. Shermer M: Why People Believe Weird Things: Pseudoscience, 
Superstition, and other Confusions of our Time. New York, WH Freeman and 
Company, 1997  
 142. Natural Therapy Pages- Live Blood Analysis [Internet] 2016 [cited 
2016 Feb 17]. Available from: 
http://www.naturaltherapypages.com.au/schools/live_blood_analysis_courses 
 143. Calder Chiropractic Centre: Our services-Hemaview [Internet] 2016 
[cited 2016 Feb 17]. Available from: http://www.chiropractors.co.nz/our-
services/what-hemaview%E2%84%A2 
 144. Gupta S: Lotus Holistic Medicine. Holistic Bliss 29:12, 2011 
 145. Teut M, Ludtke R, Warning A: Reliability of Enderlein's darkfield 
analysis of live blood. Altern Ther Health Med 12:36-41, 2006 
 146. Ullmann R: A modern scientific perspective on Prof Dr Enderlein's 
concept of microbial life cycles. Townsend Let Doct 238:72-79, 2003 
 147. El-Safadi S, Tinneberg HR, von Georgi R, et al: Does dark field 
microscopy according to Enderlein allow for cancer diagnosis? A prospective study. 
Forsch Komplementarmed Klass Naturheilkd 12:148-51, 2005 
 148. Ernst E: Intrigued by the spectacular claims made for Live Blood 
Analysis? Don't be. It doesn't work. The Guardian [Internet] 2005 Jul 13 [cited 2015 
Oct 26]; Available from: 
https://www.theguardian.com/society/2005/jul/12/health.science 
 149. Vickers A, Zollman C: ABC of complementary medicine. 
Homoeopathy. BMJ 319:1115-8, 1999 
 127 
 150. Ernst E: Is it ethical for pharmacists to sell unproven or disproven 
medicines? Pharm J 281:75-76, 2008 
 151. NewsTeam: RPS calls for advertising of homoeopathic products to 
specify lack of evidence. Pharm J 285:538, 2010 
 152. Mills E, Ernst E, Singh R, et al: Health food store recommendations: 
implications for breast cancer patients. Breast Cancer Res 5:R170-4, 2003 
 153. Hare RD, Hart SD, Harpur TJ: Psychopathy and the DSM-IV criteria 
for antisocial personality disorder. J Abnorm Psychol 100:391-8, 1991 
 154. Clizer D, Jarvis, J: Cancer Cure Secrets [ebook]. 2001[cited 2015 Dec 
20] Available from:  https://www.tldm.org/misc/cancer%20cures.pdf 
 155. Bardia A, Nisly NL, Zimmerman MB, et al: Use of herbs among adults 
based on evidence-based indications: findings from the National Health Interview 
Survey. Mayo Clin Proc 82:561-6, 2007 
 156. Ryan JL, Heckler CE, Roscoe JA, et al: Ginger (Zingiber officinale) 
reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. 
Support Care Cancer 20:1479-89, 2012 
 157. Alsawaf MA, Jatoi A: Shopping for nutrition-based complementary 
and alternative medicine on the Internet: how much money might cancer patients be 
spending online? J Cancer Educ 22:174-6, 2007 
 158. Verhoef MJ, Mulkins A, Carlson LE, et al: Assessing the role of 
evidence in patients' evaluation of complementary therapies: a quality study. Integr 
Cancer Ther 6:345-53, 2007 
 159. Molassiotis A, Xu M: Quality and safety issues of web-based 
information about herbal medicines in the treatment of cancer. Complement Ther Med 
12:217-27, 2004 
 160. Matthews SC, Camacho A, Mills PJ, et al: The internet for medical 
information about cancer: help or hindrance? Psychosomatics 44:100-3, 2003 
 161. Schmidt K, Ernst E: Assessing websites on complementary and 
alternative medicine for cancer. Ann Oncol 15:733-42, 2004 
 162. Milazzo S, Ernst E: Newspaper coverage of complementary and 
alternative therapies for cancer--UK 2002-2004. Support Care Cancer 14:885-9, 2006 
 163. Mercurio R, Eliott JA: Trick or treat? Australian newspaper portrayal 
of complementary and alternative medicine for the treatment of cancer. Support Care 
Cancer 19:67-80, 2011 
 128 
 164. Ernst E: Complementary and alternative medicine: between evidence 
and absurdity. Perspect Biol Med 52:289-303, 2009 
 165. Wahlberg A: A quackery with a difference-new medical pluralism and 
the problem of 'dangerous practitioners' in the United Kingdom. Soc Sci Med 
65:2307-16, 2007 
 166. Verhoef MJ, Rose MS, White M, et al: Declining conventional cancer 
treatment and using complementary and alternative medicine: a problem or a 
challenge? Curr Oncol 15 Suppl 2:s101-6, 2008 
 167. Jarvis WT: How Quackery Harms Cancer Patients [Internet] 1997 
[cited 2015 Mar 28]. Available from: 
http://www.quackwatch.com/01QuackeryRelatedTopics/harmquack.html  
 168. International Wellness Directory: Cancer Loves Sugar [Internet] 2009 
[cited 2015 Nov 23]. Available from: 
http://www.mnwelldir.org/docs/nutrition/sugar.htm  
 169. Penson RT: Sugar fuels cancer. Cancer 115:918-21, 2009 
 170. Warburg O, Wind F, Negelein E: The Metabolism of Tumors in the 
Body. J Gen Physiol 8:519-30, 1927 
 171. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, 
obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N 
Engl J Med 348:1625-38, 2003 
 172. Challis GB, Stam HJ: The spontaneous regression of cancer. A review 
of cases from 1900 to 1987. Acta Oncol 29:545-50, 1990 
 173. Chodorowski Z, Anand JS, Wisniewski M, et al: [Spontaneous 
regression of cancer--review of cases from 1988 to 2006]. Przegl Lek 64:380-2, 2007 
 174. Papac RJ: Spontaneous regression of cancer: possible mechanisms. In 
Vivo 12:571-8, 1998 
 175. Bausell RB: Snake Oil Science: The Truth About Complementary and 
Alternative Medicine. New York, Oxford University Press, 2007  
 176. Diederich NJ, Goetz CG: The placebo treatments in neurosciences: 
New insights from clinical and neuroimaging studies. Neurology 71:677-84, 2008 
 177. de la Fuente-Fernandez R, Ruth TJ, Sossi V, et al: Expectation and 
dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 
293:1164-6, 2001 
 129 
 178. Zubieta JK, Bueller JA, Jackson LR, et al: Placebo effects mediated by 
endogenous opioid activity on mu-opioid receptors. J Neurosci 25:7754-62, 2005 
 179. Su C, Lichtenstein GR, Krok K, et al: A meta-analysis of the placebo 
rates of remission and response in clinical trials of active Crohn's disease. 
Gastroenterology 126:1257-69, 2004 
 180. Suchman AL, Ader R: Classic conditioning and placebo effects in 
crossover studies. Clin Pharmacol Ther 52:372-7, 1992 
 181. Hall KT, Loscalzo J, Kaptchuk TJ: Genetics and the placebo effect: the 
placebome. Trends Mol Med 21:285-94, 2015 
 182. Benedetti F, Lanotte M, Lopiano L, et al: When words are painful: 
unraveling the mechanisms of the nocebo effect. Neuroscience 147:260-71, 2007 
 183. Humpel N, Jones SC: Gaining insight into the what, why and where of 
complementary and alternative medicine use by cancer patients and survivors. Eur J 
Cancer Care (Engl) 15:362-8, 2006 
 184. Giveon SM, Liberman N, Klang S, et al: A survey of primary care 
physicians' perceptions of their patients' use of complementary medicine. 
Complement Ther Med 11:254-60, 2003 
 185. Cauffield JS: The psychosocial aspects of complementary and 
alternative medicine. Pharmacotherapy 20:1289-94, 2000 
 186. Rosenberg W, Donald A: Evidence based medicine: an approach to 
clinical problem-solving. BMJ 310:1122-6, 1995 
 187. Yeung KS, Gubili J, Cassileth B: Evidence-based botanical research: 
applications and challenges. Hematol Oncol Clin North Am 22:661-70, viii, 2008 
 188. World Health Organisation: General guidelines for methadologies on 
research and evaluation of traditional medicine [Internet] 2000 [cited 2016 Jun 27]. 
Available from: 
http://apps.who.int/iris/bitstream/10665/66783/1/WHO_EDM_TRM_2000.1.pdf 
 189. NationalCancerInstitute: What are clinical trials? [Internet] 2011 
[updated 2016 Jun 27; cited 2016 Jul 29]. Available from: 
http://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials 
 190. Hishida I, Nanba H, Kuroda H: Antitumor activity exhibited by orally 
administered extract from fruit body of Grifola frondosa (maitake). Chem Pharm Bull 
(Tokyo) 36:1819-27, 1988 
 130 
 191. Vickers AJ: How to design a phase I trial of an anticancer botanical. J 
Soc Integr Oncol 4:46-51, 2006 
 192. Daugherty CK, Ratain MJ, Emanuel EJ, et al: Ethical, scientific, and 
regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin 
Oncol 26:1371-8, 2008 
 193. Bland J: Does complementary and alternative medicine represent only 
placebo therapies? Altern Ther Health Med 14:16-8, 2008 
 194. Miyasaka LS, Atallah AN, Soares BG: Valerian for anxiety disorders. 
Cochrane Database Syst Rev:CD004515, 2006 
 195. Linde K, Mulrow CD: St John's wort for depression. Cochrane 
Database Syst Rev:CD000448, 2000 
 196. Furlan AD, van Tulder M, Cherkin D, et al: Acupuncture and dry-
needling for low back pain: an updated systematic review within the framework of the 
cochrane collaboration. Spine (Phila Pa 1976) 30:944-63, 2005 
 197. Wears RL, Lewis RJ: Statistical models and Occam's razor. Acad 
Emerg Med 6:93-4, 1999 
 198. Cassileth BR, Lusk EJ, Guerry D, et al: Survival and quality of life 
among patients receiving unproven as compared with conventional cancer therapy. N 
Engl J Med 324:1180-5, 1991 
 199. Murphy RA, Mourtzakis M, Chu QS, et al: Supplementation with fish 
oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell 
lung cancer. Cancer 117:3774-80, 2011 
 200. Sakamoto J, Morita S, Oba K, et al: Efficacy of adjuvant 
immunochemotherapy with polysaccharide K for patients with curatively resected 
colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. 
Cancer Immunol Immunother 55:404-11, 2006 
 201. Osterlund P, Ruotsalainen T, Korpela R, et al: Lactobacillus 
supplementation for diarrhoea related to chemotherapy of colorectal cancer: a 
randomised study. Br J Cancer 97:1028-34, 2007 
 202. MacGregor G, Smith AJ, Thakker B, et al: Yoghurt biotherapy: 
contraindicated in immunosuppressed patients? Postgrad Med J 78:366-7, 2002 
 203. Mehta A, Rangarajan S, Borate U: A cautionary tale for probiotic use 
in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with 
 131 
mantle cell lymphoma undergoing hematopoietic SCT. Bone Marrow Transplant 
48:461-2, 2013 
 204. Murphy RA, Mourtzakis M, Chu QS, et al: Nutritional intervention 
with fish oil provides a benefit over standard of care for weight and skeletal muscle 
mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 
117:1775-82, 2011 
 205. Gupta D, Lis CG, Grutsch JF: Perceived cancer-related financial 
difficulty: implications for patient satisfaction with quality of life in advanced cancer. 
Support Care Cancer 15:1051-6, 2007 
 206. Thaker PH, Han LY, Kamat AA, et al: Chronic stress promotes tumor 
growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939-
44, 2006 
 207. Folkman S: Thoughts about psychological factors, PNI, and cancer. 
Adv Mind Body Med 15:255-9; discussion 275-81, 1999 
 208. Gruzelier JH: A review of the impact of hypnosis, relaxation, guided 
imagery and individual differences on aspects of immunity and health. Stress 5:147-
63, 2002 
 209. Deng GE, Cassileth BR, Cohen L, et al: Integrative Oncology Practice 
Guidelines. J Soc Integr Oncol 5:65-84, 2007 
 210. Miner W: Training massage therapists to work in oncology. J Soc 
Integr Oncol 5:163-6, 2007 
 211. Collinge W, Kahn J, Yarnold P, et al: Couples and cancer: feasibility 
of brief instruction in massage and touch therapy to build caregiver efficacy. J Soc 
Integr Oncol 5:147-54, 2007 
 212. Myers CD, Walton T, Small BJ: The value of massage therapy in 
cancer care. Hematol Oncol Clin North Am 22:649-60, viii, 2008 
 213. Ernst E: Acupuncture. Lancet Oncol 11:20, 2010 
 214. Lu W, Dean-Clower E, Doherty-Gilman A, et al: The value of 
acupuncture in cancer care. Hematol Oncol Clin North Am 22:631-48, viii, 2008 
 215. Ezzo JM, Richardson MA, Vickers A, et al: Acupuncture-point 
stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst 
Rev:CD002285, 2006 
 132 
 216. Lee J, Dodd M, Dibble S, et al: Review of acupressure studies for 
chemotherapy-induced nausea and vomiting control. J Pain Symptom Manage 
36:529-44, 2008 
 217. Lee MS, Choi TY, Park JE, et al: Moxibustion for cancer care: a 
systematic review and meta-analysis. BMC Cancer 10:130, 2010 
 218. Knols R, Aaronson NK, Uebelhart D, et al: Physical exercise in cancer 
patients during and after medical treatment: a systematic review of randomized and 
controlled clinical trials. J Clin Oncol 23:3830-42, 2005 
 219. Harder H, Parlour L, Jenkins V: Randomised controlled trials of yoga 
interventions for women with breast cancer: a systematic literature review. Support 
Care Cancer 20:3055-64, 2012 
 220. Bower JE, Garet D, Sternlieb B, et al: Yoga for persistent fatigue in 
breast cancer survivors: a randomized controlled trial. Cancer 118:3766-75, 2012 
 221. Richardson J, Smith JE, McCall G, et al: Hypnosis for nausea and 
vomiting in cancer chemotherapy: a systematic review of the research evidence. Eur J 
Cancer Care (Engl) 16:402-12, 2007 
 222. Eremin O, Walker MB, Simpson E, et al: Immuno-modulatory effects 
of relaxation training and guided imagery in women with locally advanced breast 
cancer undergoing multimodality therapy: a randomised controlled trial. Breast 18:17-
25, 2009 
 223. Billhult A, Bergbom I, Stener-Victorin E: Massage relieves nausea in 
women with breast cancer who are undergoing chemotherapy. J Altern Complement 
Med 13:53-7, 2007 
 224. Quattrin R, Zanini A, Buchini S, et al: Use of reflexology foot massage 
to reduce anxiety in hospitalized cancer patients in chemotherapy treatment: 
methodology and outcomes. J Nurs Manag 14:96-105, 2006 
 225. Carlson LE, Speca M, Faris P, et al: One year pre-post intervention 
follow-up of psychological, immune, endocrine and blood pressure outcomes of 
mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. 
Brain Behav Immun 21:1038-49, 2007 
 226. Cramer H, Lauche R, Paul A, et al: Mindfulness-based stress reduction 
for breast cancer-a systematic review and meta-analysis. Curr Oncol 19:e343-52, 
2012 
 133 
 227. Ferrer AJ: The effect of live music on decreasing anxiety in patients 
undergoing chemotherapy treatment. J Music Ther 44:242-55, 2007 
 228. Lin MF, Hsieh YJ, Hsu YY, et al: A randomised controlled trial of the 
effect of music therapy and verbal relaxation on chemotherapy-induced anxiety. J 
Clin Nurs 20:988-99, 2011 
 229. Stanton AL, Danoff-Burg S, Sworowski LA, et al: Randomized, 
controlled trial of written emotional expression and benefit finding in breast cancer 
patients. J Clin Oncol 20:4160-8, 2002 
 230. Horneber M, Bueschel G, Dennert G, et al: How many cancer patients 
use complementary and alternative medicine: a systematic review and metaanalysis. 
Integr Cancer Ther 11:187-203, 2012 
 231. Feveile H, Olsen O, Hogh A: A randomized trial of mailed 
questionnaires versus telephone interviews: response patterns in a survey. BMC Med 
Res Methodol 7:27, 2007 
 232. Bishop FL, Yardley L, Lewith GT: Treat or treatment: a qualitative 
study analyzing patients' use of complementary and alternative medicine. Am J Public 
Health 98:1700-5, 2008 
 233. Tourangeau R, Yan T: Sensitive questions in surveys. Psychol Bull 
133:859-83, 2007 
 234. Gama H, Correia S, Lunet N: Questionnaire design and the recall of 
pharmacological treatments: a systematic review. Pharmacoepidemiol Drug Saf 
18:175-87, 2009 
 235. Abu-Realh MH, Magwood G, Narayan MC, et al: The use of 
complementary therapies by cancer patients. Nursingconnections 9:3-12, 1996 
 236. Tippens K, Marsman K, Zwickey H: Is prayer CAM? J Altern 
Complement Med 15:435-8, 2009 
 237. National Health Performance Authority: Immunisation rates for 
children in 2012–13 [Internet] 2014 [cited 2016 Jun 30]. Available from: 
http://www.nhpa.gov.au/internet/nhpa/publishing.nsf/Content/Report-Download-
Immunisation-rates-for-children-in-2012-13 
 238. Ho PM, Peterson PN, Masoudi FA: Evaluating the evidence: is there a 
rigid hierarchy? Circulation 118:1675-84, 2008 
 134 
 239. Bishop FL, Lewith GT: Who Uses CAM? A Narrative Review of 
Demographic Characteristics and Health Factors Associated with CAM Use. Evid 
Based Complement Alternat Med 7:11-28, 2010 
 240. Gianni AM, Piccart MJ: Optimising chemotherapy dose density and 
dose intensity. new strategies to improve outcomes in adjuvant therapy for breast 
cancer. Eur J Cancer 36 Suppl 1:S1-3, 2000 
 241. Hudis C, Dang C: The development of dose-dense adjuvant 
chemotherapy. Breast J 21:42-51, 2015 
 242. Yasueda A, Urushima H, Ito T: Efficacy and Interaction of Antioxidant 
Supplements as Adjuvant Therapy in Cancer Treatment: A Systematic Review. Integr 
Cancer Ther 15:17-39, 2015 
 243. Daenen LM, Cirkel GA, Houthuijzen JM, et al: Increased plasma 
levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and 
fish oil. JAMA Oncol 314:736, 2015 
 244. Somasundaram S, Edmund NA, Moore DT, et al: Dietary curcumin 
inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer 
Res 62:3868-75, 2002 
 245. Milazzo S, Horneber M: Laetrile treatment for cancer. Cochrane 
Database Syst Rev 4:CD005476, 2015 
 246. Greenlee H, Balneaves LG, Carlson LE, et al: Clinical Practice 
Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated 
for Breast Cancer. JNCI Monographs 2014:346-358, 2014 
 247. Lee RT, Barbo A, Lopez G, et al: National Survey of US Oncologists' 
Knowledge, Attitudes, and Practice Patterns Regarding Herb and Supplement Use by 
Patients With Cancer. J Clin Oncol 32:4095-101, 2014 
 248. Navo MA, Phan J, Vaughan C, et al: An assessment of the utilization 
of complementary and alternative medication in women with gynecologic or breast 
malignancies. J Clin Oncol 22:671-7, 2004 
 249. Badowski SA, Rosenbloom D, Dawson PH: Clinical importance of 
pharmacist-obtained medication histories using a validated questionnaire. Am J Hosp 
Pharm 41:731-2, 1984 
 250. Reeder TA, Mutnick A: Pharmacist- versus physician-obtained 
medication histories. Am J Health Syst Pharm 65:857-60, 2008 
 135 
 251. Downey L, Tyree PT, Huebner CE, et al: Pediatric vaccination and 
vaccine-preventable disease acquisition: associations with care by complementary and 
alternative medicine providers. Matern Child Health J 14:922-30, 2010 
 252. Du J, Cullen JJ, Buettner GR: Ascorbic acid: chemistry, biology and 
the treatment of cancer. Biochimica et Biophysica Acta 1826:443-57, 2012 
 253. Thakerar A, Sanders J, Moloney M, et al: Pharmacist advice on the 
safety of complementary and alternative medicines during conventional anticancer 
treatment. J Pharm Pract Res 44:231-237, 2014 
 254. Smith PJ, Clavarino AM, Long JE, et al: Evaluation of a Patient CAM-
with-Chemotherapy Educational Brochure. Evid Based Complement Alternat Med 
[Internet]. 2015: 5 pages, 2015 Available from: 
http://dx.doi.org/10.1155/2015/408430 
 255. Lang, T. Developing Patient Education Handouts.[ebook]. Tom Lang 
Communications. 1999 [cited 2015 Nov 18]. Available from: 
http://tomlangcommunications.com/Expanded_Patient_Ed_Chapter.pdf 
 256. Melbourne Primary Care Network: Health literacy checklist for written 
consumer resources [Internet] 2014 [updated 2014 Nov 25; cited 2016 Jun 30]. 
Available from: http://nwmphn.org.au/services/dsp-default.cfm?loadref=125 
 257. Badarudeen S, Sabharwal S: Assessing readability of patient education 
materials: current role in orthopaedics. Clin Orthop Relat Res 468:2572-80, 2010 
 258. Smith PJ, Clavarino A, Long J, et al: CAM use by patients receiving 
curative intent chemotherapy. Eur J Oncol Pharm 8 Supp 2:S42, 2014 
 259. Sotelo JL, Musselman D, Nemeroff C: The biology of depression in 
cancer and the relationship between depression and cancer progression. Int Rev 
Psychiatry 26:16-30, 2014 
 260. Mehta A, Rangarajan S, Borate U: A cautionary tale for probiotic use 
in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with 
mantle cell lymphoma undergoing hematopoietic SCT. Bone Marrow Transplant 
48:461, 2012 
 261. Smith PJ, Clavarino AM, Long JE, et al: Complementary and 
alternative medicine use by patients receiving curative-intent chemotherapy  
Asia Pac J of Clin Oncol 4 Apr 2016 doi: 10.1111/ajco.12490 [Epub ahead of print] 
 262. Svaneborg N, Kristensen SD, Hansen LM, et al: The acute and short-
time effect of supplementation with the combination of n-3 fatty acids and 
 136 
acetylsalicylic acid on platelet function and plasma lipids. Thromb Res 105:311-6, 
2002 
 263. Ang CD, Alviar MJ, Dans AL, et al: Vitamin B for treating peripheral 
neuropathy. Cochrane Database Syst Rev:CD004573, 2008 
 264. Lee RT, Barbo A, Lopez G, et al: National survey of US oncologists' 
knowledge, attitudes, and practice patterns regarding herb and supplement use by 
patients with cancer. J Clin Oncol 32:4095-101, 2014 
 265. King N, Balneaves LG, Levin GT, et al: Surveys of Cancer Patients 
and Cancer Health Care Providers Regarding Complementary Therapy Use, 
Communication, and Information Needs. Integr Cancer Ther 14: 515-524, 2015 
 266. Oh B, Butow P, Mullan B, et al: Patient-doctor communication: use of 
complementary and alternative medicine by adult patients with cancer. J Soc Integr 
Oncol 8:56-64, 2010 
 267. Bannerman B, Xu L, Jones M, et al: Preclinical evaluation of the 
antitumor activity of bortezomib in combination with vitamin C or with 
epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 
68:1145-54, 2011 
 268. Edwards GV, Aherne NJ, Horsley PJ, et al: Prevalence of 
complementary and alternative therapy use by cancer patients undergoing radiation 
therapy. Asia Pac J Clin Oncol 10:346-53, 2014 
 269. Tovey P, Broom A: Oncologists' and specialist cancer nurses' 
approaches to complementary and alternative medicine and their impact on patient 
action. Soc Sci Med 64:2550-64, 2007 
 270. Leach LS, Butterworth P, Whiteford H: Private health insurance, 
mental health and service use in Australia. Aust N Z J Psychiatry 46:468-75, 2012 
 271. Zeller T, Muenstedt K, Stoll C, et al: Potential interactions of 
complementary and alternative medicine with cancer therapy in outpatients with 
gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol 
139:357-65, 2013 
 137 
 
 
 
 
 
 
 
 
 
APPENDIX A  
  
Patient Study Consent Form 
 
 
  
 138 
 
 
Participant Information Sheet and Consent Form 
 
Study Title:   Complementary and alternative medicine use by patients 
receiving chemotherapy     
This Participant Information and Consent Form is 4 pages long.  Please make sure 
that you have all the pages. 
You are being asked to take part in a research study. 
This Participant Information Sheet contains detailed information about the research 
study.  Its purpose is to explain to you as openly and clearly as possible what you 
would be required to do in the study before you decide whether or not to take part in 
it. 
Please read this Participant Information Sheet carefully.  Feel free to ask questions 
about any information in the document.  You may also wish to discuss the study with 
a relative or friend or your local health worker.  Feel free to do this. 
Once you understand what the study is about and if you agree to take part in it, you 
will be asked to sign the Consent Form.  By signing the Consent form, you indicate 
that you understand the information and that you give your consent to participate in 
the research project. 
You will be given a copy of the Participant Information Sheet and Consent form to 
keep as a record. 
This study is being conducted by Cancer Care Services of Nambour General 
Hospital  
1.  What is the purpose of this study? 
This study aims at finding in the population of cancer patients presenting first time for 
chemotherapy administration, what complementary approaches to healthcare they 
are choosing and why they are choosing them. 
 
2.  Why have I been asked to participate in this study? 
You have been selected to participate in this study because you are being treated 
with chemotherapy curatively to treat a solid tumour cancer.  Knowledge gained 
through this study may help health professionals working in cancer care to better 
anticipate and communicate with patients who want to take complementary and 
alternative medicine (CAM) during chemotherapy treatment. Better understanding of 
the selection process leading to CAM taken at the same time as chemotherapy may 
better prepare conventional professionals to ask the right questions and have 
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appropriate resources to ensure patient safety. Your information is important to us 
and may help people facing chemotherapy in the future.  
 
3.  What if I don’t want to take part in this study, or if I want to withdraw later? 
Participation in this study is voluntary.  It is completely up to you whether or not you 
wish to participate.  Your choice to not participate will not affect the treatment you 
receive now or in the future.  Whatever your decision, it will not affect your 
relationship with the staff caring for you.  
4.  What does this study involve? 
If you agree to take part in this study, you will be asked additional questions to the 
medication history questions routinely asked by the cancer pharmacist in the day 
cancer unit when you are receiving chemotherapy for the first time. These questions 
have been designed to find out what complementary medicines you are taking and 
your reasons for selecting them. Some additional personal questions will also be 
asked.   If you agree to participate in this study, you will be asked to sign the 
Participant Consent Form. 
 
5.  Are there risks to me in taking part in this study? 
There are no physical risks involved in this study. Taking part in the study has no 
effect on your treatment or follow-up which will be decided by you and you’re treating 
doctors according to best standard practice. 
Your medical record will be accessed by the researcher involved in the study for 
further details, however all of your personal details and answers are strictly 
confidential and will not be revealed to anyone outside the study. Study information 
will be kept secure at all times and will be destroyed after seven years, according to 
local hospital policy. Reports of the study will be published, but these will not include 
details that reveal the identities of patients who took part. 
6.  What happens if I suffer injury or complications as a result of the study? 
It is most unlikely that you will suffer any injury or complications as a result of taking 
part in this study. By signing the consent form, you have not waived any legal or 
other right to seek compensation. 
7.  Will I benefit from the study? 
The study aims to further knowledge and to help future people faced with similar 
decisions in the future, however it may not directly benefit you. You may benefit from 
having the opportunity to discuss in depth your CAM use and concerns.  
8.  Will taking part in this study cost me anything? 
No. 
9.  How will my confidentiality be protected? 
Study information gathered will not be able to be identified to source. Any identifiable 
information that is collected about you in connection with this study will remain 
confidential and will not be disclosed without your permission. This study is to be 
conducted as part of the requirement of the researcher to achieve a research higher 
degree through the Graduate School of the University of Queensland. University 
supervisors will have access to de-identified information gathered in this study. 
 
10.  What happens with the results? 
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If you give permission by signing the Consent Form, results of this study will be used 
by the researcher to submit a research thesis and may also be published in peer-
reviewed journals.  In any publication, information will be provided in such a way that 
you cannot be identified. 
 
12.  Further Information or Any Problems 
You are encouraged to ask questions at any time during the study interview.  If you 
have any questions about this study, or if you require further information, or you are 
dissatisfied or unhappy with any aspect of the study, you should first contact the 
investigator:  
The investigator responsible for this study is 
Peter Smith (Principal Investigator) 
Telephone: 07 5470 6490. 
 
13.  Who should I contact if I have concerns about the conduct of this study? 
This study has been reviewed and approved by the The Prince Charles Hospital 
Research, Ethics and Governance Unit, Metro North Health Service District.  Should 
you wish to discuss the study in relation to your rights as a participant, or should you 
wish to make an independent complaint, you can contact the Executive Officer, The 
Research, Ethics and Governance Unit, The Prince Charles Hospital, Rode Road, 
Chermside, Qld 4032 or telephone (07) 3139 4500  
 
 
Thank you for taking the time to consider being part of this study. 
If you wish to take part in this study, please sign the attached consent form. 
This information sheet is for you to keep. 
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Oncology Trials  
Sunshine Coast Cancer Care Centre 
Nambour General Hospital 
Principal Investigator:  Mr Peter Smith 
 
Participant Informed Consent 
 
Pre chemotherapy patient education review 
 
My signature on this consent form means the following:  
 
• I have read and understood the information in this consent form, Version 2. May 
21, 2012 (or it has been read to me). 
• The study has been fully explained to me and all of my questions have been 
answered, 
• I have been made aware of the procedures involved in the study, including any 
known or expected inconvenience, risk, discomfort or side effect, and of their 
implications as far as they are currently known by the researchers. 
• I understand the purpose of this study and what my participation in it will involve, 
• I authorise the use and disclosure of my health information to the parties listed in 
the confidentiality section of this consent for the purposes described above. 
• I understand that the research project will be carried out according to the 
principles in the National Health & Medical Research Council Statement on 
Ethical Conduct in Research Involving Humans.  
• I give my free and informed consent to take part in the study and agree to the 
conditions detailed above. 
• I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected.  If I withdraw from the study I agree to the use of the information 
collected up to the time of withdrawal. 
• I have been informed that The Prince Charles Hospital Research, Ethics and 
Governance Unit, Metro North Health Service District has approved the study. 
• I will receive a copy of this Patient Information Sheet and consent form with my 
signature on it. 
• My signature below indicates that I agree to take part in this study. However my 
consent does not release the research staff from their responsibilities. I keep all the 
rights granted by the law. 
 
     
Printed name of patient                Signature of patient  Date 
 
Printed name of witness  Signature of witness  Date 
Statement and signature of person who conducted the informed consent 
discussion: 
I acknowledge that I have explained the information sheet/consent form to the study participant and I 
believe the patient understood the potential risks and benefits of participation in this trial. 
     
Printed name of Investigator or 
designated person 
 Signature  Date 
Note: All parties signing the consent form must date their own signature 
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                             Nambour General Hospital 
Sunshine Coast Cancer Service 
 
CAM STUDY QUESTIONNAIRE  
(Interviewer guided) 
Researcher: Peter Smith University of Queensland 
(Affix Patient Label Here) 
 UR: ..........................................................  
Family name: 
Given names: ................................................................................................................................................  
Date of birth .................................................................................................... Sex:  M  F 
Date:  
Socio-demographic information (circle) 
Marital status  married/ live in partner/ (divorced/ separated/ widowed)/  single   
Household income ($ gross)  0-30k / 30-59k/ 60-100k/ over100k 
Highest educational level primary/ secondary/ tertiary/ post tertiary  
Previous CAM use No/ yes (routinely/ recent/ rare)    what?  
 
Disease characteristics and treatment  
Primary cancer type and stage    
Chemotherapy treatment (curative intent)  
Co- morbidities  
Concurrent conventional cancer treatment Surgery/ radiotherapy / hormone therapy / other 
 
Complementary and alternative medicines use  
Nutritional supplements 
(eg Vitamins , minerals, other antioxidants, probiotics) 
 
 
 
 
Special diet and foods 
(Gerson diet,  “detox”, stopping sugar, apricot kernel, 
shark cartilage) 
 
Herbal medicines and teas 
 
 
 
 
Homoeopathy  
 
Complementary therapies (specified) 
 
 
 
Other  (specified) 
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                             Nambour General Hospital 
Sunshine Coast Cancer Service 
 
CAM STUDY QUESTIONNAIRE  
(Interviewer guided) 
Researcher: Peter Smith University of Queensland 
(Affix Patient Label Here) 
 UR: ..........................................................  
Family name: ................................................................................................................................................  
Given names: ................................................................................................................................................  
Date of birth: .................................................................................................. Sex:  M  F 
Date: 
Previously communicated CAM use with treating cancer consultant, other cancer health professional or GP?   
  Yes / No 
 
Why/ why not? (harmless/ not asked/ forgot/ afraid) 
Expected benefits from use  
 
 
 
 
 
 
 
Do you expect any side-effects from CAM 
use? 
Treat unrelated condition / lessen chemotherapy side-effects / 
 treat cancer / improve  chemotherapy effectiveness / 
manage disease symptoms / improve immune system / boost energy / live a 
healthy lifestyle / feel in control / reduce stress / help sleep / 
other  (specified)? 
 
 
Yes /  No  
 
Selection information source 
Complementary medicine/therapy practitioner (specific)/  conventional 
practitioner (specify) / cancer support group/ other patient, friends, family, 
magazines, books, television, internet, health food store, pharmacy, other 
(specified). 
 
Specific questions ( if applicable):  
“Is the person you receive CAM selection advice from in favour of you receiving chemotherapy?”  Yes / No 
 
“Would you have liked to receive from us specific information on what complementary medicines are safe to use with 
chemotherapy ?  Yes / No 
 
If yes : 
• From whom?  Consultant/ Nurse/ Pharmacist/ GP, other (specify) 
 
• When would this be most useful?  Initial consultation/ Other time 
 
• What?  Referenced guide / Verbal advice  / Other?  (specify) 
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Sunshine Coast Health Service District 
Nambour General Hospital 
Sunshine Coast Cancer Service 
MEDICATION HISTORY 
(Affix Patient Label Here) 
 UR: ..........................................................  
Family name: ................................................................................................................................................  
Given names: ................................................................................................................................................  
Date of birth: .................................................................................................. Sex:  M  F 
Date: 
Source of History:  □  Patient              □  Carer              □ Other:   
ADVERSE DRUG EVENT or ALLERGY Patient states they have an allergy    □ YES      □ NO 
Drug / Food Reaction When 
   
   
   
PRESCRIPTION MEDICATIONS (prescribed prior to Admission) 
Generic Name Dose and Frequency 
When 
Started Indication per patient 
    
    
    
    
    
    
    
    
    
    
OVER THE COUNTER MEDICATIONS 
Does the patient use any medications bought from a chemist, health food store or supermarket? 
Generic Name Dose and Frequency 
When 
Started Indication per patient 
    
    
    
    
Signature: Name: Designation: 
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What complementary and alternative medicine 
(CAM) can I safely use with chemotherapy? 
 
Evidence-based information for patients  
Peter J Smith,1,2 Alexandra Clavarino,1 Jeremy Long2 and Kathryn J Steadman1 
1University of Queensland, Brisbane, Australia 
2Sunshine Coast Cancer Care Services, Nambour, Australia 
 
Version 1, 2014
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Introduction 
This brochure is designed to advise you on what we currently know about 
complementary and alternative medicine (CAM) use at the time of receiving 
chemotherapy.  It does not cover CAM use at other times, for example, when you 
have completed conventional treatment.  It is also not in any way a criticism of all 
CAM use, just a summation of current evidence-based studies on CAM effectiveness 
and assured safety at this time.   
 
This brochure will provide you with evidence-based information on which CAM we 
know is safe for you to use, if you wish, during treatment with chemotherapy. 
 
What is CAM? 
Complementary and alternative medicine (CAM) are products and treatments which 
are not widely used by conventional healthcare professionals.2  CAM that is 
absorbed into the bloodstream, such as herbs and vitamin supplements, may 
interfere with chemotherapy effectiveness.11,12  
 
Herbs and vitamin supplements are absorbed into the bloodstream and may 
interfere with chemotherapy effectiveness 
 
 
Mind-body CAM  
Mind-body CAM such as massage, meditation, music, imagery, hypnosis, self-
expression, mild exercise and acupuncture have established evidence and are able to 
be used safely with standard treatment.  Mind-body therapies should be your first 
consideration when looking for safe, complementary cancer care. (Table 1)   
 
Mind-body therapies are safe and effective complementary treatments you can use 
while receiving chemotherapy.  
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Table 1. 
Safe, evidence- based mind-body CAM that may help during chemotherapy 
treatment17 
* Acupuncture, hypnosis and massage should be administered by specially trained 
practitioners  
 
Mind-body 
therapy CAM 
Supportive care use 
Acupuncture* 
 
• decreases acute vomiting  caused by chemotherapy 
 
Hypnosis* • decreases nausea and vomiting caused by chemotherapy 
Imagery and 
relaxation 
(body relaxation 
combined with  
visualisation e.g. 
imagining immune cells 
as powerful medieval 
knights, or big brooms, 
dispatching cancer cells) 
• positively modulates immune functioning during 
treatment 
Massage*  
 
• decreases nausea and vomiting caused by chemotherapy 
• reflexology (foot massage) decreases anxiety during 
treatment 
Meditation 
(combines relaxation 
with self-awareness, 
which brings the person 
into the moment,  free 
from  anxiety concerning 
the  past or future)  
 
• alters immune patterns by decreasing stress 
• decreases anxiety and depression 
Music • reduces anxiety  
Self-expression 
(includes written or 
verbal expression, 
artwork, humour and 
movement) 
• decreases dark feelings and improves outlook  
Mild exercise  
(includes yoga) 
• reduces fatigue and enhances life satisfaction 
 
 
 
Other mind-body CAM that is safe to use during chemotherapy treatment: 
 
Aromatherapy (inhaled), Bowen therapy, Qi gong, Reiki, Tai Chi, Therapeutic touch 
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Evidence to use CAM 
To treat cancer  
There is not yet enough conclusive evidence to recommend to you any CAM to treat 
cancer. Delaying conventional treatment to use CAM alone to try and treat cancer 
may potentially sacrifice years of your life, particularly if your cancer is at an early 
stage.65  
 
For chemotherapy support 
Apart from mind-body therapies (Table 1) and ginger for the treatment of nausea, it 
is very difficult to find consistent, high quality studies which show beyond doubt that 
a CAM is effective, is safe, and is able to be recommended to you when you are 
receiving chemotherapy.  Probiotics have shown some benefit to lessen diarrhoea, 
which can be a side effect of particular chemotherapy and fish oil has helped some 
lung cancer patients resist weight loss (Table 2). 
 
Table 2.  
 
Oral CAM that may help during chemotherapy treatment17  
 
Oral CAM Supportive care use 
Ginger 
 
• reduces nausea caused by chemotherapy 
Probiotics/ 
Yoghurt 
• decreased diarrhoea caused by chemotherapy 
 
Caution 
Probiotics are normally well tolerated; however, there have been rare 
cases of very ill patients receiving chemotherapy developing serious 
probiotic-caused infections  
 
Fish oil 
supplements 
• fish oil taken daily may provide benefit to patients with 
lung cancer through maintenance of weight during 
chemotherapy administration  
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I am already using CAM to treat something else  
You may already be taking herbal medicines or vitamin supplements regularly to 
treat existing conditions, or occasionally for example to treat cold symptoms.  It is 
important that you declare this CAM use, as there may be a chance of interaction 
depending on the chemotherapy you are receiving.7  
How may CAM interfere with chemotherapy? 
Practitioners carefully calculate chemotherapy doses individually for you, as accuracy 
is crucial in ensuring that you get the maximum anticancer action with the least side 
effects possible.  CAM such as herbal medicines, which are absorbed into the 
bloodstream, may potentially interfere with your chemotherapy in a way that 
lessens the anticancer effect or gives you more side effects by making the 
chemotherapy more toxic to you.11,12 (Table 3)   
Potential interactions with CAM may make chemotherapy more toxic to you, or may 
lessen the anticancer effect of the chemotherapy. 
 
Antioxidants: can I take them? 
The use of supplemental antioxidants by cancer patients receiving chemotherapy 
remains controversial.  Beneficial effects of taking antioxidant supplements to 
reduce side effects may be at the cost of lessening the chemotherapy anticancer 
effect, depending on which chemotherapy you are receiving.114 (Table 3)  Until 
further, definitive research is done, caution is advised when taking antioxidant 
supplements at the time of receiving chemotherapy.73   
Beneficial effects of taking antioxidants to reduce side effects may be at the cost of 
lessening the chemotherapy anticancer effect 
 
Fortunately, eating antioxidant-containing foods in your normal diet is safe with 
chemotherapy.114 
 
Antioxidant-containing foods in your normal diet do not achieve high enough levels 
to interact with chemotherapy.  
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Table 3.  
CAM and potential interactions with chemotherapy271  
CAM  Interaction with 
chemotherapy 
Explanation 
Antioxidant 
supplements  
 
Interaction likely with 
particular chemotherapy 
 
Diminishes radiotherapy 
effectiveness 
 
Concern that antioxidant 
supplements may protect 
cancer cells as well as normal 
cells 
 
Herbs,  
Chinese herbs, 
Medical herbal teas 
It has been estimated that 
herbal interactions are 
responsible for a substantial 
number of unexpected 
toxicities of chemotherapy 
and possible under treatment 
seen in cancer patients 
 
Chinese herbal mixtures 
often contain many different 
plant extracts which are 
highly biologically-active, 
increasing chance of 
interaction 
There is indirect evidence for 
both positive and negative 
effects of herbal use with 
chemotherapy; however, 
currently, there is not enough 
information available about 
herb-chemotherapy 
interactions to make definite 
recommendations  
Medicinal 
mushrooms 
(Coriolus versicolor 
“PSK”, Ganoderma 
lucidum “Reishi”)  
 
Interaction unlikely with 
most chemotherapy 
 
 
No reported negative 
interactions  
Trace mineral 
supplements 
Interaction unlikely with very 
small doses of minerals 
 
No information or valid 
explanations available for 
potential negative interactions  
 
Homeopathy 
(also Bach flower 
remedies, bush flower 
essences, Schuessler’s 
tissue salts)  
Interaction unlikely 
 
Homeopathic products are so 
diluted that there is little 
chance of interaction.  
 
I still want to take CAM  
If you decide to take CAM at the time you are receiving chemotherapy, for example 
if you have an advanced cancer, and are willing to accept potential interaction risk, it 
is still very important that you declare this use to your cancer specialist or 
pharmacist for documentation, to enable the best care to be given to you.   
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Require more information? 
National Cancer Institute 
Complementary and alternative medicine in cancer treatment: 
http://www.cancer.gov/cancertopics/pdq/cam/cam-cancer-treatment/patient  
Thinking about complementary and alternative medicine: A guide for people with cancer 
http://www.cancer.gov/cancertopics/cam/thinking-about-CAM  
 
Memorial Sloan Kettering Cancer Center 
Complementary therapies to ease the way during cancer treatment and recovery 
http://www.mskcc.org/cancer-care/patient-education/resources/complementary-therapies-ease-
way-during-treatment-and-recovery  
 
Cancer Council Australia 
Complementary and alternative therapies: 
http://www.cancer.org.au/about-cancer/treatment/complementary-therapies-and-cancer.html  
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Brochure Evaluation Study Prescriber Feedback 
Form  
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Brochure Feedback Form 
• I am a (please tick): 
 Oncologist  Haematologist  Rotational registrar  
 Training oncology registrar   Training  haematology registrar   Other (please clarify below) 
  
 
• Do you think there is a need for this brochure? (please tick) 
 yes 
 no 
 
• Would you recommend this brochure to your patients? 
 yes 
 no (skip to feedback at bottom) 
 
• Which patients receiving chemotherapy would you recommend this brochure to?  
(tick more than one answer if required) 
 all patients 
 patients /carers  who ask about CAM , or are using 
CAM 
 only early stage/ curative intent patients 
 other (specify) 
 
• Who should give this brochure to the patient?  
(tick more than one answer if required) 
 treating consultant/ registrar 
 nurse at clinic education 
 other cancer care professional (specify):  
 general practitioner   
 other (specify) 
 
• Please add any other feedback/suggestions/ criticisms: 
 
 
 
 
 
 
Please return this form to Peter Smith, Cancer Care Pharmacy, Nambour General 
Hospital.  peter.smith@health.qld.gov.au  
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CAM-chemotherapy brochure post intervention prescriber survey  
1. I am a (please tick): 
 Oncologist  Haematologist  
 Oncology registrar   Haematology registrar   
 
2. Do you think there is a need for this brochure? (please tick) 
 yes 
 no 
 
 
3. Do you recommend this brochure to your patients?  
 yes 
 no 
 
 
4. Do you think this brochure makes it easier for you to discuss CAM with your 
patients?  
 yes  
 no 
 
Please comment:  
 
 
 
 
 
 
 
 
5. Has the brochure saved you time during patient consultations? 
 yes 
 no 
 
Please comment:  
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6. Which patients do you recommend this brochure to?  
(tick more than one answer if required) 
 all patients receiving chemotherapy 
 patients you know are using CAM  
 patients /carers  who ask about CAM  
 only early stage/ curative intent patients 
 I wouldn’t recommend it to any patients  
 other (specify) 
 
7. Who should be able to give the brochure to your patients?  
(tick more than one answer if required) 
 treating consultant/ registrar  
 nurse at clinic education 
 any nurse in cancer care day unit 
 cancer pharmacist 
 any health professional in cancer care day unit  
 displayed in the day unit waiting room ( for anyone to 
take) 
 GP 
 other (specify) 
 
8. Who would you prefer to give the brochure to your patients?  
(only one answer please) 
 treating consultant/ registrar  
 nurse at clinic education 
 any nurse in cancer care day unit 
 cancer pharmacist 
 any health professional in cancer care day unit  
 displayed in the day unit waiting room ( for anyone to 
take) 
 GP 
 Other (specify) 
 
Please add any other feedback/suggested additions or omissions for the next edition: 
 
 
 
 
 
 
Please return this form to Peter Smith, Cancer Care Pharmacy, Nambour General 
Hospital.  peter.smith@health.qld.gov.au  
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 187 
 
 
 188 
 
 
 
 
 
 
 
 
 
APPENDIX N 
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